

CITATION REPORT

List of articles citing

Elevated circulating levels of tumor necrosis factor in severe chronic heart failure

DOI: 10.1056/nejm199007263230405

New England Journal of Medicine, 1990, 323, 236-41.

Source: <https://exaly.com/paper-pdf/21642521/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2218	In-vitro production of cytokines in serum. 1990 , 336, 687-688		8
2217	Elevated circulating tumor necrosis factor levels in Alzheimer's disease. 1991 , 129, 318-20		410
2216	Tumor necrosis factor-alpha in human arterial wall with atherosclerosis. 1991 , 89, 247-54		184
2215	Cardiac cachexia. 1991 , 302, 301-2		19
2214	A study of the serum concentration of tumor necrosis factor-alpha in thyroidal and nonthyroidal illnesses. 1991 , 72, 1113-6		70
2213	The pathogenesis of sepsis. 1991 , 115, 457-69		991
2212	Detectable serum levels of tumor necrosis factor alpha may predict early mortality in elderly institutionalized patients. 1991 , 39, 891-4		30
2211	The kidney in congestive heart failure. 1991 , 12 Suppl C, 14-20		13
2210	Congestive heart failure in the elderly. 1991 , 39, 810-25		50
2209	Reversible acquired immunodeficiency in the elderly: A review. 1991 , 14, 83-89		5
2208	Cytokines and sepsis: What are the therapeutic implications?. 1991 , 6, 172-182		13
2207	Misoprostol but not antacid prevents endotoxin-induced gastric mucosal injury: role of tumor necrosis factor-alpha. 1991 , 36, 1562-8		15
2206	Effects of acetate dialysate on transforming growth factor beta 1, interleukin, and beta 2-microglobulin plasma levels. 1991 , 40, 1110-7		22
2205	The molecular action of tumor necrosis factor-alpha. 1991 , 202, 3-14		205
2204	Dissociation between plasma and monocyte-associated cytokines during sepsis. 1991 , 21, 2177-84		139
2203	Plasma levels of atrial natriuretic peptide and tumor necrosis factor-alpha during transient myocardial ischemia in patients with stable angina. 1991 , 69, 944		4
2202	Detection of circulating tumour necrosis factor- α after elective cardiopulmonary bypass. 1991 , 6, 51-54		7

2201	Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure. 1991 , 66, 356-8	263
2200	Cachexia and tumour necrosis factor-alpha in cytomegalovirus infection. 1991 , 44, 519-20	12
2199	Studies on the role of tumor necrosis factor in adult respiratory distress syndrome. 1992 , 146, 694-700	75
2198	The role of nutrition in cardiovascular disease. 1992 , 4, 13-21	
2197	Skeletal muscle failure in heart failure. 1992 , 85, 1621-3	43
2196	Exercise training in heart failure patients. Does reversing the peripheral abnormalities protect the heart?. 1992 , 85, 2323-5	20
2195	Report of the Conference on Low Blood Cholesterol: Mortality Associations. 1992 , 86, 1046-60	539
2194	Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. 1992 , 85, 1364-73	600
2193	In reply. 1992 , 40, 299-299	
2192	Skeletal muscle function, morphology, and metabolism in patients with congestive heart failure. 1992 , 101, 333S-339S	38
2191	Administration of anti-TNF antibody improves left ventricular function in septic shock patients. Results of a pilot study. 1992 , 101, 810-5	197
2190	Multiple organ failure. Pathophysiology and potential future therapy. 1992 , 216, 117-34	973
2189	Tumour necrosis factor (TNF) in neuroimmunology. 1992 , 2, 125-138	7
2188	The cardiodepressant and vasodepressant effects of tumour necrosis factor in rat isolated atrial and aortic tissues. 1992 , 106, 942-7	13
2187	Skeletal muscle in heart failure. 1992 , 340, 1383-1384	8
2186	The uremic dyslipidemia: a cross-sectional and longitudinal study. 1992 , 20, 324-35	84
2185	Pathophysiology of chronic heart failure. 1992 , 340, 88-92	228
2184	The push, the pull and the periphery. 1992 , 22, 587-91	

2183	Impaired endothelium-mediated vasodilation in the peripheral vasculature of patients with congestive heart failure. 1992 , 19, 918-25	339
2182	The cytokine network in the critically ill. 1992 , 20, 288-302	65
2181	Tungsten treatment prevents tumor necrosis factor-induced injury of brain endothelial cells. 1992 , 16, 13-9	24
2180	Endothelial function in chronic congestive heart failure. 1992 , 69, 1596-601	484
2179	Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop. 1992 , 69, 1458-66	349
2178	Autocrine and paracrine mechanisms in the pathophysiology of heart failure. 1992 , 70, 4C-11C	77
2177	Immune cytokines and cardiac disease. 1992 , 2, 145-51	18
2176	Sepsis, severe sepsis or sepsis syndrome: need for clarification. 1992 , 18, 255-7	32
2175	Inflammatory mediators in the critically ill. 1992 , 6, 253-290	2
2174	The effect of endotoxin and tumour necrosis factor on erythrocyte and leucocyte deformability in vitro. 1993 , 83, 130-7	48
2173	Elevated breath pentane in heart failure reduced by free radical scavenger. 1993 , 14, 643-7	95
2172	Local contractile and growth modulators in the myocardium. 1993 , 16, 115-9	21
2171	Serum-soluble CD4 as clinical and immunological marker in patients with dilated cardiomyopathy. 1993 , 38, 103-9	5
2170	Immune function in patients with chronic stable congestive heart failure. 1993 , 125, 1651-8	13
2169	Endothelial function in congestive heart failure. 1993 , 126, 761-4	78
2168	The treatment of heart failure--what next?. 1993 , 35, 557-63	1
2167	Platelet function, thrombin and fibrinolytic activity in patients with heart failure. 1993 , 14, 205-12	178
2166	Effect of balloon mitral valvuloplasty on exercise capacity, ventilation and skeletal muscle oxygenation. 1993 , 21, 856-65	55

2165	Trends in patient selection for heart transplantation. 1993 , 21, 975-81	25
2164	Factors contributing to the exercise limitation of heart failure. 1993 , 22, 93A-98A	81
2163	Increased levels of serum neopterin and decreased production of neutrophil superoxide anions in chronic heart failure with elevated levels of tumor necrosis factor-alpha. 1993 , 22, 1897-901	81
2162	Tumor necrosis factor-alpha as a myocardial depressant substance. 1993 , 42, 231-8	52
2161	Tumour necrosis factor alpha in severe congestive cardiac failure. 1993 , 70, 141-3	123
2160	The search for the ideal positive inotropic agent. <i>New England Journal of Medicine</i> , 1993 , 329, 201-2	59.2 61
2159	Biochemical and morphological alterations in xylazine-induced pulmonary edema. 1993 , 21, 562-71	20
2158	Intensive care. 1993 , 69, 340-58	
2157	Release of bioactive interleukin 6 but not of tumour necrosis factor- α after elective cardiopulmonary bypass. 1993 , 8, 233-238	9
2156	The Clinical Evaluation of New Drugs for Sepsis. 1993 , 270, 1233	108
2155	Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. 1993 , 119, 771-8	755
2154	Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple organ failure. 1993 , 218, 769-76	474
2153	Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. 1994 , 108, 626-635	344
2152	Increased resting metabolic rate in patients with congestive heart failure. 1994 , 121, 860-2	142
2151	Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. 1994 , 89, 955-8	133
2150	Peripheral circulatory adaptations to pump failure of the heart. 1994 , 72, S22-7	4
2149	Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. 1994 , 105, 897-904	313
2148	Differential expression of the cell adhesion molecules ICAM-1, VCAM-1, and E-selectin in normal and posttransplantation myocardium. Cell adhesion molecule expression in human cardiac allografts. 1994 , 89, 1760-8	64

2147	Plasma levels of tumor necrosis factor and endothelial response in patients with chronic arterial obstructive disease or Raynaud's phenomenon. 1994 , 45, 1015-22	16
2146	Increased circulating cytokines in patients with myocarditis and cardiomyopathy. 1994 , 72, 561-6	394
2145	Key references on heart failure. 1994 , 90, 1093-100	
2144	Clinical immunology of aging. 1994 , 4, 187-197	4
2143	Delayed tumor necrosis factor alpha blockade attenuates pulmonary dysfunction and metabolic acidosis associated with experimental gram-negative sepsis. 1994 , 129, 80-9	32
2142	Therapeutic effect of anti-tumor necrosis factor-alpha antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus. 1994 , 89, 846-51	121
2141	Cardiac failure in an elderly population. 1994 , 4, 199-211	
2140	Vasodilatory effects of C-type natriuretic peptide on forearm resistance vessels are distinct from those of atrial natriuretic peptide in chronic heart failure. 1994 , 90, 1210-4	43
2139	Beneficial effects of metoprolol treatment in congestive heart failure. Reversal of sympathetic-induced alterations of immunologic function. 1994 , 90, 1774-80	56
2138	Immune mechanisms of cardiac disease. <i>New England Journal of Medicine</i> , 1994 , 330, 1129-35	59.2 97
2137	Comparative Analysis of the Inductive Activity of Interleukin-1 β Versus Tumor Necrosis Factor α on G-CSF and GM-CSF Production by Human Vascular Endothelial Cells. 1994 , 1, 245-250	
2136	Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. 1994 , 150, 1453-5	377
2135	Endomyocardial HLA expression is increased to the same extent in idiopathic and secondary dilated cardiomyopathy. 1994 , 41, 59-66	6
2134	Endothelial control of vascular and myocardial function in heart failure. 1994 , 8, 437-46	14
2133	Patterns of systemic oxygen utilization in cardiac ischemic syndromes: oxygen utilization in cardiac ischemia. 1994 , 28, 205-14	3
2132	Protein-energy malnutrition in patients with ischemic and nonischemic dilated cardiomyopathy and congestive heart failure. 1994 , 73, 908-10	23
2131	Spontaneous endothelin production by circulating mononuclear cells from patients with chronic heart failure but not from normal subjects. 1994 , 21, 311-3	15
2130	Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure. Relation to nitric oxide-dependent vasodilation in the forearm circulation. 1994 , 90, 12-6	193

2129	Increased nitric oxide production in heart failure. 1994 , 344, 373-4	233
2128	Vesnarinone prolongs survival and reduces lethality in a murine model of lethal endotoxemia. 1994 , 55, 1735-41	14
2127	Inhibition of cytokine production by a new inotropic agent, vesnarinone, in human lymphocytes, T cell line, and monocytic cell line. 1994 , 54, PL11-6	25
2126	Cytokines as mediators in the regulation of the hypothalamic-pituitary-adrenocortical function. 1994 , 17, 141-55	16
2125	Vesnarinone inhibits induction of nitric oxide synthase in J774 macrophages and rat cardiac myocytes in culture. 1995 , 30, 187-192	7
2124	Evidence for inflammation as a cause of hypocholesterolemia in older people. 1995 , 43, 264-6	48
2123	Signal transduction mechanisms controlling cardiac contractility and their alterations in chronic heart failure. 1995 , 30, 570-584	55
2122	Role of nitric oxide in the regulation of myocardial function. 1995 , 38, 155-66	136
2121	The role of endothelium-derived vasoactive substances in the pathophysiology of exercise intolerance in patients with congestive heart failure. 1995 , 38, 23-50	53
2120	Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. 1995 , 76, 803-8	146
2119	New concepts regarding events that lead to end-stage heart disease. 1995 , 9 Suppl 3, 489-92	4
2118	Can tumor necrosis factor-alpha (TNF-alpha) be reliably measured in blood?. 1995 , 19, 226-30	5
2117	Tumor necrosis factor-alpha and the failing human heart. 1995 , 18, IV20-7	50
2116	Strategies for pharmacologic modulation of the heart failure phenotype. 1995 , 18, IV28-35	
2115	Cell death in the failing heart: role of an unnatural growth response to overload. 1995 , 18, IV36-44	24
2114	Evidence against a role of nitric oxide in the indirect negative inotropic-effect of M-cholinoceptor stimulation in human ventricular myocardium. 1995 , 352, 308-12	9
2113	Lack of role for nitric oxide (NO) in the selective destabilization of endothelial NO synthase mRNA by tumor necrosis factor-alpha. 1995 , 15, 52-7	65
2112	Therapeutic potential for cytokine antagonists: Thalidomide and pentoxifylline in Hansen's disease. 1995 , 6, 30-3	

2111	Tumor necrosis factor, natural killer activity and other measures of immune function and inflammation in elderly men with heart failure. 1995 , 41, 45-56	12
2110	Endogenous nitric oxide in cardiovascular disease and transplantation. 1995 , 27, 395-406	46
2109	Erratum. 1995 , 43, 266-266	
2108	Sarcopenia in aging humans: the impact of menopause and disease. 1995 , 50 Spec No, 73-7	14
2107	Heart Hypertrophy and Failure. 1995 ,	
2106	Nutrition support affects the distribution and organ uptake of cachectin/tumor necrosis factor in rats. 1995 , 19, 341-50	12
2105	Tumor necrosis factor-alpha and X-linked adrenoleukodystrophy. 1995 , 61, 161-9	45
2104	Use of aprotinin in LVAD recipients reduces blood loss, blood use, and perioperative mortality. 1995 , 59, 1063-7; discussion 1068	115
2103	TNF alpha receptor expression in rat cardiac myocytes: TNF alpha inhibition of L-type Ca ²⁺ current and Ca ²⁺ transients. 1995 , 376, 24-30	94
2102	Outcome of protein-energy malnutrition in elderly medical patients. 1995 , 98, 67-74	229
2101	Immune modulation of cardiac function: a new frontier. 1995 , 1, 331-5	10
2100	Effects of exercise training in patients with congestive heart failure: a critical review. 1995 , 25, 789-96	142
2099	Skeletal muscle fiber composition and capillarization in patients with chronic heart failure: relation to exercise capacity and central hemodynamics. 1995 , 1, 267-72	49
2098	Vesnarinone: a new inotropic agent for treating congestive heart failure. 1995 , 1, 249-57	18
2097	Why do patients with emphysema lose weight?. 1995 , 345, 1190-1	34
2096	Effects of methyl mercury on cytokines, inflammation and virus clearance in a common infection (coxsackie B3 myocarditis). 1996 , 89, 19-28	58
2095	Vesnarinone: a potential cytokine inhibitor. 1996 , 2, 251-8	15
2094	The effect of tumor necrosis factor-alpha on cardiac structure and function: a tale of two cytokines. 1996 , 2, S165-72	36

2093	Regulation of nitric oxide synthase gene expression by cytokines. 1996 , 2, S179-85	13
2092	Immunomodulation: a new horizon for medical treatment of heart failure. 1996 , 2, S287-94	18
2091	Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). 1996 , 27, 1201-6	976
2090	Tumor necrosis factor-alpha is released from the isolated heart undergoing ischemia and reperfusion. 1996 , 28, 247-52	145
2089	Blood ketone bodies in congestive heart failure. 1996 , 28, 665-72	116
2088	Intracarotid tumor necrosis factor-alpha administration increases the blood-brain barrier permeability in cerebral cortex of the newborn pig: quantitative aspects of double-labelling studies and confocal laser scanning analysis. 1996 , 208, 85-8	75
2087	Amélioration du métabolisme oxydatif du muscle squelettique chez l'insuffisant cardiaque après transplantation. Étude par spectroscopie de résonance magnétique nucléaire du phosphore 31. 1996 , 11, 28-33	
2086	Tumour necrosis factor is expressed in cardiac tissues of patients with heart failure. 1996 , 54, 217-25	46
2085	Inotropic agents differentially inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages. 1996 , 59, PL121-5	15
2084	Impact of left ventricular dysfunction on cytokines, hemodynamics, and outcome in bypass grafting. 1996 , 62, 184-90	105
2083	Basic mechanisms in heart failure: the cytokine hypothesis. 1996 , 2, 243-9	338
2082	Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. 1996 , 347, 1151-5	310
2081	Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. 1996 , 28, 964-71	404
2080	Exercise limitation in chronic heart failure: central role of the periphery. 1996 , 28, 1092-102	404
2079	Slow isolated ultrafiltration for the treatment of congestive heart failure. 1996 , 28, S67-S73	20
2078	Interleukin-6 correlates with hemodynamic impairment during dobutamine administration in chronic heart failure. 1996 , 57, 129-34	30
2077	The potential biological and clinical significance of the soluble tumor necrosis factor receptors. 1996 , 7, 231-40	228
2076	Stress activated cytokines and the heart. 1996 , 7, 341-54	78

2075	Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. 1996 , 153, 633-7	260
2074	The role of nitric oxide in heart failure. Potential for pharmacological intervention. 1996 , 8, 452-8	13
2073	Diastolic mitral annular motion: assessment of left ventricular filling. 1996 , 17, 1606-7	1
2072	Biochemical analysis of muscle biopsy in overnight fasting patients with severe chronic heart failure. 1996 , 17, 1686-93	32
2071	Plasma cytokine levels in cardiac chambers of patients with mitral stenosis with congestive heart failure. 1996 , 87, 476-80	9
2070	Endothelial function in heart failure: some unsolved issues. 1996 , 17, 1775-7	6
2069	Assessment of myocardial injury by serum tumour necrosis factor alpha measurements in acute myocardial infarction. 1996 , 17, 1852-9	39
2068	Exercise and heart failure. A review. 1996 , 110, 1317-27	24
2067	Peripheral and respiratory muscles in chronic heart failure. 1996 , 9, 2161-7	35
2066	Evolving concepts regarding selection of patients for cardiac transplantation. Assessing risks and benefits. 1996 , 109, 223-32	13
2065	Right atrial thrombus presenting in a patient with heart failure and disseminated intravascular coagulation. 1996 , 17, 1605-6	3
2064	Cytokines in acute rheumatic fever. 1997 , 156, 25-9	57
2063	Elevated circulating levels of tumor necrosis factor in patients with mitral valve disease and ventricular septum defect. 1996 , 11, 218-20	1
2062	Heart transplant candidates at high risk can be identified at the time of initial evaluation. 1996 , 9, 38-45	17
2061	Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. 1996 , 77, 723-7	207
2060	Delayed improvement in skeletal muscle metabolism and exercise capacity in patients with mitral stenosis following immediate hemodynamic amelioration by percutaneous transvenous mitral commissurotomy. 1996 , 77, 492-7	18
2059	Energy expenditure and symptom severity in men with heart failure. 1996 , 77, 1250-2	55
2058	Positive inotropic therapy: an update and new agents. 1996 , 21, 521-81	8

2057	Molecular Pathology of Dilated Cardiomyopathies. 1996 , 21, 99-144	6
2056	Transplant candidate's clinical status rather than right ventricular function defines need for univentricular versus biventricular support. 1996 , 111, 773-82; discussion 782-3	128
2055	New concepts in the pathophysiology of heart failure: beneficial and deleterious interaction of endogenous haemodynamic and neurohormonal mechanisms. 1996 , 239, 327-33	38
2054	Cytokine profile in chronic cardiac failure. 1996 , 26, 1018-22	38
2053	Subchronic exposure of cardiomyocytes to low concentrations of tumor necrosis factor alpha attenuates the positive inotropic response not only to catecholamines but also to cardiac glycosides and high calcium concentrations. 1996 , 156, 135-43	9
2052	Activation of the neuroendocrine response in heart failure: adaptive or maladaptive process?. 1996 , 10 Suppl 2, 623-9	9
2051	Role of a cytokine-inducible nitric oxide synthase in the control of myocardial contractile state. 1996 , 1, 193-201	1
2050	Effects of proinflammatory cytokines on the contractility of mammalian heart. 1996 , 1, 203-210	17
2049	Tumor necrosis factor- α and tumor necrosis factor receptors in human heart failure. 1996 , 1, 211-219	11
2048	Immunomodulatory therapy and survival with cardiac disease. 1996 , 1, 221-227	
2047	Endothelial control of lower limb blood flow in chronic heart failure. 1996 , 75, 469-76	33
2046	Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. 1996 , 51, 819-24	323
2045	Explaining fatigue in congestive heart failure. 1996 , 47, 241-56	96
2044	Histological abnormalities of muscle from limb, thorax and diaphragm in chronic heart failure. 1996 , 17, 1239-50	94
2043	The clinical relevance of circulating tumor necrosis factor-alpha in acute decompensated chronic heart failure without cachexia. 1996 , 110, 992-5	66
2042	Hypercoagulability in heart failure. 1997 , 23, 543-5	52
2041	Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian cardiac myocyte. 1997 , 272, 4836-42	262
2040	Failure to thrive in old age: follow-up on a workshop. 1997 , 52, M333-6	11

2039	Endothelial cytosolic proteins bind to the 3' untranslated region of endothelial nitric oxide synthase mRNA: regulation by tumor necrosis factor alpha. 1997 , 17, 5719-26	119
2038	Cytokines and cardiomyocyte death. 1997 , 29, 339-43	90
2037	Haemodynamic, neuroendocrine and metabolic correlates of circulating cytokine concentrations in congestive heart failure. 1997 , 18, 1620-5	60
2036	Skeletal muscle abnormalities and evidence for their role in symptom generation in chronic heart failure. 1997 , 18, 1865-72	60
2035	The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. 1997 , 18, 259-69	159
2034	Soluble tumor necrosis factor receptors are elevated in relation to severity of congestive heart failure. 1997 , 61, 657-64	44
2033	Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. 1997 , 18, 470-9	204
2032	Molecular and immune mechanisms in the pathogenesis of cardiomyopathy--role of viruses, cytokines, and nitric oxide. 1997 , 61, 275-91	65
2031	Unusual Clinical Manifestations Reported in Patients with Parvovirus B19 Infection. 1997 , 20, 61-92	10
2030	[Not Available]. 1997 , 7, 107-18	
2029	[Heart pathology of extracardiac origin (I). Cardiac involvement in AIDS]. 1997 , 50, 721-8	2
2028	Adverse cardiovascular effects of NSAIDs in patients with congestive heart failure. 1997 , 17, 166-80	21
2027	Cardiac-specific overexpression of tumor necrosis factor-alpha causes lethal myocarditis in transgenic mice. 1997 , 3, 117-24	130
2026	Exercise for patients with congestive heart failure. 1997 , 23, 75-92	27
2025	Mechanisms of nitrate accumulation in plasma during pacing-induced heart failure in conscious dogs. 1997 , 1, 386-96	15
2024	Nitric oxide inhalation reduces pulmonary tidal volume during exercise in severe chronic heart failure. 1997 , 134, 737-44	10
2023	Association of serum albumin and mortality risk. 1997 , 50, 693-703	424
2022	Nutritional support of the hospitalized patient. 1997 , 43, 349-426	4

2021	Circulatory resuscitation with left ventricular assist device support reduces interleukins 6 and 8 levels. 1997 , 63, 971-4	75
2020	Wasting as independent risk factor for mortality in chronic heart failure. 1997 , 349, 1050-3	1033
2019	Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link?. 1997 , 349, 1391-2	247
2018	Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. 1997 , 29, 1214-20	137
2017	Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Randomized Amlodipine Survival Evaluation. 1997 , 30, 35-41	103
2016	Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. 1997 , 30, 997-1001	159
2015	Anti-tumor necrosis factor-alpha improves myocardial recovery after ischemia and reperfusion. 1997 , 30, 1554-61	131
2014	Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. 1997 , 30, 1758-64	310
2013	Elevated plasma levels of tumor necrosis factor in chronic heart failure with cachexia. 1997 , 58, 257-61	59
2012	Ischemic versus idiopathic cardiomyopathy: differing neurohumoral profiles despite comparable peak oxygen uptake. 1997 , 61, 261-8	18
2011	The use of cytokine inhibitors. A new therapeutic insight into heart failure. 1997 , 62 Suppl 1, S3-12	14
2010	Calcium channel blocker-induced protection against cardiovascular damage. 1997 , 62 Suppl 2, S39-46	15
2009	The importance of cachexia in the syndrome of heart failure. 1997 , 18, 187-9	12
2008	QT dispersion and sudden cardiac death. 1997 , 18, 189-90	14
2007	Adrenomedullin in experimental congestive heart failure: cardiorenal activation. 1997 , 273, R1392-9	16
2006	Forebrain parasympathetic control of heart activity: retrograde transneuronal viral labeling in rats. 1997 , 273, H2926-30	35
2005	Daily energy expenditure in free-living heart failure patients. 1997 , 272, E469-75	35
2004	Enhanced generation of interleukins 1 beta and 6 may contribute to the cachexia of chronic disease. 1997 , 65, 876-82	89

2003	Changes in skeletal muscle biochemistry and histology relative to fiber type in rats with heart failure. 1997 , 83, 1291-9	74
2002	Nitric oxide synthases and cardiac muscle. Autocrine and paracrine influences. 1997 , 17, 1846-58	215
2001	Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm. 1997 , 17, 2843-7	231
2000	Apoptosis and congestive heart failure. 1997 , 7, 249-55	28
1999	Endothelial dysfunction: clinical implications. 1997 , 39, 287-324	224
1998	Effect of mitral valvuloplasty in mitral stenosis on coagulation activity. 1997 , 79, 1131-5	20
1997	Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. 1997 , 79, 1426-30	311
1996	Serum levels of soluble form of Fas molecule in patients with congestive heart failure. 1997 , 79, 1698-701	55
1995	Delayed recovery of postexercise blood pressure in patients with chronic heart failure. 1997 , 79, 1701-4	18
1994	Molecular and cellular mechanisms of myocardial failure. 1997 , 80, 15L-25L	242
1993	Circulating interleukin-6 in severe heart failure. 1997 , 79, 1128-31	181
1992	Changes in skeletal muscle morphology and biochemistry after cardiac transplantation. 1997 , 79, 630-4	26
1991	Distribution of myocardial macrophages in the normal human heart. 1997 , 191 (Pt 3), 417-23	22
1990	Nitric oxide and cardiac failure. 1997 , 20, 837-41	30
1989	Increased inducible nitric oxide synthase in skeletal muscle biopsies from patients with chronic heart failure. 1997 , 61, 152-60	53
1988	Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. 1997 , 11 Suppl 1, 247-56	70
1987	Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo. 1997 , 36, 49-55	77
1986	Taming TNF: strategies to restrain this proinflammatory cytokine. 1997 , 18, 487-92	237

1985	Inotropic agents in the treatment of heart failure: despair or hope?. 1997 , 10, 703-9	12
1984	Is there a role for warfarin or aspirin therapy in heart failure?. 1997 , 1, 271-276	3
1983	Heart failure ketosis. 1997 , 242, 231-8	51
1982	The Role of the Tumor Suppressor Gene p53 in Cardiomyocyte Apoptosis. 1998 , 3, 45-61	2
1981	Serum interleukin-6 in congestive heart failure secondary to idiopathic dilated cardiomyopathy. 1998 , 82, 688-90, A8	77
1980	Comparison of effects of ascorbic acid on endothelium-dependent vasodilation in patients with chronic congestive heart failure secondary to idiopathic dilated cardiomyopathy versus patients with effort angina pectoris secondary to coronary artery disease. 1998 , 82, 762-7	42
1979	Tumor necrosis factor in congestive heart failure: a mechanism of disease for the new millennium?. 1998 , 41, 25-30	43
1978	Exercise training in heart failure. 1998 , 41, 175-90	26
1977	Antiplatelet and anticoagulant therapy in the prevention of thromboemboli in chronic heart failure. 1998 , 41, 225-36	15
1976	Effects of nitric oxide inhibition on basal forearm blood flow in patients with nonischemic chronic heart failure. 1998 , 13, 142-6	10
1975	[Circulating adhesion molecules (cICAM-1, lcVCAM-1) in patients with suspected inflammatory heart muscle disease]. 1998 , 87, 84-93	11
1974	Tumor necrosis factor-alpha is expressed by monocytes/macrophages following cardiac microembolization and is antagonized by cyclosporine. 1998 , 93, 97-107	75
1973	Downregulation of right ventricular phosphodiesterase PDE-3A mRNA and protein before the development of canine heart failure. 1998 , 29, 67-88	13
1972	Inhibition of systemic TNF-alpha cytotoxicity in cancer patients by D-peptidoglycan. 1998 , 15, 37-43	4
1971	The activated immune system and the renin-angiotensin-aldosterone system in congestive heart failure. 1998 , 243, 93-8	14
1970	Captopril and lisinopril suppress production of interleukin-12 by human peripheral blood mononuclear cells. 1998 , 62, 25-31	120
1969	Monocyte activation in congestive heart failure due to coronary artery disease and idiopathic dilated cardiomyopathy. 1998 , 63, 237-44	50
1968	Humoral response in patients with chronic heart failure. 1998 , 65, 227-32	8

1967	Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. 1998 , 351, 1091-3	178
1966	New targets for heart-failure therapy: endothelin, inflammatory cytokines, and oxidative stress. 1998 , 352 Suppl 1, S134-8	96
1965	The molecular and cellular pathophysiology of heart failure. 1998 , 27, 3-19; quiz 20-1	44
1964	Nutritional alterations and the effect of fish oil supplementation in dogs with heart failure. 1998 , 12, 440-8	102
1963	Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. 1998 , 62, 2425-30	176
1962	Increased myocardial tumor necrosis factor-alpha in a crystalloid-perfused model of cardiac ischemia-reperfusion injury. 1998 , 65, 439-43	103
1961	Monocyte tissue factor expression and ongoing complement generation in ventricular assist device patients. 1998 , 65, 1071-6	27
1960	Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. 1998 , 31, 391-8	414
1959	Increased oxidative stress in patients with congestive heart failure. 1998 , 31, 1352-6	454
1958	Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. 1998 , 32, 393-7	164
1957	Denopamine, a beta1-adrenergic agonist, prolongs survival in a murine model of congestive heart failure induced by viral myocarditis: suppression of tumor necrosis factor-alpha production in the heart. 1998 , 32, 808-15	19
1956	Inducible nitric oxide synthase in skeletal muscle of patients with chronic heart failure. 1998 , 32, 964-9	49
1955	Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. 1998 , 32, 955-63	146
1954	The role of cytokines in the failing human heart. 1998 , 16, 645-56, viii	92
1953	Oxidative stress and the pathogenesis of heart failure. 1998 , 16, 665-75, viii-ix	41
1952	Evidence of phenotypic alteration as a cause of systolic dysfunction in the failing heart. 1998 , 16, 677-89, ix	
1951	Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. 1998 , 97, 1921-9	568
1950	Monocyte chemoattractant protein 1 (MCP-1) gene expression in dilated cardiomyopathy. 1998 , 10, 739-46	37

1949	Elective orthopedic surgery, a model for the study of cytokine activation and regulation. 1998 , 10, 897-903	38
1948	Adenosine reduces cardiac TNF-alpha production and human myocardial injury following ischemia-reperfusion. 1998 , 76, 117-23	75
1947	Release of tumor necrosis factor-alpha from coronary smooth muscle: activation of NF-kappaB and inhibition by elevated cyclic AMP. 1998 , 80, 129-35	20
1946	Role of cytokines in heart failure. 1998 , 135, 181-6	82
1945	Effect of vesnarinone on cardiac function in patients with severe congestive heart failure. 1998 , 136, 769-77	5
1944	Cytokine generation capacities of monocytes are reduced in patients with severe heart failure. 1998 , 136, 991-1002	21
1943	The pathophysiology of advanced heart failure. 1998 , 135, S216-30	63
1942	Skeletal muscle myosin heavy chains in heart failure: correlation between magnitude of the isozyme shift, exercise capacity, and gas exchange measurements. 1998 , 135, 130-7	34
1941	Predicting short-term outcome in severely ill heart failure patients: implications regarding listing for urgent cardiac transplantation and patient selection for temporary ventricular assist device support. 1998 , 4, 169-75	7
1940	Role of nitric oxide in ventricular dysfunction. 1998 , 4, 249-60	2
1939	Genetically engineered mice: model systems for left ventricular failure. 1998 , 4, 349-61	19
1938	Predictors of myocardial dysfunction in human immunodeficiency virus-infected patients. 1998 , 4, 19-26	4
1937	Medical therapy of chronic heart failure. Role of ACE inhibitors and beta-blockers. 1998 , 16, 711-25, ix	8
1936	Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. 1998 , 83, 969-79	263
1935	Experimental autoimmune myocarditis produced by adoptive transfer of splenocytes after myocardial infarction. 1998 , 82, 458-63	77
1934	Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. 1998 , 98, 794-9	441
1933	Tumor necrosis factor-alpha confers resistance to hypoxic injury in the adult mammalian cardiac myocyte. 1998 , 97, 1392-400	129
1932	Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. 1998 , 98, 149-56	368

1931	Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. 1998 , 97, 1382-91	690
1930	Tumor necrosis factor-alpha and cardiomyopathy. 1998 , 97, 1340-1	53
1929	Effects of tumor necrosis factor gene polymorphisms on patients with congestive heart failure. VEST Investigators for TNF Genotype Analysis. Vesnarinone Survival Trial. 1998 , 97, 2499-501	89
1928	Production and secretion of adrenomedullin in cultured rat cardiac myocytes and nonmyocytes: stimulation by interleukin-1beta and tumor necrosis factor-alpha. 1998 , 139, 4576-80	76
1927	Hepatocyte growth factor and keratinocyte growth factor in the pulmonary edema fluid of patients with acute lung injury. Biologic and clinical significance. 1998 , 158, 386-94	117
1926	Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. 1998 , 97, 1375-81	524
1925	Adenosine inhibits lipopolysaccharide-induced cardiac expression of tumor necrosis factor-alpha. 1998 , 82, 47-56	108
1924	Uric acid in chronic heart failure: a marker of chronic inflammation. 1998 , 19, 1814-22	194
1923	Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of beta-adrenergic inotropic responsiveness. 1998 , 97, 161-6	151
1922	Adenosine inhibits lipopolysaccharide-induced secretion of tumor necrosis factor-alpha in the failing human heart. 1998 , 97, 521-4	75
1921	Adrenomedullin production in fibroblasts: its possible function as a growth regulator of Swiss 3T3 cells. 1998 , 139, 2552-63	90
1920	Altered Oxygen Availability and the Role of Nitric Oxide in the Development of Heart Failure. 1998 , 4, 171-192	
1919	AgNORs in the myocardium in ischaemic heart disease complicated by heart failure: a postmortem study. 1998 , 51, 102-4	10
1918	Pathophysiology of heart failure update: the role of neurohumoral activation in the progression of heart failure. 1998 , 9, 157-71	9
1917	Risk stratification in chronic heart failure. 1998 , 19, 696-710	149
1916	Cytokine expression increases in nonmyocytes from rats with postinfarction heart failure. 1998 , 275, H250-8	44
1915	Tumor necrosis factor in the heart. 1998 , 274, R577-95	276
1914	Nitric oxide modulates cardiac contractility and oxygen consumption without changing contractile efficiency. 1998 , 275, H41-9	17

1913	Angiotensin II and mechanical stretch induce production of tumor necrosis factor in cardiac fibroblasts. 1999 , 276, H1968-76	40
1912	TNF-alpha enhances cardiac myocyte NO production through MAP kinase-mediated NF-kappaB activation. 1999 , 277, H1641-6	22
1911	Differential regulation of cardiac expression of IL-6 and TNF-alpha by A2- and A3-adenosine receptors. 1999 , 276, H2141-7	17
1910	Myocardial tumor necrosis factor-alpha secretion in hypertensive and heart failure-prone rats. 1999 , 277, H543-50	21
1909	Special considerations in design of trials with elderly subjects: unexplained weight loss, body composition and energy expenditure. 1999 , 129, 260S-263S	6
1908	Alveolar epithelial fluid transport and the resolution of clinically severe hydrostatic pulmonary edema. 1999 , 87, 1301-12	137
1907	Improving outcomes in congestive heart failure. 1999 , 56, 1445-50	
1906	Haemostatic Abnormalities, Cardiac Involvement and Serum Tumor Necrosis Factor Levels in X-linked Dystrophic Patients. 1999 , 81, 543-546	51
1905	Plasma viscosity and fibrinogen in relation to haemodynamic findings in chronic congestive heart failure. 1999 , 1, 293-5	12
1904	Malnutrition, Cardiac Disease, and Mortality. 1999 , 19, 309-314	19
1903	The TNF-alpha system in heart failure and after heart transplantation: plasma protein levels, mRNA expression, soluble receptors and plasma buffer capacity. 1999 , 20, 833-40	14
1902	Novel approaches to retard ventricular remodeling in heart failure. 1999 , 1, 17-23	10
1901	Cardiac cachexia--lean and mean. 1999 , 20, 1609-11	5
1900	TNF-alpha in patients with chronic failure is not only a proinflammatory cytokine. 1999 , 20, 1445-6	4
1899	Induction of functional inducible nitric oxide synthase in monocytes of patients with congestive heart failure. Link with tumour necrosis factor-alpha. 1999 , 20, 1503-13	28
1898	Tumor necrosis factor-alpha serum activity during treatment of acute decompensation of cachectic and non-cachectic patients with advanced congestive heart failure. 1999 , 33, 344-50	23
1897	Increased superoxide in heart failure: a biochemical baroreflex gone awry. 1999 , 100, 216-8	137
1896	Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor-alpha. 1999 , 100, 1983-91	191

1895	Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support : A potential mechanism for cardiac recovery. 1999 , 100, 1189-93	219
1894	TNF-alpha and heart failure. The difference between proof of principle and hypothesis testing. 1999 , 99, 3213-4	28
1893	Inappropriately low plasma leptin concentration in the cachexia associated with chronic heart failure. 1999 , 82, 352-6	66
1892	Clinical implications of tumour necrosis factor alpha antagonism in patients with congestive heart failure. 1999 , 58 Suppl 1, I103-6	8
1891	Exercise improves flow-mediated vasodilatation of skeletal muscle arteries in rats with chronic heart failure. Role of nitric oxide, prostanoids, and oxidant stress. 1999 , 99, 2951-7	120
1890	Tumor necrosis factor-alpha-converting enzyme and tumor necrosis factor-alpha in human dilated cardiomyopathy. 1999 , 99, 3260-5	106
1889	Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium. 1999 , 99, 1492-8	318
1888	alpha- and beta-adrenergic pathways differentially regulate cell type-specific apoptosis in rat cardiac myocytes. 1999 , 100, 305-11	165
1887	Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure. 1999 , 99, 2113-7	131
1886	Genetic factors in septic shock. 1999 , 282, 579-81	20
1885	Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. The Christchurch Cardioendocrine Research Group. 1999 , 81, 114-20	116
1884	Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. 1999 , 96, 8144-9	503
1883	Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic renal failure?. 1999 , 246, 503-7	94
1882	Progress in Interventional Cardiology. 1999 , 12, 397-400	
1881	Effects of tumour necrosis factor-alpha on left ventricular function in the rat isolated perfused heart: possible mechanisms for a decline in cardiac function. 1999 , 126, 189-96	40
1880	Septic shock without documented infection: an uncommon entity with a high mortality. 1999 , 25, 1267-70	31
1879	Oxidative Stress Status in the Transition of Hypertrophy to Heart Failure. 1999 , 4, 353-360	3
1878	Transition from Compensated to Decompensated Cardiac Hypertrophy. 1999 , 4, 379-388	1

1877	Mitochondrial Function in Heart Failure. 1999 , 4, 229-244	6
1876	Oxidative Stress in Heart Failure: Current Understanding and Prospective. 1999 , 4, 1-10	1
1875	Activated Oxygen Species in Heart Failure. 1999 , 4, 1-12	2
1874	Oxidative Stress, Vascular Dysfunction and Heart Failure. 1999 , 4, 1-13	6
1873	Molecular Mechanisms of Apoptosis in Heart Failure. 1999 , 4, 1-7	
1872	Changes in Gene Expression during the Transition from Compensated Hypertrophy to Heart Failure. 1999 , 4, 361-378	
1871	Endothelial Dysfunction in Congestive Heart Failure: Effects of Carvedilol. 1999 , 4, 53-64	1
1870	Exercise Training in Chronic Heart Failure: Why?. 1999 , 3, 287-297	1
1869	Serial circulating concentrations of C-reactive protein, interleukin (IL)-4, and IL-6 in patients with acute left heart decompensation. 1999 , 22, 811-3	122
1868	Chronic heart failure and cardiac cachexia and links between the endocrine and immune systems. 1999 , 88, S018-23	4
1867	Effect of elective antibiotic therapy on resting energy expenditure and inflammation in cystic fibrosis. 1999 , 158, 711-6	9
1866	Physical training as an adjunct therapy in patients with congestive heart failure: patient selection, training protocols, results, and future directions. 1999 , 1, 38-46	5
1865	Vesnarinone and amrinone reduce the systemic inflammatory response syndrome. 1999 , 117, 375-82	35
1864	Correspondence. 1999 , 83, 1A-38A	142
1863	Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. 1999 , 83, 376-82	390
1862	Effects of amiodarone on tumor necrosis factor-alpha levels in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. 1999 , 83, 388-91	22
1861	Loss of bone mineral in patients with cachexia due to chronic heart failure. 1999 , 83, 612-5, A10	101
1860	From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. 1999 , 99, 1091-100	427

1859	The pathophysiology of advanced heart failure. 1999 , 28, 87-101	43
1858	The changes of circulating tumor necrosis factor levels in patients with congestive heart failure influenced by therapy. 1999 , 69, 77-82	34
1857	Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: the potential importance of bacterial translocation. 1999 , 72, 3-10	98
1856	Elevated tumor necrosis factor alpha of blood mononuclear cells in patients with congestive heart failure. 1999 , 71, 257-61	25
1855	Increased resting energy expenditure is related to plasma TNF-alpha concentration in stable COPD patients. 1999 , 18, 269-74	51
1854	Endotoxin and immune activation in chronic heart failure: a prospective cohort study. 1999 , 353, 1838-42	644
1853	Hormones and hemodynamics in heart failure. <i>New England Journal of Medicine</i> , 1999 , 341, 577-85	59.2 906
1852	Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis. 1999 , 33, 1400-7	74
1851	The role of TNF in cardiovascular disease. 1999 , 40, 97-105	131
1850	Muscle plasticity and metabolism: effects of exercise and chronic diseases. 1999 , 20, 319-73	27
1849	Selección y evaluación de pacientes candidatos a trasplante cardíaco. 1999 , 52, 604-616	1
1848	Angiotensin-converting enzyme inhibitors and cytokines in heart failure: dose and effect?. 1999 , 34, 2068-71	10
1847	Skeletal Muscle Dysfunction in Chronic Obstructive Pulmonary Disease. 1999 , 159, S2-S40	46
1846	Cardiac and peripheral responses to exercise in patients with chronic heart failure. 1999 , 20, 931-45	33
1845	Cellular basis for the acute inhibitory effects of IL-6 and TNF- alpha on excitation-contraction coupling. 1999 , 31, 1457-67	78
1844	Tumor necrosis factor-alpha at acute myocardial infarction in rats and effects on cardiac fibroblasts. 1999 , 31, 1949-59	61
1843	Pro-inflammatory cytokines stimulate mitogen-activated protein kinase subfamilies, increase phosphorylation of c-Jun and ATF2 and upregulate c-Jun protein in neonatal rat ventricular myocytes. 1999 , 31, 2087-99	61
1842	Role of TNF in mediating renal insufficiency following cardiac surgery: evidence of a postbypass cardiorenal syndrome. 1999 , 85, 185-99	81

1841	High doses of digitalis increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis: a possible mechanism of digitalis toxicity. 1999 , 63, 934-40	51
1840	Repetitive coxsackievirus infection induces cardiac dilatation in post-myocarditic mice. 1999 , 63, 794-802	16
1839	The impact of cachexia on cardiorespiratory reflex control in chronic heart failure. 1999 , 20, 1667-75	27
1838	Cytokines in heart failure: pathogenetic mechanisms and potential treatment. 1999 , 111, 423-8	47
1837	Tumor necrosis factor-alpha: a mediator of disease progression in the failing human heart. 1999 , 115, 1170-4	52
1836	Circulating cytokines and complements in chronic heart failure. 1999 , 50, 403-8	12
1835	Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. 1999 , 115, 836-47	299
1834	Heart failure as a metabolic problem. 1999 , 1, 127-31	20
1833	How are cytokines activated in heart failure?. 1999 , 1, 309-12	44
1832	New insights into the pathophysiological role for cytokines in heart failure. 1999 , 42, 557-64	46
1831	The pulmonary cachexia syndrome: aspects of energy balance. 1999 , 58, 321-8	66
1830	Severe thrombocytopenia caused by digitoxin intoxication in a patient with heart failure associated with Sjögren's syndrome. 2000 , 64, 309-11	6
1829	Preoperative and postoperative endotoxemia in children with congenital heart disease. 2000 , 117, 1706-12	91
1828	Tumour necrosis factor- β gene expression and production in human umbilical arterial endothelial cells. 2000 , 98, 461-470	7
1827	Cardiotrophin-1: a new cardiac marker?. 2000 , 99, 91-92	
1826	Tumour necrosis factor- β gene expression and production in human umbilical arterial endothelial cells. 2000 , 98, 461	5
1825	Skeletal muscle dysfunction in chronic obstructive pulmonary disease and chronic heart failure: underlying mechanisms and therapy perspectives. 2000 , 71, 1033-47	286
1824	Interaction between nutrition and inflammation in end-stage renal disease. 2000 , 18, 333-6	10

1823	Cardiovascular pharmacology: new drugs and new indications. 2000 , 13, 5-13	1
1822	Stimulation of beta-adrenergic receptors inhibits the release of tumor necrosis factor-alpha from the isolated rat heart. 2000 , 28, 3593-8	8
1821	Monocyte chemoattractant protein-1 is upregulated in rats with volume-overload congestive heart failure. 2000 , 102, 1315-22	99
1820	Mitral valve repair in heart failure. 2000 , 2, 365-71	35
1819	Catabolism in chronic heart failure. 2000 , 21, 521-32	104
1818	Expression of tumor necrosis factor-alpha protein in the myocardium in fatal myocarditis. 2000 , 42, 43-7	6
1817	Defects in insulin action in chronic heart failure. 2000 , 2, 203-12	9
1816	Recent advances in the management of chronic heart failure. 2000 , 30, 475-82	2
1815	Bench to bedside: tumor necrosis factor-alpha: from inflammation to resuscitation. 2000 , 7, 930-41	24
1814	The systemic inflammatory response in heart failure. 2000 , 11, 219-230	6
1813	Left ventricular assist device as a bridge to patient and myocardial recovery. 2000 , 43, 5-18	20
1812	Clinical and neurohormonal correlates of circulating granulocyte-macrophage colony-stimulating factor in severe heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. 2000 , 86, 707-10, A9-10	21
1811	Sites of interleukin-6 release in patients with acute coronary syndromes and in patients with congestive heart failure. 2000 , 86, 913-8	79
1810	Soluble antiapoptotic molecules and immune activation in chronic heart failure and unstable angina pectoris. 2000 , 20, 101-6	9
1809	Postinfarction left ventricular remodeling: a pathophysiological and therapeutic review. 2000 , 14, 243-52	21
1808	Free radicals, cytokines and nitric oxide in cardiac failure and myocardial infarction. 2000 , 215, 145-52	68
1807	Effects of EDTA on trace elements and cardiovascular function in the anesthetised rabbit. 2000 , 76, 133-48	8
1806	L-arginine reduces heart rate and improves hemodynamics in severe congestive heart failure. 2000 , 23, 205-10	33

1805	New and emerging pharmacologic strategies in the management of chronic heart failure. 2000 , 23, 724-30	7
1804	Insights into pathogenesis and treatment of cytokines in cardiomyopathy. 2000 , 2, 120-8	10
1803	The role of tumor necrosis factor alpha in the pathophysiology of congestive heart failure. 2000 , 2, 189-97	26
1802	Oxidative stress in congestive heart failure. 2000 , 2, 206-11	49
1801	Molecular Aspects of Myocarditis. 2000 , 2, 308-314	14
1800	Plasma nitric oxide products correlate with cardiac index of congenital heart disease. 2000 , 21, 378-81	11
1799	[Pathophysiology of chronic heart failure]. 2000 , 41, 93-104	
1798	Respiratory muscle/circulation interaction in congestive heart failure. 2000 , 37, 352-360	
1797	Microvascular response in patients with cardiogenic shock. 2000 , 28, 1290-4	64
1796	CXC-chemokines, a new group of cytokines in congestive heart failure--possible role of platelets and monocytes. 2000 , 45, 428-36	93
1795	A direct requirement of nuclear factor-kappa B for suppression of apoptosis in ventricular myocytes. 2000 , 279, H939-45	78
1794	Effects of cardiotrophin-1 on hemodynamics and endocrine function of the heart. 2000 , 279, H388-96	24
1793	New therapies for heart failure: is thalidomide the answer?. 2000 , 93, 305-11	24
1792	Negative inotropic effects of recombinant interleukin 2 in patients without left ventricular dysfunction. 2000 , 2, 167-73	13
1791	In vivo and in vitro evidence for impaired arginine transport in human heart failure. 2000 , 102, 2707-12	61
1790	Tumor necrosis factor-alpha is expressed in donor heart and predicts right ventricular failure after human heart transplantation. 2000 , 102, 326-31	96
1789	Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). 2000 , 15, 953-60	599
1788	Apoptosis in Cardiac Biology. 2000 ,	1

- 1787 Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. **2000**, 87, 596-602 161
- 1786 Perioperative Treatment of Congestive Heart Failure. **2000**, 4, 223-235
- 1785 TNF-alpha system in CHF. A reply. **2000**, 21, 782-783
- 1784 Tumor necrosis factor-alpha induces apoptosis via inducible nitric oxide synthase in neonatal mouse cardiomyocytes. **2000**, 45, 595-602 138
- 1783 Blood biocompatibility analysis in the setting of ventricular assist devices. **2000**, 11, 1239-59 13
- 1782 Acute Congestive Heart Failure and Tumor Necrosis Factor Alpha. **2000**, 9, 76-80 5
- 1781 Cardiac-specific overexpression of tumor necrosis factor-alpha causes oxidative stress and contractile dysfunction in mouse diaphragm. **2000**, 102, 1690-6 195
- 1780 Plasma cytokine parameters and mortality in patients with chronic heart failure. **2000**, 102, 3060-7 634
- 1779 Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. **2000**, 101, 2149-53 765
- 1778 Predictors of disease course in patients with acute myocarditis. **2000**, 102, 2829-35 76
- 1777 Role of Ca(2+)-independent phospholipase A(2) in the regulation of inducible nitric oxide synthase in cardiac myocytes. **2000**, 35, 249-54 33
- 1776 Activation of cytokines as a mechanism of disease progression in heart failure. **2000**, 59 Suppl 1, i90-3 17
- 1775 Nitric oxide enhances expression and shedding of tumor necrosis factor receptor I (p55) in endothelial cells. **2000**, 20, 1506-11 16
- 1774 Nitric oxide spares myocardial oxygen consumption through attenuation of contractile response to beta-adrenergic stimulation in patients with idiopathic dilated cardiomyopathy. **2000**, 101, 1925-30 42
- 1773 Amlodipine inhibits the production of cytokines induced by ouabain. **2000**, 12, 294-7 29
- 1772 Tumour necrosis factor-alpha expression in idiopathic dilated cardiomyopathy: correlation to myocardial inflammatory activity. **2000**, 12, 1261-6 18
- 1771 gp130-Dependent signalling pathway is not enhanced in gp130 transgenic heart after LIF stimulation. **2000**, 12, 1512-8 17
- 1770 Carvedilol stimulates nitric oxide synthesis in rat cardiac myocytes. **2000**, 32, 333-9 14

1769	Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. 2000 , 76, 125-33	112
1768	Prospective evaluation of the Batista procedure with circulating atrial natriuretic peptides. 2000 , 74, 145-52	1
1767	Nitric oxide in heart failure. 2000 , 73, 131-4	2
1766	Hemostatic abnormalities in patients with congestive heart failure: diagnostic significance and clinical challenge. 2000 , 75, 15-21	52
1765	Leptin serum levels in cachectic heart failure patients. Relationship with tumor necrosis factor-alpha system. 2000 , 76, 117-22	53
1764	The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1. 2000 , 72, 175-86	140
1763	Inflammatory mediators in heart failure. 2000 , 72, 209-13	31
1762	Beneficial effect(s) of n-3 fatty acids in cardiovascular diseases: but, why and how?. 2000 , 63, 351-62	185
1761	Circulating levels of cytokines and their site of production in patients with mild to severe chronic heart failure. 2000 , 140, E28	47
1760	Prognostic value of serum cytokines in patients with congestive heart failure. 2000 , 19, 419-25	102
1759	Cardiac troponin I as diagnostic and prognostic marker in severe heart failure. 2000 , 19, 644-52	155
1758	Expression of proinflammatory cytokines in the failing human heart: comparison of recent-onset and end-stage congestive heart failure. 2000 , 19, 819-24	111
1757	Nitric oxide synthase II mRNA expression in cardiac tissue of patients with heart failure undergoing cardiac transplantation. 2000 , 19, 139-44	12
1756	Pimobendan inhibits the activation of transcription factor NF-kappaB: a mechanism which explains its inhibition of cytokine production and inducible nitric oxide synthase. 2000 , 67, 2513-9	27
1755	Peripheral muscle dysfunction in chronic obstructive pulmonary disease. 2000 , 21, 665-77	72
1754	Heart Failure. 2000 ,	
1753	Circulating interleukin-6 significantly correlates to thyroid hormone in acute myocardial infarction but not in chronic heart failure. 2000 , 23, 509-14	6
1752	From the sarcomere to the nucleus: role of genetics and signaling in structural heart disease. 2000 , 1, 179-223	56

1751	Tissue wasting in patients with chronic obstructive pulmonary disease. 2000 , 18, 245-62	28
1750	Role of tumour necrosis factor-alpha in the progression of heart failure: therapeutic implications. 2000 , 59, 745-51	28
1749	Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications. 2000 , 60, 1245-57	58
1748	Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. 2000 , 35, 1628-37	704
1747	The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. 2000 , 35, 1737-44	534
1746	Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. 2000 , 36, 208-12	88
1745	Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies. 2000 , 36, 529-33	52
1744	Expression of tumor necrosis factor-alpha--converting enzyme and tumor necrosis factor-alpha in human myocarditis. 2000 , 36, 1288-94	49
1743	High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. 2000 , 36, 1587-93	341
1742	Neutrophil superoxide anion--generating capacity, endothelial function and oxidative stress in chronic heart failure: effects of short- and long-term vitamin C therapy. 2000 , 36, 1474-82	121
1741	Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. 2000 , 36, 2081-9	114
1740	Lack of association between polymorphisms of eight candidate genes and idiopathic dilated cardiomyopathy: the CARDIGENE study. 2000 , 35, 29-35	56
1739	Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. 2000 , 35, 714-21	161
1738	The role of tumor necrosis factor in the pathophysiology of heart failure. 2000 , 35, 537-44	377
1737	Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. 2000 , 35, 701-5	208
1736	Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. 2000 , 35, 569-82	1782
1735	Usefulness of (123)I-BMIPP with myocardial imaging for evaluation of the efficacy of drug therapy in patients with chronic heart failure. 2001 , 7, 257-64	5
1734	Relationship between plasma levels of cardiac natriuretic peptides and soluble Fas: plasma soluble Fas as a prognostic predictor in patients with congestive heart failure. 2001 , 7, 322-8	21

1733	Interaction between paracrine tumor necrosis factor-alpha and paracrine angiotensin II during myocardial ischemia. 2001 , 37, 316-22	24
1732	Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. 2001 , 37, 412-7	190
1731	Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?. 2001 , 37, 1493-505	121
1730	Chronic heart failure and micronutrients. 2001 , 37, 1765-74	182
1729	Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy. 2001 , 38, 1485-90	54
1728	Leukocyte mitochondria depolarization and apoptosis in advanced heart failure: clinical correlations and effect of therapy. 2001 , 38, 1693-700	14
1727	High tumour necrosis factor-alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients. 2001 , 15, 80-6	66
1726	Chronic Chagas' disease cardiomyopathy patients display an increased IFN-gamma response to Trypanosoma cruzi infection. 2001 , 17, 99-107	142
1725	Changes in calcium cycling precede cardiac dysfunction during autoimmune myocarditis in mice. 2001 , 33, 449-60	7
1724	Differential regulation of myocardial NF kappa B following acute or chronic TNF-alpha exposure. 2001 , 33, 1263-71	37
1723	Pathophysiology of chronic heart failure. 2001 , 110 Suppl 7A, 37S-46S	177
1722	Increased plasma adhesion molecule levels in patients with heart failure who have ischemic heart disease and dilated cardiomyopathy. 2001 , 141, 277-80	35
1721	Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction. 2001 , 141, 435-8	81
1720	Serum complement activation in congestive heart failure. 2001 , 141, 684-90	40
1719	Plasma nitrate accumulation during the development of pacing-induced dilated cardiac myopathy in conscious dogs is due to renal impairment. 2001 , 5, 7-17	9
1718	Endothelial dysfunction in chronic heart failure: clinical implications and therapeutic options. 2001 , 81, 1-8	11
1717	Pathophysiological role of cytokines in congestive heart failure. 2001 , 52, 15-27	116
1716	New and emerging pharmacological strategies in the management of chronic heart failure. 2001 , 1, 126-33	6

1715	Insulin resistance and cardiovascular disease. 2001 , 14, 116S-125S	65
1714	Captopril inhibits the production of tumor necrosis factor-alpha by human mononuclear cells in patients with congestive heart failure. 2001 , 304, 85-90	19
1713	Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. 2001 , 71, 1428-32	119
1712	Managing heart failure with immunomodulatory agents. 2001 , 19, 617-25	7
1711	Fisiopatología de la insuficiencia ventricular izquierda y derecha. 2001 , 8, 1939-1945	
1710	Nutritional strategy in the management of heart failure in adults. 2001 , 1, 363-73	25
1709	Differential effects of natriuretic peptides and NO on LV function in heart failure and normal dogs. 2001 , 281, H146-54	27
1708	Inhibition of Tumor Necrosis Factor- β Improves Postischemic Recovery of Hypertrophied Hearts. 2001 , 104,	
1707	Advanced Glycation Endproducts: Activators of Cardiac Remodeling in Primary Fibroblasts From Adult Rat Hearts. 2001 , 7, 543-551	51
1706	Targeted disruption of ICAM-1, P-selectin genes improves cardiac function and survival in TNF-alpha transgenic mice. 2001 , 280, H1464-71	10
1705	Increased L-arginine uptake and inducible nitric oxide synthase activity in aortas of rats with heart failure. 2001 , 280, H859-67	25
1704	TNF-alpha induces protein synthesis through PI3-kinase-Akt/PKB pathway in cardiac myocytes. 2001 , 280, H1861-8	21
1703	Overexpression of cardiac I-kappaBalpha prevents endotoxin-induced myocardial dysfunction. 2001 , 280, H962-8	68
1702	Effects of soluble TNF receptor treatment on lipopolysaccharide-induced myocardial cytokine expression. 2001 , 280, H2281-91	33
1701	Vitamin C and quinapril abrogate LVH and endothelial dysfunction in aortic-banded guinea pigs. 2001 , 281, H1704-10	28
1700	OPC-8212, a quinoline derivative, counteracts the reduction in type III collagen mRNA due to lipopolysaccharides in cultured rat cardiac fibroblasts. 2001 , 42, 125-34	4
1699	Biomarkers and Exercise Training: A Possible Missing Link between Physical Activity and Mortality Benefit in Patients with Heart Failure. 2001 , 1, 110-124	
1698	Lipophilic statins augment inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. 2001 , 38, 69-77	48

1697	. 2001 , 8, 279-282	20
1696	The role of tumor necrosis factor in cardiac disease. 2001 , 3, 319-25	5
1695	Dietary and blood antioxidants in patients with chronic heart failure. Insights into the potential importance of selenium in heart failure. 2001 , 3, 661-9	86
1694	Muscle high-energy metabolites and metabolic capacity in patients with heart failure. 2001 , 33, 442-8	9
1693	Risk stratification in middle-aged patients with congestive heart failure: prospective comparison of the Heart Failure Survival Score (HFSS) and a simplified two-variable model. 2001 , 3, 577-85	55
1692	Possible role of uncoupling protein in regulation of myocardial energy metabolism in aortic regurgitation model rats. 2001 ,	4
1691	Inflammatory and atherosclerotic interactions in the depleted uremic patient. 2001 , 19, 53-61	168
1690	Activation of the cardiac interleukin-6 system in advanced heart failure. 2001 , 3, 415-21	56
1689	A glossary of circulating cytokines in chronic heart failure. 2001 , 3, 517-26	94
1688	Elevated interleukin-1beta in pericardial fluid of patients with ischemic heart disease. 2001 , 12, 567-71	17
1687	Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study. 2001 , 103, 1083-8	105
1686	Treatment of protein-energy malnutrition in chronic nonmalignant disorders. 2001 , 74, 6-24	158
1685	Heart failure, redox alterations, and endothelial dysfunction. 2001 , 38, 1400-5	108
1684	[Cytokines in heart diseases]. 2001 , 42, 75-84	10
1683	[Leptin: a parameter for metabolic changes in heart failure]. 2001 , 90, 280-5	7
1682	Impaired beta-adrenergic control of immune function in patients with chronic heart failure: reversal by beta1-blocker treatment. 2001 , 96, 290-8	16
1681	The role of apoptotic cell death in cardiovascular disease. 2001 , 170, 132-40	8
1680	Debate: Statins should be used in patients with heart failure. 2001 , 2, 268-270	9

1679	Cytokines as new treatment targets in chronic heart failure. 2001 , 2, 271-277	34
1678	Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives. 2001 , 21, 661-72	95
1677	Myocardial gene expression of leukaemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failure. 2001 , 31, 389-97	66
1676	The value of serum albumin and high-density lipoprotein cholesterol in defining mortality risk in older persons with low serum cholesterol. 2001 , 49, 1142-7	93
1675	The tangled web of heart failure: a complex network of surrogates and correlates. 2001 , 12, 301-2	2
1674	Cytokines and their receptors in cardiovascular diseases--role of gp130 signalling pathway in cardiac myocyte growth and maintenance. 2000 , 81, 1-16	41
1673	Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice. 2001 , 104, 700-4	243
1672	Interactions between cytokines and neurohormonal systems in the failing heart. 2001 , 6, 119-27	15
1671	Mitral valve reconstruction in the patient with heart failure. 2001 , 6, 177-85	27
1670	Recent insights into the role of tumor necrosis factor in the failing heart. 2001 , 6, 71-80	65
1669	Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched?. 2001 , 6, 301-15	16
1668	The role of inflammatory mediators in the failing heart: immunomodulation of cytokines in experimental models of heart failure. 2001 , 6, 129-36	21
1667	Neurohormones, cytokines and programmed cell death in heart failure: a new paradigm for the remodeling heart. 2001 , 15, 529-37	3
1666	The pharmacokinetics of etanercept in patients with heart failure. 2001 , 51, 191-2	14
1665	Heart failure in 2001: a prophecy revisited. 2001 , 87, 1383-6	5
1664	Evidence for increased peripheral production of tumor necrosis factor-alpha in advanced congestive heart failure. 2001 , 88, 578-81	12
1663	[Drug prospects in the treatment of heart insufficiency]. 2001 , 50, 38-49	1
1662	Is insulin an antiinflammatory molecule?. 2001 , 17, 409-13	114

1661	Metabolic and nutritional disorders in cardiac cachexia. 2001 , 17, 756-60	52
1660	The Syndrome of Cardiac Cachexia. 2001 , 93-103	
1659	Effect of losartan on circulating TNFalpha levels and left ventricular systolic performance in patients with heart failure. 2001 , 8, 279-82	12
1658	Inhibition of tumor necrosis factor-alpha improves postischemic recovery of hypertrophied hearts. 2001 , 104, 1350-5	43
1657	Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women's health and aging study. 2001 , 103, 947-53	361
1656	Ventricular assist device in severe heart failure: effects on cytokines, complement and body weight. 2001 , 22, 2275-83	41
1655	Treatment of congestive heart failure: guidelines for the primary care physician and the heart failure specialist. 2001 , 161, 342-52	47
1654	Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. 2001 , 104, 3023-5	118
1653	Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. 2001 , 104, 1430-5	411
1652	Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model. 2001 , 104, 1094-7	87
1651	Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. 2001 , 104, 2034-8	374
1650	Inflammatory mediators and the failing heart: past, present, and the foreseeable future. 2002 , 91, 988-98	758
1649	Combined endurance/resistance training reduces plasma TNF-alpha receptor levels in patients with chronic heart failure and coronary artery disease. 2002 , 23, 1854-60	132
1648	Redefining symptom management. 2002 , 5, 301-4	3
1647	Nitric oxide modulates myocardial oxygen consumption in the failing heart. 2002 , 106, 273-9	65
1646	Imbalance of catabolic and anabolic pathways in chronic heart failure. 2002 , 46, 3-10	8
1645	Do cytokines enable risk stratification to be improved in NYHA functional class III patients? Comparison with other potential predictors of prognosis. 2002 , 23, 70-8	49
1644	Muscular Alterations in Chronic Obstructive Pulmonary Disease and Chronic Heart Failure at Rest and during Exercise. 2002 , 32, 18-29	1

1643	Tumour necrosis factor-alpha, inflammatory biomarkers, and atherogenesis. 2002 , 23, 345-7	17
1642	Immunoabsorption as a new therapeutic principle for treatment of dilated cardiomyopathy. 2002 , 4, 163-168	4
1641	Who are the enemies? Inflammation and autoimmune mechanisms. 2002 , 4, G27-G32	6
1640	Subacute and chronic effects of quinapril on cardiac cytokine expression, remodeling, and function after myocardial infarction in the rat. 2002 , 39, 842-50	32
1639	Relationship between interleukin-6 production in the lungs and pulmonary vascular resistance in patients with congestive heart failure. 2002 , 121, 1195-202	18
1638	Chromogranin A and tumor necrosis factor-alpha (TNF) in chronic heart failure. 2000 , 482, 351-9	47
1637	L-Carnitine: a potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure. 2002 , 283, C802-10	103
1636	Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: involvement of muscle myofilaments. 2002 , 166, 479-84	249
1635	Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. 2002 , 105, 1727-33	434
1634	The malnutrition, inflammation, and atherosclerosis (MIA) syndrome -- the heart of the matter. 2002 , 17 Suppl 11, 28-31	405
1633	The effect of high dose digoxin on cytokines in healthy dogs. 2002 , 11, 261-3	
1632	Angiotensin II induces tumor necrosis factor biosynthesis in the adult mammalian heart through a protein kinase C-dependent pathway. 2002 , 105, 2198-205	111
1631	Plasma concentrations of tumor necrosis factor-alpha in cats with congestive heart failure. 2002 , 63, 640-2	16
1630	Cardiac-specific overexpression of inducible nitric oxide synthase does not result in severe cardiac dysfunction. 2002 , 90, 93-9	126
1629	Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. 2002 , 106, 3073-8	417
1628	Tumour necrosis factor alpha gene polymorphism: a predisposing factor to non-ischaemic myocardial dysfunction?. 2002 , 87, 153-5	19
1627	Current limitations in treatment of heart failure: new avenues and treatment options. 2002 , 13, S53-6	5
1626	Biopsy coupled to quantitative immunofluorescence: a new method to study the human vascular endothelium. 2002 , 92, 1331-8	70

1625	Differential Effects of Amrinone and Milrinone Upon Myocardial Inflammatory Signaling. 2002 , 106,	14
1624	Immunomodulatory effect of pentoxifylline in suppressing experimental autoimmune myocarditis. 2002 , 66, 499-504	17
1623	Oxygen free radicals and heart failure: new insight into an old question. 2002 , 283, L237-8	13
1622	Sphingosine modulates myocyte electrophysiology, induces negative inotropy, and decreases survival after myocardial ischemia. 2002 , 39, 18-28	28
1621	Neurohormonal assessment of cardiac function. 2002 , 13, 415-9	
1620	Cardiac involvement in myositis. 2002 , 14, 663-5	13
1619	Myocardial inflammatory activation in children with congenital heart disease. 2002 , 30, 827-32	39
1618	Exercise as a treatment modality for congestive heart failure. 2002 , 4, 110-6	4
1617	Polymorphisms in cytokine genes do not predict progression to end-stage heart failure in children. 2002 , 12, 461-4	3
1616	Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6. 2002 , 30, 1987-94	90
1615	Heart failure and depression. 2002 , 4, 401-2	5
1614	Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). 2002 , 66, 149-57	72
1613	Increased nitric oxide in proportion to the severity of heart failure in patients with dilated cardiomyopathy: close correlation of tumor necrosis factor-alpha with systemic and local production of nitric oxide. 2002 , 66, 627-32	25
1612	Abundant Apoptosis in Nutmeg Liver of Cardiomyopathic HamstersApoptotic Cell Death as a Possible Mechanism of Hepatic Remodeling by Congestion. 2002 , 198, 291-298	
1611	Is insulin an endogenous cardioprotector?. 2002 , 6, 389-93	41
1610	Lethal effect of cytokine-induced nitric oxide and peroxynitrite on cultured rat cardiac myocytes. 2002 , 34, 583-96	25
1609	The cardiac fibroblast, another therapeutic target for mending the broken heart?. 2002 , 34, 1273-8	30
1608	Amiodarone inhibits interleukin 6 production and attenuates myocardial injury induced by viral myocarditis in mice. 2002 , 17, 197-202	21

1607	Reactive oxygen species induce cardiomyocyte apoptosis partly through TNF-alpha. 2002 , 18, 179-83	43
1606	The antioxidant N-2-mercaptpropionyl glycine attenuates left ventricular hypertrophy in in vivo murine pressure-overload model. 2002 , 39, 907-12	132
1605	The interleukin-6/interleukin-6-receptor system is activated in donor hearts. 2002 , 39, 1508-12	70
1604	Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure. 2002 , 8, 306-14	26
1603	Tumor necrosis factor-alpha blockade as a therapeutic strategy in heart failure (RENEWAL and ATTACH): unsuccessful, to be specific. 2002 , 8, 365-8	19
1602	Circulating levels of interleukin 18 reflect etiologies of heart failure: Th1/Th2 cytokine imbalance exaggerates the pathophysiology of advanced heart failure. 2002 , 8, 21-7	52
1601	Chromogranins. 2002 ,	3
1600	Soluble tumor necrosis factor receptor levels identify a subgroup of heart failure patients with increased cardiomyocyte apoptosis. 2002 , 320, 65-7	10
1599	The cardiac component of cardiac cachexia. 2002 , 144, 45-50	32
1598	Current treatment and future directions in heart failure. 2002 , 2, 148-53	4
1597	Cytokines and anti-cytokine therapeutic approaches to chronic heart failure. 2002 , 13, 356	5
1596	Insulin resistance in moderate chronic heart failure is related to hyperleptinaemia, but not to norepinephrine or TNF-alpha. 2002 , 83, 73-81	69
1595	Oxidative stress and neutrophil activation--the two keystones of ischemia/reperfusion injury. 2002 , 86, 41-59	255
1594	Cardiac cachexia in early literature: a review of research prior to Medline. 2002 , 85, 7-14	35
1593	Nutritional abnormalities contributing to cachexia in chronic illness. 2002 , 85, 23-31	41
1592	Chronic heart failure: an example of a systemic chronic inflammatory disease resulting in cachexia. 2002 , 85, 33-49	68
1591	The syndrome of cardiac cachexia. 2002 , 85, 51-66	219
1590	Neurohormonal factors in the development of catabolic/anabolic imbalance and cachexia. 2002 , 85, 111-21, discussion 121-4	37

1589	Cardiac cachexia: time for intervention trials. 2002 , 85, 121-124	3
1588	Chronic heart failure and skeletal muscle catabolism: effects of exercise training. 2002 , 85, 141-9	65
1587	Cytokines, apoptosis and cachexia: the potential for TNF antagonism. 2002 , 85, 161-71	121
1586	Cachexia: a therapeutic approach beyond cytokine antagonism. 2002 , 85, 173-83	62
1585	[Inflammation and cardiac disease]. 2002 , 118, 177-9	
1584	Captopril-impaired production of tumor necrosis factor- α -induced interleukin-1 β in human monocytes is associated with altered intracellular distribution of nuclear factor- κ B. 2002 , 140, 103-109	14
1583	Importancia del factor de necrosis tumoral alfa en la patogenia de la insuficiencia cardıaca. 2002 , 55, 61-66	11
1582	Tumor necrosis factor receptor levels are associated with carotid atherosclerosis. 2002 , 33, 31-7	108
1581	Decreased hematopoiesis in bone marrow of mice with congestive heart failure. 2002 , 282, R166-72	94
1580	Arachidonic acid mediates dual effect of TNF- α on Ca ²⁺ transients and contraction of adult rat cardiomyocytes. 2002 , 282, C1339-47	61
1579	Structural, functional, and molecular characterization of the SHHF model of heart failure. 2002 , 283, H1775-84	76
1578	Heart failure as an inflammatory condition: potential role for androgens as immune modulators. 2002 , 4, 673-80	29
1577	Captopril-impaired production of tumor necrosis factor- α -induced interleukin-1 β in human monocytes is associated with altered intracellular distribution of nuclear factor- κ B. 2002 , 140, 103-9	15
1576	Comparison of effects of carvedilol versus metoprolol on cytokine levels in patients with idiopathic dilated cardiomyopathy. 2002 , 89, 996-9	27
1575	Impact of an exercise-induced increase in cardiac troponin I in chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. 2002 , 90, 547-50	7
1574	Relation of tissue Doppler-derived myocardial velocities to serum levels and myocardial gene expression of tumor necrosis factor- α and inducible nitric oxide synthase in patients with ischemic cardiomyopathy having coronary artery bypass grafting. 2002 , 90, 708-12	10
1573	Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. 2002 , 90, 1118-22	69
1572	Tumor necrosis factor- α in cardiovascular biology and the potential role for anti-tumor necrosis factor- α therapy in heart disease. 2002 , 94, 123-35	104

1571	Oxidative stress and endothelial dysfunction in heart failure. 2002 , 8, 165-72	44
1570	The nitric oxide pathway and oxidative stress in heart failure. 2002 , 8, 142-7, 155	18
1569	Immune and neurohormonal pathways in chronic heart failure. 2002 , 8, 23-8, 48	23
1568	The role of tumor necrosis factor alpha blockade in the treatment of congestive heart failure. 2002 , 8, 275-9	22
1567	A new screening model for safety evaluation of superantigen-antibody recombinant fusion proteins (mAb Fab-SEA/E) using telemetric monitoring in conscious rabbits. 2002 , 48, 31-9	5
1566	Lipopolysaccharide administration increases acid and alkaline phosphatase reactivity in the cardiac muscle. 2002 , 58, 421-6	9
1565	New molecular insights into heart failure and cardiomyopathy: potential strategies and therapies. 2002 , 171, 99-104	3
1564	[Stress and stress tolerance in chronic heart failure]. 2002 , 27, 179-86	3
1563	[Pathophysiology of heart failure today]. 2002 , 27, 75-91	8
1562	Chronic exposure to interleukin 1beta induces a delayed and reversible alteration in excitation-contraction coupling of cultured cardiomyocytes. 2002 , 445, 246-56	32
1561	Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. 2002 , S12-22	280
1560	Biological mechanisms in the relationship between depression and heart disease. 2002 , 26, 941-62	178
1559	Effects of quinapril on myocardial function, ventricular remodeling and cardiac cytokine expression in congestive heart failure in the rat. 2002 , 16, 29-36	6
1558	Role of nitric oxide in the regulation of substrate metabolism in heart failure. 2002 , 7, 141-8	13
1557	Inotropic agents and immune modulation. 2002 , 16, 237-43	4
1556	Molecular and cellular mechanisms of myocardial remodeling. 2002 , 9, 319-27	21
1555	Abundant apoptosis in nutmeg liver of cardiomyopathic hamsters. Apoptotic cell death as a possible mechanism of hepatic remodeling by congestion. 2002 , 198, 291-8	1
1554	Are cardiovascular diseases a subspeciality of clinical immunology?. 2002 , 23, 243-5	

1553	Chronic heart failure and the immune system. 2002 , 23, 325-40	16
1552	The balance between pro-apoptotic and anti-apoptotic pathways in the failing myocardium. 2003 , 3, 191-206	20
1551	Low urinary 6-sulfatoxymelatonin levels in patients with severe congestive heart failure. 2003 , 22, 245-8	32
1550	Cellular remodeling in heart failure disrupts K(ATP) channel-dependent stress tolerance. 2003 , 22, 1732-42	73
1549	Molecular mechanisms of angiotensin II-induced vascular injury. 2003 , 5, 73-9	125
1548	Adrenomedullin and nitrite levels in children with dilated cardiomyopathy. 2003 , 24, 381-5	6
1547	High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure: role in reduction of plasma nitric oxide level. 2003 , 18, 177-82	53
1546	Muscular levels of proinflammatory cytokines correlate with a reduced expression of insulinlike growth factor-I in chronic heart failure. 2003 , 98, 267-74	69
1545	Skeletal muscle abnormalities in rats with experimentally induced heart hypertrophy and failure. 2003 , 98, 114-23	10
1544	Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. 2003 , 91, 18F-40F	85
1543	Elevated circulating levels of inflammatory cytokines and bacterial endotoxin in adults with congenital heart disease. 2003 , 92, 188-93	104
1542	Leukocytosis and adverse hospital outcomes after acute myocardial infarction. 2003 , 92, 368-72	56
1541	Immunomodulating therapy: new treatment modality in congestive heart failure. 2003 , 9, 64-9	11
1540	Inflammatory mediators and reversible myocardial dysfunction. 2003 , 195, 1-11	29
1539	Effects of a superantigen-antibody recombinant fusion protein (r-C242 Fab-SEA) on toxicological responses in the anaesthetised rabbit. 2003 , 185, 161-74	8
1538	Indirect determination of nitric oxide in cats with cardiomyopathy and arterial thromboembolism. 2003 , 13, 71-76	2
1537	Prognostic significance of soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy. 2003 , 33, 443-8	11
1536	Leisure-time physical activity and reduced plasma levels of obesity-related inflammatory markers. 2003 , 11, 1055-64	162

1535	Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. 2003 , 108, 839-43	349
1534	[Prognostic value of serum levels of tumor necrosis factor-alpha in patients with heart failure]. 2003 , 56, 160-7	3
1533	Metabolic modulation and optimization of energy consumption in heart failure. 2003 , 87, 493-507, xii-xiii	9
1532	Leptin, ghrelin, and proinflammatory cytokines: compounds with nutritional impact in chronic kidney disease?. 2003 , 10, 332-45	31
1531	Interleukin-6 and tumor necrosis factor alpha in relation to myocardial infarct size and collagen formation. 2003 , 9, 325-32	35
1530	The role of anticytokine therapy in heart failure: recent lessons from preclinical and clinical trials?. 2003 , 87, 419-40	9
1529	Ventricular remodeling. 2003 , 15, 407-11	13
1528	Oxidative stress-induced signal transduction pathways in cardiac myocytes: involvement of ROS in heart diseases. 2003 , 5, 789-94	167
1527	Leptin and the ventilatory response to exercise in heart failure. 2003 , 42, 1644-9	37
1526	Induction of left ventricular remodeling and dysfunction in the recipient heart after donor heart myocardial infarction: new insights into the pathologic role of tumor necrosis factor-alpha from a novel heterotopic transplant-coronary ligation rat model. 2003 , 42, 173-81	19
1525	Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis. 2003 , 26, 23-32	26
1524	Blood coagulation in patients with chronic heart failure: evidence for hypercoagulable state and potential for pharmacological intervention. 2003 , 63, 565-76	25
1523	Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure. 2003 , 9, 464-8	51
1522	Stress-activated cytokines and the heart: from adaptation to maladaptation. 2003 , 65, 81-101	223
1521	Prognostic importance of the oxidized product of catecholamines, adrenolutin, in patients with severe heart failure. 2003 , 145, 926-32	17
1520	ASK1 associates with troponin T and induces troponin T phosphorylation and contractile dysfunction in cardiomyocytes. 2003 , 163, 243-51	54
1519	Serum nitrate and nitrite in dogs with spontaneous cardiac disease. 2003 , 17, 315-8	24
1518	Nitric oxide and excitation-contraction coupling. 2003 , 35, 719-29	150

1517	Regulation of the human tumor necrosis factor-alpha promoter by angiotensin II and lipopolysaccharide in cardiac fibroblasts: different cis-acting promoter sequences and transcriptional factors. 2003 , 35, 1197-205	37
1516	Stresses of a failing heart. 2003 , 35, 1017-9	3
1515	Complexity of transcriptional regulation of the tumor necrosis factor-alpha gene. 2003 , 35, 1179-81	
1514	Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. 2003 , 361, 1077-83	546
1513	Ghrelin, a novel growth hormone-releasing peptide, in the treatment of chronic heart failure. 2003 , 114, 71-7	75
1512	Interleukin-6 and tumor necrosis factor-alpha levels increase in response to maximal exercise in patients with chronic heart failure. 2003 , 87, 83-90	32
1511	The relationship between age and production of tumour necrosis factor-alpha in healthy volunteers and patients with chronic heart failure. 2003 , 90, 197-204	15
1510	Tumor necrosis factor-alpha promoter polymorphisms in Mexican patients with rheumatic heart disease. 2003 , 21, 59-63	54
1509	Ghrelin improves left ventricular dysfunction and cardiac cachexia in heart failure. 2003 , 3, 146-51	72
1508	Sleep-disordered breathing in heart failure: characteristics and implications. 2003 , 136, 153-65	41
1507	Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites. 2003 , 46, 2261-70	102
1506	Elevated plasma amylase levels in advanced chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy: correlation with circulating interleukin-6 activity. 2003 , 23, 329-33	9
1505	Cyclooxygenase-2 (COX-2) in acute myocardial infarction: cellular expression and use of selective COX-2 inhibitor. 2003 , 81, 114-9	39
1504	Therapeutic inhibition of tumour necrosis factor alpha in patients with heart failure: cooling an inflamed heart. 2003 , 89, 14-8	24
1503	IRAK1 deletion disrupts cardiac Toll/IL-1 signaling and protects against contractile dysfunction. 2003 , 285, H597-606	56
1502	A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1beta, TNF-alpha, or L-NMMA. 2003 , 17, 1742-4	60
1501	Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. 2003 , 107, 1486-91	562
1500	Acute inhibition of myoglobin impairs contractility and energy state of iNOS-overexpressing hearts. 2003 , 92, 1352-8	56

1499	Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. 2003 , 107, 3133-40	1113
1498	A novel form of spontaneous coronary vasospasm: bead-like vasospasm in an elderly man. 2003 , 89, 18	7
1497	Myoglobin protects the heart from inducible nitric-oxide synthase (iNOS)-mediated nitrosative stress. 2003 , 278, 21761-6	68
1496	Upregulation of cardiac ghrelin mRNA in leptin-deficient and leptin receptor-deficient mice with viral myocarditis. 2003 , 31, 503-8	3
1495	Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. 2003 , 107, 223-5	657
1494	Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. 2003 , 5, 609-14	126
1493	Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. 2003 , 5, 629-37	53
1492	Myocardial proinflammatory cytokine expression and left ventricular remodeling in patients with chronic mitral regurgitation. 2003 , 107, 831-7	66
1491	Circulating levels of tumor necrosis factor correlate with indexes of depressed heart rate variability: a study in patients with mild-to-moderate heart failure. 2003 , 123, 716-24	72
1490	DGEM-Leitlinie Enterale Ernährung:Kardiologie und Pneumologie. 2003 , 28, 110-113	2
1489	Association of lipoproteins with cytokines and cytokine receptors in heart failure patients. Differences between ischaemic versus idiopathic cardiomyopathy. 2003 , 24, 2221-6	12
1488	Insulin: an endogenous cardioprotector. 2003 , 9, 375-83	74
1487	Quantification of proinflammatory cytokines in the urine of congestive heart failure patients. Its relationship with plasma levels. 2003 , 5, 27-31	18
1486	A role for cardiac mast cells in the pathogenesis of hypertensive heart disease. 2003 , 21, 1935-44	96
1485	Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. 2003 , 5, 33-40	126
1484	Prolonged alveolocapillary barrier damage after acute cardiogenic pulmonary edema. 2003 , 31, 1060-7	60
1483	Cytokine mediation of experimental heart failure-induced anhedonia. 2003 , 284, R666-73	47
1482	Metabolism and physiological functions of sphingolipids. 2003 , 33, 463-502	

1481	Calcium-dependent arrhythmias in transgenic mice with heart failure. 2003 , 284, H431-41	92
1480	Case reports of heart failure after therapy with a tumor necrosis factor antagonist. 2003 , 138, 807-11	304
1479	Catabolic/anabolic balance and muscle wasting in patients with COPD. 2003 , 124, 83-9	158
1478	Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure. 2003 , 105, 45-50	76
1477	Important factors other than dialysis adequacy associated with inadequate dietary protein and energy intakes in patients receiving maintenance peritoneal dialysis. 2003 , 77, 834-41	60
1476	Tumor necrosis factor-alpha polymorphism in Turkish patients with dilated cardiomyopathy. 2003 , 5, 161-3	11
1475	Enhanced expression of the apoptosis inducing ligand TRAIL in mononuclear cells after myocardial infarction. 2003 , 44, 833-44	19
1474	The origin of proinflammatory cytokines in patients with idiopathic dilated cardiomyopathy. 2003 , 18, 791-6	5
1473	Increased plasma levels of tumor necrosis factor-alpha in asymptomatic/"indeterminate" and Chagas disease cardiomyopathy patients. 2003 , 98, 407-11	88
1472	Overexpression of tumor necrosis factor-alpha increases production of hydroxyl radical in murine myocardium. 2003 , 284, H449-55	33
1471	Serum but not myocardial TNF-alpha concentration is increased in pacing-induced heart failure in rabbits. 2003 , 285, R463-9	31
1470	. 2003 ,	7
1469	Gender-related differences in myocardial inflammatory and contractile responses to major burn trauma. 2004 , 286, H202-13	40
1468	Effect of insulin therapy on nonglycemic variables during acute illness. 2004 , 10 Suppl 2, 63-70	19
1467	Etanercept: Questions and Answers. 2004 , 10a, 4-6	
1466	Chronic Inflammation in Peritoneal Dialysis: The Search for the Holy Grail?. 2004 , 24, 327-339	76
1465	Mechanism of cardiac depression after trauma-hemorrhage: increased cardiomyocyte IL-6 and effect of sex steroids on IL-6 regulation and cardiac function. 2004 , 287, H2183-91	85
1464	Strategies for developing biomarkers of heart failure. 2004 , 50, 265-78	37

1463	Cardiac cachexia. 2004 , 36, 518-29	124
1462	TNF and congestive heart failure: therapeutic possibilities. 2004 , 8, 203-9	15
1461	Shock overview. 2004 , 25, 619-28	8
1460	Diet and the prevention of coronary heart disease. 2004 , 21-55	0
1459	Chorea and related disorders. 2004 , 80, 527-34	66
1458	N-acetylcysteine treatment normalizes serum tumor necrosis factor-alpha level and hinders the progression of cardiac injury in hypertensive rats. 2004 , 110, 2003-9	56
1457	Elevated concentrations of CCL2 and tumor necrosis factor-alpha in chagasic cardiomyopathy. 2004 , 38, 943-50	104
1456	Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. 2004 , 15, 2186-94	194
1455	Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. 2004 , 25, 1021-8	141
1454	Cachexia in malaria and heart failure: therapeutic considerations in clinical practice. 2004 , 80, 642-9	12
1453	Tumor necrosis factor-alpha inhibits endothelial nitric-oxide synthase gene promoter activity in bovine aortic endothelial cells. 2004 , 279, 963-9	125
1452	The pro-apoptotic serum activity is an independent mortality predictor of patients with heart failure. 2004 , 25, 1620-5	15
1451	Oxidative stress during myocardial ischaemia and heart failure. 2004 , 10, 1699-711	152
1450	Resting energy expenditure and subsequent mortality risk in peritoneal dialysis patients. 2004 , 15, 3134-43	96
1449	CORRECTION. 2004 , 80, 649-649	0
1448	Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). 2004 , 109, 1594-602	856
1447	Fish oils--adjuvant therapy in chronic heart failure?. 2004 , 11, 267-74	9
1446	In vivo transfer of soluble TNF-alpha receptor 1 gene improves cardiac function and reduces infarct size after myocardial infarction in rats. 2004 , 18, 911-3	45

1445	Evidence for altered interleukin 18 (IL)-18 pathway in human heart failure. 2004 , 18, 1752-4	120
1444	Inflammatory mediators in chronic heart failure: an overview. 2004 , 90, 464-70	416
1443	Suppression of cytokines and nitric oxide production, and protection against lethal endotoxemia and viral myocarditis by a new NF-kappaB inhibitor. 2004 , 6, 137-44	32
1442	Pentoxifylline in ischemic, hypertensive and idiopathic-dilated cardiomyopathy: effects on left-ventricular function, inflammatory cytokines and symptoms. 2004 , 6, 195-201	29
1441	Transcardiac increase in tumor necrosis factor-alpha and left ventricular end-diastolic volume in patients with dilated cardiomyopathy. 2004 , 6, 173-80	17
1440	Inhibition of tumor necrosis factor receptor-1-mediated pathways has beneficial effects in a murine model of postischemic remodeling. 2004 , 287, H1369-77	51
1439	New insights into the pathological role of TNF-alpha in early cardiac dysfunction and subsequent heart failure after infarction in rats. 2004 , 287, H340-50	58
1438	Human endothelial progenitor cells tolerate oxidative stress due to intrinsically high expression of manganese superoxide dismutase. 2004 , 24, 2021-7	203
1437	N-acetylcysteine prevents the deleterious effect of tumor necrosis factor-(alpha) on calcium transients and contraction in adult rat cardiomyocytes. 2004 , 109, 406-11	63
1436	Studies on intragastric PCO2 at rest and during exercise as a marker of intestinal perfusion in patients with chronic heart failure. 2004 , 6, 403-7	51
1435	Restrictive filling pattern is associated with increased humoral activation and impaired exercise capacity in dilated cardiomyopathy. 2004 , 6, 735-43	12
1434	Elevated circulating levels of thioredoxin and stress in chronic heart failure. 2004 , 6, 883-90	73
1433	Increased expression of tumor necrosis factor-alpha converting enzyme and tumor necrosis factor-alpha in peripheral blood mononuclear cells in patients with advanced congestive heart failure. 2004 , 6, 869-75	24
1432	TNFalpha-induced ATF3 expression is bidirectionally regulated by the JNK and ERK pathways in vascular endothelial cells. 2004 , 9, 59-70	68
1431	Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation. 2004 , 126, 85-92	46
1430	Overexpression of tumor necrosis factor (TNF)alpha and TNFalpha receptor I in human viral myocarditis: clinicopathologic correlations. 2004 , 17, 1108-18	60
1429	Tumor necrosis factor alpha polymorphism in heart failure/cardiomyopathy. 2004 , 10, 289-92	17
1428	Inflammation and chronic heart failure-potential therapeutic role of intravenous immunoglobulin. 2004 , 3, 221-7	34

1427	Role of adenosine monophosphate deaminase-1 gene polymorphism in patients with congestive heart failure (influence on tumor necrosis factor-alpha level and outcome). 2004 , 93, 1260-4	20
1426	Outcome of subsequent pregnancy in patients with documented peripartum cardiomyopathy. 2004 , 93, 1441-3, A10	63
1425	Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. 2004 , 1033, 79-91	173
1424	The effect of medical treatment on the level of C-Reactive protein and leukocyte count in patients with congestive heart failure. 2004 , 13, 168-172	
1423	Beneficial effects of statins in patients with non-ischemic heart failure. 2004 , 93, 103-8	62
1422	[Immunactivation in chronic heart failure. Inflammatory mediators]. 2004 , 93 Suppl 4, IV24-30	3
1421	Tumour necrosis factor-alpha and the failing heart--pathophysiology and therapeutic implications. 2004 , 99, 18-28	106
1420	TNFalpha in patients with congestive heart failure. 2004 , 99, 12-7	6
1419	Tumor necrosis factor alpha serum levels and inflammatory response in acute ischemic stroke patients. 2004 , 24, 390-6	89
1418	Decreased total nitric oxide production in patients with duchenne muscular dystrophy. 2004 , 11, 534-7	20
1417	New pharmacological strategies in chronic heart failure. 2004 , 18, 491-501	4
1416	[From hypertension to heart failure-a pathophysiological continuum]. 2004 , 29, 239-47	1
1415	Physiology of the abnormal response of heart failure patients to exercise. 2004 , 6, 176-81	2
1414	Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here?. 2004 , 50, 1040-50	81
1413	TNF-alpha in vivo stimulates apoptosis in fibroblasts through caspase-8 activation and modulates the expression of pro-apoptotic genes. 2004 , 201, 341-8	49
1412	Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. 2004 , 109, 750-5	97
1411	Therapeutic potential of anticytokine therapy in congestive heart failure. 2004 , 4, 169-77	9
1410	Therapeutic effects of angiotensin (AT1) receptor antagonists: potential contribution of mechanisms other than AT1 receptor blockade. 2004 , 4, 361-8	18

1409	Norepinephrine induces apoptosis in neonatal rat cardiomyocytes through a reactive oxygen species-TNF alpha-caspase signaling pathway. 2004 , 62, 558-67	88
1408	Risk factors for heart failure. 2004 , 88, 1145-72	83
1407	Genetic predisposition to heart failure. 2004 , 88, 1173-92	17
1406	Utilidad clínica de los marcadores neurohormonales en la insuficiencia cardíaca. 2004 , 57, 347-356	9
1405	Clinical Use of Markers of Neurohormonal Activation in Heart Failure. 2004 , 57, 347-356	
1404	Relation of serum levels of mast cell tryptase of left ventricular systolic function, left ventricular volume or congestive heart failure. 2004 , 10, 31-5	10
1403	Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. 2004 , 43, 1439-44	492
1402	Anemia as a risk factor and therapeutic target in heart failure. 2004 , 44, 959-66	192
1401	Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. 2004 , 64, 1767-77	57
1400	Cardiovascular Pharmacogenetics. 2004 ,	
1399	Optimising outcomes in end-stage heart failure: differences in therapeutic responses between diverse ethnic groups. 2004 , 27 Suppl 1, 19-24	1
1398	Endotoxin sensitivity and immune competence in chronic heart failure. 2004 , 343, 135-9	8
1397	IL-6 levels in acute and post myocardial infarction: their relation to CRP levels, infarction size, left ventricular systolic function, and heart failure. 2004 , 15, 523-528	78
1396	Cytokines are not upregulated in adriamycin-induced cardiomyopathy and heart failure. 2004 , 36, 683-90	35
1395	Cytokine-induced nitric oxide inhibits mitochondrial energy production and induces myocardial dysfunction in endotoxin-treated rat hearts. 2004 , 37, 775-84	40
1394	Transplanted bone marrow cells repair heart tissue and reduce myocarditis in chronic chagasic mice. 2004 , 164, 441-7	79
1393	Wasting of the left ventricle in patients with cardiac cachexia: a cardiovascular magnetic resonance study. 2004 , 97, 15-20	25
1392	Endothelial function and proinflammatory cytokines in patients with ischemic heart disease and dilated cardiomyopathy. 2004 , 94, 301-5	63

1391	Towards defining heart failure in adults with congenital heart disease. 2004 , 97 Suppl 1, 15-23	44
1390	Change in circulating cytokines after 2 forms of exercise training in chronic stable heart failure. 2004 , 147, 100-5	68
1389	Microvascular alterations in patients with acute severe heart failure and cardiogenic shock. 2004 , 147, 91-9	334
1388	Infarction induced ventricular remodeling. 2004 , 78, 1507-10	2
1387	Lymphocyte Subpopulations and Hematologic Variables in Dogs with Congestive Heart Failure. 2004 , 18, 505-509	15
1386	Association between the TNF-2 allele and a better survival in cardiogenic shock. 2004 , 125, 2232-7	10
1385	Macrophage inhibitor, semapimod, reduces tumor necrosis factor-alpha in myocardium in a rat model of ischemic heart failure. 2004 , 44, 665-71	8
1384	Cytokine response to pulmonary thromboendarterectomy. 2004 , 126, 135-41	56
1383	Proinflammatory cytokines and skeletal muscle. 2004 , 7, 265-9	127
1382	Ethanol increases tumor necrosis factor-alpha receptor-1 (TNF-R1) levels in hepatic, intestinal, and cardiac cells. 2004 , 33, 9-15	17
1381	Ongoing myocardial damage in chronic heart failure is related to activated tumor necrosis factor and Fas/Fas ligand system. 2004 , 68, 747-50	54
1380	Curcumin ameliorates left ventricular function in rabbits with pressure overload: inhibition of the remodeling of the left ventricular collagen network associated with suppression of myocardial tumor necrosis factor-alpha and matrix metalloproteinase-2 expression. 2004 , 27, 198-202	35
1379	Statin therapy in heart failure. 2005 , 16, 630-4	5
1378	Rho-associated kinase modulates myocardial inflammatory cytokine responses. 2005 , 24, 53-8	23
1377	Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction. 2005 , 97, 418-26	104
1376	Anti-inflammatory effects of physical exercise. A new mechanism to explain the benefits of cardiac rehabilitation?. 2005 , 25, 339-42	10
1375	Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. 2005 , 108, 205-13	261
1374	Decreased serum lipoprotein levels as a guide for clinical severity in patients with idiopathic dilated cardiomyopathy. 2005 , 206, 219-24	4

1373	The dilemma of the strive for apoptosis in oncology: mind the heart. 2005 , 53, 101-13	9
1372	IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly. 2005 , 67, 1216-33	588
1371	The distribution of cardiac macrophages in myocardial ischaemia and cardiomyopathy. 2005 , 46, 314-9	29
1370	Impaired bradykinin response to ischaemia and exercise in patients with mild congestive heart failure during angiotensin-converting enzyme treatment. Relationships with endothelial function, coagulation and inflammation. 2005 , 130, 113-20	12
1369	Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. 2005 , 4, 162-70	48
1368	Targeted anticytokine therapy and the failing heart. 2005 , 95, 9C-16C; discussion 38C-40C	76
1367	Biologic effects and basic science of a novel immune-modulation therapy. 2005 , 95, 24C-29C; discussion 38C-40C	82
1366	Neurohormonal inhibition in heart failure: insights from recent clinical trials. 2005 , 96, 3L-9L	204
1365	Strong association between volume status and nutritional status in peritoneal dialysis patients. 2005 , 45, 891-902	88
1364	Surgical trauma affects the proinflammatory status after cardiac surgery to a higher degree than cardiopulmonary bypass. 2005 , 129, 760-6	78
1363	Tumor necrosis factor-alpha and involuntary weight loss in elderly, community-dwelling adults. 2005 , 25, 313-9	8
1362	The impact of exercise on body composition and nutritional intake in patients with heart failure. 2005 , 20, 148-54	4
1361	Percutaneous coronary intervention triggers a systemic inflammatory response in patients treated for in-stent restenosis -- comparison with stable and unstable angina. 2005 , 54, 187-93	25
1360	Clinical modifiers for heart failure following myocardial infarction. 2005 , 2, 165-73	1
1359	Treatment of anemia in the patient with heart failure. 2005 , 7, 327-32	3
1358	Update of TNF-alpha antagonists and cardiovascular disease in rheumatoid arthritis. 2005 , 7, 395-9	3
1357	Heart failure following anterior myocardial infarction: an indication for ventricular restoration, a surgical method to reverse post-infarction remodeling. 2004 , 9, 241-54	7
1356	Apoptosis and oncosis in acute coronary syndromes: assessment and implications. 2005 , 270, 177-200	45

- 1355 AT1 receptor blockade prevents cardiac dysfunction after myocardial infarction in rats. **2005**, 19, 251-9 17
- 1354 Depression of force production and ATPase activity in different types of human skeletal muscle fibers from patients with chronic heart failure. **2005**, 99, 2189-95 36
- 1353 Side Effects of the Biologic Agents for Psoriasis. **2005**, 11a, 12-16
- 1352 Inflammation in Chronic Kidney Disease. **2005**, 232-246
- 1351 Central angiotensin II-enhanced splenic cytokine gene expression is mediated by the sympathetic nervous system. **2005**, 289, H1683-91 81
- 1350 Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. **2005**, 7, 1126-32 84
- 1349 Blockade of NF-kappaB ameliorates myocardial hypertrophy in response to chronic infusion of angiotensin II. **2005**, 67, 689-98 81
- 1348 Exercise training in chronic heart failure: effects on pro-inflammatory markers. **2005**, 7, 189-93 42
- 1347 Increased expression of bradykinin type-1 receptors in endothelium of intramyocardial coronary vessels in human failing hearts. **2005**, 288, H2317-22 20
- 1346 Natriuretic peptides and E-selectin as predictors of acute deterioration in patients with inotrope-dependent heart failure. **2005**, 27, 899-905 25
- 1345 Anaemia, Polycythaemia and Chronic Heart Failure. **2005**, 1, 117-126 1
- 1344 Free radicals trigger TNF alpha-induced cardioprotection. **2005**, 65, 239-43 47
- 1343 The Ca²⁺-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. **2005**, 7, 882-7 72
- 1342 Blockade of NF-kappaB improves cardiac function and survival without affecting inflammation in TNF-alpha-induced cardiomyopathy. **2005**, 66, 520-9 76
- 1341 N-terminal brain natriuretic peptide is a more powerful predictor of mortality than endothelin-1, adrenomedullin and tumour necrosis factor-alpha in patients referred for consideration of cardiac transplantation. **2005**, 7, 253-60 26
- 1340 Anti-tumor necrosis factor- α therapies attenuate adaptive arteriogenesis in the rabbit. **2005**, 289, H1497-505 40
- 1339 p38 MAP kinase mediates inflammatory cytokine induction in cardiomyocytes and extracellular matrix remodeling in heart. **2005**, 111, 2494-502 121
- 1338 The obesity paradox: body mass index and outcomes in patients with heart failure. **2005**, 165, 55-61 569

1337	Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure. 2005 , 91, 32-7	51
1336	End stage ischaemic heart failure. 2005 , 91, 37	
1335	Myocardial cytokine gene expression is higher in aortic stenosis than in idiopathic dilated cardiomyopathy. 2005 , 91, 926-31	37
1334	[Physical exercise in older patients with chronic heart failure]. 2005 , 130, 710-6	0
1333	The severe cardiorenal syndrome: 'Guyton revisited'. 2005 , 26, 11-7	354
1332	The Role of Apoptosis in Myocardial Infarction and Heart Failure. 2005 , 483-519	1
1331	TNF-alpha inhibitors and congestive heart failure. 2005 , 4, 363-8	23
1330	IL-12 protects against coxsackievirus B3-induced myocarditis by increasing IFN-gamma and macrophage and neutrophil populations in the heart. 2005 , 174, 261-9	113
1329	C-reactive protein in heart failure: prognostic value and the effect of valsartan. 2005 , 112, 1428-34	329
1328	Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillation. 2005 , 91, 759-63	32
1327	Muscle fiber specific apoptosis and TNF-alpha signaling in sarcopenia are attenuated by life-long calorie restriction. 2005 , 19, 668-70	213
1326	B1 kinin receptor does not contribute to vascular tone or tissue plasminogen activator release in the peripheral circulation of patients with heart failure. 2005 , 25, 772-7	12
1325	Tumor necrosis factor-alpha, biologic agents and cardiovascular risk. 2005 , 14, 780-4	60
1324	Tumor necrosis factor-alpha-induced iron sequestration and oxidative stress in human endothelial cells. 2005 , 25, 2495-501	60
1323	Angiotensin II receptor blockade and ventricular remodelling. 2005 , 6, 43-8	32
1322	Postprandial Lipaemia, Haemostasis, Inflammatory Response and other Emerging Risk Factors for Cardiovascular Disease: The Influence of Fatty Meals. 2005 , 1, 23-34	21
1321	Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice. 2005 , 97, 380-90	141
1320	Combined periprocedural evaluation of CRP and TNF- α enhances the prediction of clinical restenosis and major adverse cardiac events in patients undergoing percutaneous coronary interventions. 2005 , 16, 173	3

1319	C-reactive protein predicts death in patients with non-ischemic cardiomyopathy. 2005 , 104, 196-201	10
1318	Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. 2005 , 178, 359-63	85
1317	Factor de necrosis tumoral alfa en la insuficiencia cardíaca: más preguntas que respuestas. 2005 , 58, 470-472	7
1316	Receptor-Signaling Pathways in Heart Failure. 2005 , 123-143	
1315	Endomyocardial biopsy and natural history of myocarditis. 2005 , 1, 391-406	5
1314	Novel neurohormonal antagonist strategies: vasopressin antagonism, anticytokine therapy, and endothelin antagonism in patients who have heart failure. 2005 , 1, 103-27	1
1313	Novel pathogenetic mechanisms in myocarditis: nitric oxide signaling. 2005 , 1, 345-61	
1312	Infliximab for the treatment of early rheumatoid arthritis. 2005 , 5, 405-17	9
1311	Physiologic testosterone therapy has no effect on serum levels of tumour necrosis factor-alpha in men with chronic heart failure. 2005 , 31, 271-83	21
1310	Inhibitor-kappaB kinase-beta regulates LPS-induced TNF-alpha production in cardiac myocytes through modulation of NF-kappaB p65 subunit phosphorylation. 2005 , 289, H2103-11	43
1309	Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications. 2005 , 37, 74-85	126
1308	Agents targeting inflammation in heart failure. 2005 , 14, 557-66	31
1307	Gene expression analysis of ischemic and nonischemic cardiomyopathy: shared and distinct genes in the development of heart failure. 2005 , 21, 299-307	139
1306	Left atrial function, cytokines and soluble apoptotic markers in mitral stenosis: effects of valvular replacement. 2005 , 99, 111-5	13
1305	Inflammation and endothelial dysfunction as therapeutic targets in patients with heart failure. 2005 , 100, 347-53	60
1304	Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels. 2005 , 103, 182-6	45
1303	Alterations in alpha adrenoreceptor density and localization after mechanical left ventricular unloading with the Jarvik flowmaker left ventricular assist device. 2005 , 24, 609-13	13
1302	Intracellular monocyte cytokine production and CD 14 expression are up-regulated in severe vs mild chronic heart failure. 2005 , 24, 854-9	26

1301	Suppressed expression of GTP cyclohydrolase I mRNA and accelerated expression of inducible nitric oxide synthase mRNA in endomyocardial biopsy specimens from patients with dilated cardiomyopathy. 2005 , 353, 103-7	4
1300	Leptin as a new diagnostic tool in chronic heart failure. 2005 , 362, 1-11	51
1299	Insulin-like growth factor-1 and muscle wasting in chronic heart failure. 2005 , 37, 2023-35	26
1298	Cardiac remodeling and failure: from molecules to man (Part I). 2005 , 14, 1-11	90
1297	Neuroendocrine and cytokine profile of chronic mild stress-induced anhedonia. 2005 , 84, 697-706	179
1296	Ischemia/reperfusion injury at the intersection with cell death. 2005 , 38, 21-33	89
1295	P2 receptors in human heart: upregulation of P2X6 in patients undergoing heart transplantation, interaction with TNFalpha and potential role in myocardial cell death. 2005 , 39, 929-39	41
1294	A pilot study of associated factors of weight changes in community-dwelling patients with Alzheimer's disease. 2005 , 25, 111-118	6
1293	Determinants of inducible brain natriuretic peptide promoter activity. 2005 , 128, 169-76	30
1292	Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure. 2005 , 150, 1220-7	59
1291	Tumor Necrosis Factor-Alpha in Heart Failure: More Questions Than Answers. 2005 , 58, 470-472	1
1290	Upregulation of A2A adenosine receptor expression by TNF-alpha in PBMC of patients with CHF: a regulatory mechanism of inflammation. 2005 , 11, 67-73	34
1289	Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. 2005 , 11, 91-8	100
1288	Effects of different degrees of sympathetic antagonism on cytokine network in patients with ischemic dilated cardiomyopathy. 2005 , 11, 213-9	17
1287	Dietary fat intake and proinflammatory cytokine levels in patients with heart failure. 2005 , 11, 613-8	44
1286	Mitral valve abnormalities in congestive heart failure: an interplay between form and function?. 2005 , 45, 62-4	3
1285	Interstitial Fibrosis in Heart Failure. 2005 ,	1
1284	Pro-Inflammatory Cytokines and Cardiac Extracellular Matrix: Regulation of Fibroblast Phenotype. 2005 , 57-81	4

1283	Myocardial dysfunction in rheumatoid arthritis: epidemiology and pathogenesis. 2005 , 7, 195-207	52
1282	Cardiovascular Biomarkers. 2006 ,	2
1281	Historic Views on Cachexia in Humans with Special Reference to Cardiac Cachexia. 2006 , 31-37	
1280	Cachexia: Therapeutic Immunomodulation Beyond Cytokine Antagonism. 2006 , 741-753	1
1279	Cachexia in Cardiovascular Illness. 2006 , 349-361	1
1278	Neural and Neuroendocrine Mechanisms in Host Defense and Autoimmunity. 2006 ,	2
1277	Infliximab use in luminal Crohn's disease. 2006 , 35, 775-93	5
1276	Toxicity of infliximab in the course of treatment of Crohn's disease. 2006 , 5, 9-16	26
1275	Antioxidants and Cardiovascular Disease. 2006 ,	3
1274	Problems encountered during anti-tumour necrosis factor therapy. 2006 , 20, 757-90	169
1273	Acute renal failure: much more than a kidney disease. 2006 , 26, 105-13	105
1272	Safety of etanercept in psoriasis: a critical review. 2006 , 29, 675-85	24
1271	Therapeutic potential of ghrelin in the treatment of heart failure. 2006 , 66, 439-48	25
1270	[Heart failure, malnutrition and inflammation. Prevalence and relevant aspects in its assessment]. 2006 , 206, 122-8	1
1269	Biomarkers of Inflammation. 2006 , 295-318	
1268	B-type natriuretic peptide levels in obese patients with advanced heart failure. 2006 , 47, 85-90	186
1267	Activation of p38 mitogen-activated protein kinase contributes to the early cardiodepressant action of tumor necrosis factor. 2006 , 48, 545-55	44
1266	p38 mitogen-activated protein kinase: a future target for heart failure therapy?. 2006 , 48, 556-8	40

1265	Differential expression of MMPs and TIMPs in moderate and severe heart failure in a transgenic model. 2006 , 12, 314-25	22
1264	Effects of statin therapy on the development and progression of heart failure: mechanisms and clinical trials. 2006 , 12, 664-74	38
1263	Exercise intolerance in adults with congenital heart disease. 2006 , 24, 641-60, vii	50
1262	Protein-losing enteropathy after fontan operation: investigations into possible pathophysiologic mechanisms. 2006 , 82, 695-700	134
1261	The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure. 2006 , 151, 62-8	41
1260	The prevalence, nature, and importance of hematologic abnormalities in heart failure. 2006 , 151, 1313-21	46
1259	Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. 2006 , 152, 927.e1-6	52
1258	TNF-alpha-mediated cardiomyocyte apoptosis involves caspase-12 and calpain. 2006 , 345, 1558-64	68
1257	Understanding the pathophysiology of paediatric heart failure and its treatment. 2006 , 16, 398-405	6
1256	Cardiotrophin-1 induces monocyte chemoattractant protein-1 synthesis in human umbilical vein endothelial cells. 2006 , 33, 46-51	12
1255	TNFalpha-induced cytoprotection requires the production of free radicals within mitochondria in C2C12 myotubes. 2006 , 79, 2194-201	18
1254	Increased productivity of tumor necrosis factor-alpha in helper T cells in patients with systolic heart failure. 2006 , 111, 405-12	28
1253	Type D personality is associated with increased levels of tumour necrosis factor (TNF)-alpha and TNF-alpha receptors in chronic heart failure. 2006 , 113, 34-8	84
1252	Statin use and survival in patients with chronic heart failure--results from two observational studies with 5200 patients. 2006 , 112, 234-42	77
1251	The role of intravenous immunoglobulin in the treatment of chronic heart failure. 2006 , 112, 40-5	26
1250	Activation of JNK and xanthine oxidase by TNF-alpha impairs nitric oxide-mediated dilation of coronary arterioles. 2006 , 40, 247-57	70
1249	PPARdelta modulates lipopolysaccharide-induced TNFalpha inflammation signaling in cultured cardiomyocytes. 2006 , 40, 821-8	112
1248	Captopril prevents myosin light chain phosphatase isoform switching to preserve normal cGMP-mediated vasodilatation. 2006 , 41, 488-95	21

1247	Regulating the regulator: NF-kappaB signaling in heart. 2006 , 41, 580-91	148
1246	Neurohormones and inflammatory mediators in patients with heart failure undergoing cardiac resynchronization therapy: time courses and prediction of response. 2006 , 27, 1776-86	37
1245	Cachexia: lessons from melanocortin antagonism. 2006 , 17, 199-204	42
1244	Host Gene Profiling of Coxsackievirus B3 H3- and 10A1-infected Mouse Heart. 2006 , 36, 89	1
1243	In vitro endothelial cell activation and inflammatory responses in end-stage heart failure. 2006 , 101, 1466-73	7
1242	. 2006 ,	1
1241	Psoriasis and Co-Morbidities: Approach to Treatment with Biologics. 2006 , 12a, 10-15	1
1240	Role of Erythropoietin in the Correction of Anemia in Patients with Heart Failure. 205-216	
1239	Cycling Forward. 2006 , 26, 306-308	5
1238	Can the Inflammation Markers of Patients with High Peritoneal Permeability on Continuous Ambulatory Peritoneal Dialysis be Reduced on Nocturnal Intermittent Peritoneal Dialysis?. 2006 , 26, 341-348	18
1237	CYTOKINE MODEL OF PATHOGENESIS OF CHRONIC HEART FAILURE AND THE OPPORTUNITIES OF NEW THERAPEUTIC STRATEGY IN DECOMPENSATED PATIENTS. 2006 , 2, 63-70	3
1236	Tumor-necrosis-factor-alpha-gene-deficient mice have improved cardiac function through reduction of intercellular adhesion molecule-1 in myocardial infarction. 2006 , 70, 1635-42	12
1235	Tumor necrosis factor-alpha downregulates the voltage gated outward K ⁺ current in cultured neonatal rat cardiomyocytes: a possible cause of electrical remodeling in diseased hearts. 2006 , 70, 605-9	49
1234	Prediction of mortality by high-sensitivity C-reactive protein and brain natriuretic peptide in patients with dilated cardiomyopathy. 2006 , 70, 857-63	57
1233	Central neurotensin, alpha-melanocyte-stimulating hormone (alpha-MSH) is upregulated in patients with congestive heart failure. 2006 , 45, 429-34	12
1232	Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support. 2006 , 110, 483-9	76
1231	Diagnostic usefulness of B-type natriuretic peptide and functional consequences of muscle alterations in COPD and chronic heart failure. 2006 , 130, 1220-30	7
1230	Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. 2006 , 27, 2300-9	169

1229	Nutrition and cardiac cachexia. 2006 , 9, 18-23	24
1228	Nutritional recommendations for patients with heart failure. 2006 , 21, 261-8	19
1227	Nutrition in chronic heart failure with coexisting chronic kidney disease. 2006 , 21, 56-62	2
1226	Ghrelin, a novel growth hormone-releasing peptide, in the treatment of cardiopulmonary-associated cachexia. 2006 , 45, 127-34	49
1225	Anti-inflammatory effect of cardiac resynchronization therapy. 2006 , 29, 753-8	34
1224	The effects of pentoxifylline on the myocardial inflammation and ischemia-reperfusion injury during cardiopulmonary bypass. 2006 , 21, 57-61	17
1223	Heart failure alters MyoD and MRF4 expressions in rat skeletal muscle. 2006 , 87, 219-25	11
1222	Heart failure alters matrix metalloproteinase gene expression and activity in rat skeletal muscle. 2006 , 87, 437-43	23
1221	Myocardial apoptosis associated with the expression of proinflammatory cytokines during the course of myocardial infarction. 2006 , 19, 588-98	56
1220	Altered chemokine receptor profile on circulating leukocytes in human heart failure. 2006 , 44, 83-101	11
1219	The NF-kappaB regulatory network. 2006 , 6, 111-30	398
1218	Novel and potential future biomarkers for assessment of the severity and prognosis of chronic heart failure : a clinical review. 2006 , 11, 333-4	22
1217	Metabolic and immunologic derangements in cardiac cachexia: where to from here?. 2006 , 11, 57-64	23
1216	Micronutrients and their supplementation in chronic cardiac failure. An update beyond theoretical perspectives. 2006 , 11, 65-74	35
1215	Systemic inflammation in heart failure--the whys and wherefores. 2006 , 11, 83-92	208
1214	Low-level laser therapy can reduce lipopolysaccharide-induced contractile force dysfunction and TNF-alpha levels in rat diaphragm muscle. 2006 , 21, 238-44	22
1213	Inhibitory effects of edaravone on the production of tumor necrosis factor-alpha in the isolated heart undergoing ischemia and reperfusion. 2006 , 21, 108-15	16
1212	Future pharmacologic agents for treatment of heart failure in children. 2006 , 27, 533-51	19

1211	The effect of anemia on mortality in indigent patients with mild-to-moderate chronic heart failure. 2006 , 12, 75-9	7
1210	Inflammatory biomarkers in heart failure. 2006 , 12, 324-8	54
1209	Dynamic expression of the membrane attack complex (MAC) of the complement system in failing human myocardium. 2006 , 97, 1626-9	13
1208	ESPEN Guidelines on Enteral Nutrition: Cardiology and pulmonology. 2006 , 25, 311-8	95
1207	Cardiovascular biomarkers in CKD: pathophysiology and implications for clinical management of cardiac disease. 2006 , 48, 341-60	62
1206	Usefulness of neurohormonal markers in the diagnosis and prognosis of heart failure. 2006 , 8, E12-E17	1
1205	Continuous renal replacement therapy for congestive heart failure: the wearable continuous ultrafiltration system. 2006 , 52, 59-61	22
1204	A method of determining the dose of digoxin for heart failure in the modern era. 2006 , 166, 2539-45	25
1203	Comparative effects of pranidipine with amlodipine in rats with heart failure. 2006 , 77, 1-10	9
1202	Acute insulin resistance in myocardial ischemia: causes and consequences. 2006 , 10, 215-9	15
1201	Therapy insight: Use of melanocortin antagonists in the treatment of cachexia in chronic disease. 2006 , 2, 459-66	49
1200	Interleukin-8 synthesis, regulation, and steroidogenic role in H295R human adrenocortical cells. 2006 , 147, 891-8	27
1199	The tumor necrosis factor superfamily in heart failure. 2006 , 2, 101-11	10
1198	Associations between renal function, volume status and endotoxaemia in chronic kidney disease patients. 2006 , 21, 2788-94	107
1197	Statins in the treatment of chronic heart failure: biological and clinical considerations. 2006 , 71, 443-54	33
1196	Circulating levels of tumor necrosis factor-alpha correlate positively with severity of peripheral oedema in patients with right heart failure. 2006 , 8, 141-6	11
1195	Mechanisms leading to reversible mechanical dysfunction in severe CAD: alternatives to myocardial stunning. 2006 , 291, H2570-82	19
1194	Electrical remodeling of cardiac myocytes from mice with heart failure due to the overexpression of tumor necrosis factor-alpha. 2006 , 290, H2098-107	78

1193	Implantation of a biventricular defibrillator system in a patient with persistent left and absent right superior vena cava. 2006 , 92, 1424	2
1192	Circulating adiponectin concentrations in patients with congestive heart failure. 2006 , 92, 1420-4	152
1191	Risk Factor Analysis of Plasma Cytokines in Patients With Coronary Artery Disease by a Multiplexed Fluorescent Immunoassay. 2006 , 125, 906-913	40
1190	Aldose reductase mediates the lipopolysaccharide-induced release of inflammatory mediators in RAW264.7 murine macrophages. 2006 , 281, 33019-29	120
1189	The prognostic value of anemia, right-heart catheterization and neurohormones in chronic heart failure. 2006 , 4, 51-7	2
1188	Cardiovascular complications of severe acute respiratory syndrome. 2006 , 82, 140-4	228
1187	The future of cardiovascular biomarkers. 2006 , 4, 228-31	6
1186	Relationship between cytokines and tumour markers in patients with chronic heart failure. 2006 , 8, 270-4	77
1185	Differential effects of chitooligosaccharides on serum cytokine levels in aged subjects. 2006 , 9, 427-30	30
1184	Acute kidney injury associated with cardiac surgery. 2006 , 1, 19-32	704
1183	Heart transplantation in heart failure: the prognostic importance of body mass index at time of surgery and subsequent weight changes. 2007 , 9, 839-44	24
1182	Serum HER2 levels are increased in patients with chronic heart failure. 2007 , 9, 173-7	45
1181	Prognostic role of myocardial tumor necrosis factor-alpha and terminal complement complex expression in patients with dilated cardiomyopathy. 2007 , 9, 51-4	12
1180	Inhibition of L-type Ca ²⁺ channel current and negative inotropy induced by arachidonic acid in adult rat ventricular myocytes. 2007 , 293, C1594-604	19
1179	Delayed expression of cytokines after reperfused myocardial infarction: possible trigger for cardiac dysfunction and ventricular remodeling. 2007 , 293, H3014-9	33
1178	Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. 2007 , 73, 298-309	183
1177	Risk Factors for Development of Heart Failure. 2007 , 3, 1-9	1
1176	Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. 2007 , 28, 821-8	72

1175	Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. 2007 , 28, 829-35	139
1174	Chromogranin A: friend or foe of the failing myocardium?. 2007 , 28, 1052-3	4
1173	Role of bacterial endotoxin in chronic heart failure: the gut of the matter. 2007 , 28, 15-23	67
1172	Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. 2007 , 148, 3004-12	143
1171	Does nitric oxide contribute to progressive cardiac tissue damage and dysfunction after infarction?. 2007 , 9, 757-63	2
1170	Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. 2007 , 115, 1398-407	284
1169	TNFR1 and TNFR2 signaling interplay in cardiac myocytes. 2007 , 282, 35564-73	67
1168	What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. 2007 , 66, 1132-6	89
1167	Long-term survival after heart failure: a contemporary population-based perspective. 2007 , 167, 490-6	140
1166	N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. 2007 , 18, 321-30	110
1165	Effect of carnitine Q-gel (ubiquinol and carnitine) on cytokines in patients with heart failure in the Tishcon study. 2007 , 62, 349-54	27
1164	Inhibition of PPAR-alpha activity in mice with cardiac-restricted expression of tumor necrosis factor: potential role of TGF-beta/Smad3. 2007 , 292, H1443-51	29
1163	Mechanical stretch and angiotensin II increase interleukin-13 production and interleukin-13 receptor alpha2 expression in rat neonatal cardiomyocytes. 2008 , 72, 647-53	11
1162	Myocardial structural changes in long-term human severe sepsis/septic shock may be responsible for cardiac dysfunction. 2007 , 27, 10-8	68
1161	Different ventricular remodelling and autonomic modulation after long-term beta-blocker treatment in hypertensive, ischaemic and idiopathic dilated cardiomyopathy. 2007 , 8, 840-5	4
1160	Melanocortin interventions in cachexia: how soon from bench to bedside?. 2007 , 10, 457-62	20
1159	Genetic disruption of guanylyl cyclase/natriuretic peptide receptor-A upregulates ACE and AT1 receptor gene expression and signaling: role in cardiac hypertrophy. 2007 , 31, 193-202	21
1158	Progress in clinical neurosciences: The 'antiplatelet' agents and the role of the endothelium. 2007 , 34, 270-9	6

1157	Utility of plasma apelin and other indices of cardiac dysfunction in the clinical assessment of patients with dilated cardiomyopathy. 2007 , 140, 178-84	46
1156	Heart failure: a disease for the Internist. 2007 , 28 Suppl 1, S27-9	
1155	CX3CR1 receptor is up-regulated in monocytes of coronary artery diseased patients: impact of pre-inflammatory stimuli and renin-angiotensin system modulators. 2007 , 121, 387-95	34
1154	Enhanced activation of pro-inflammatory cytokines in mice lacking natriuretic peptide receptor-A. 2007 , 28, 893-9	37
1153	Nitric oxide (NO) is a new clinical biomarker of survival in the elderly patients and its efficacy might be nearly equal to albumin. 2007 , 16, 157-63	15
1152	Immune status evaluation of patients with chronic heart failure. 2007 , 37, 150-4	10
1151	Ligustrazine attenuates acute myocardium injury after thermal trauma. 2007 , 33, 321-7	12
1150	TNFalpha is required to confer protection in an in vivo model of classical ischaemic preconditioning. 2007 , 80, 1686-91	30
1149	Tumor necrosis factor-alpha alters calcium handling and increases arrhythmogenesis of pulmonary vein cardiomyocytes. 2007 , 80, 1806-15	82
1148	Association of polymorphisms within the promoter region of the tumor necrosis factor-alpha with clinical outcomes of rheumatic fever. 2007 , 44, 1873-8	56
1147	Endotoxin hypersensitivity in chronic heart failure. 2007 , 115, 159-63	12
1146	Atrial fibrillation is associated with increased neurohumoral activation and reduced exercise tolerance in patients with non-ischemic dilated cardiomyopathy. 2007 , 118, 206-14	28
1145	Nuclear factor-kappaB activity in peripheral blood mononuclear cells in cachectic and non-cachectic patients with chronic heart failure. 2007 , 122, 111-6	10
1144	Functional capacity and changes in the neurohormonal and cytokine status after long-term CRT in heart failure patients. 2007 , 121, 68-73	25
1143	Interferon-gamma induces chronic active myocarditis and cardiomyopathy in transgenic mice. 2007 , 171, 463-72	74
1142	A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure: the ACCLAIM trial rationale and design. 2007 , 23, 369-76	12
1141	Recent advances of TNF-alpha antagonists in rheumatoid arthritis and chronic heart failure. 2007 , 7, 617-25	25
1140	Central haemodynamics and peripheral muscle function during exercise in patients with chronic heart failure. 2007 , 32, 318-31	24

1139	Potential mechanisms of benefit with thalidomide in chronic heart failure. 2007 , 7, 127-34	5
1138	Thiol-based mechanisms of the thioredoxin and glutaredoxin systems: implications for diseases in the cardiovascular system. 2007 , 292, H1227-36	273
1137	Potential complications associated with the use of biologic agents for psoriasis. 2007 , 25, 207-13, vii	14
1136	Major depressive disorder and inflammatory markers in elderly patients with heart failure. 2007 , 48, 319-24	20
1135	Telomere length of circulating leukocytes is decreased in patients with chronic heart failure. 2007 , 49, 1459-64	219
1134	Altered intestinal function in patients with chronic heart failure. 2007 , 50, 1561-9	355
1133	Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. 2007 , 50, 1657-65	271
1132	Cardiac resynchronization improves microcirculation. 2007 , 13, 95-9	19
1131	French maritime pine bark extract inhibits viral replication and prevents development of viral myocarditis. 2007 , 13, 785-91	14
1130	Leg flow-mediated arterial dilation in elderly patients with heart failure and normal left ventricular ejection fraction. 2007 , 292, H1427-34	66
1129	Immune-inflammatory activation in heart failure. 2007 , 89, 183-90, 201-8	13
1128	. 2007 ,	2
1127	Diabetes, Left Ventricular Systolic Dysfunction and Chronic Heart Failure. 93-134	
1126	Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. 2007 , 56, 2905-12	427
1125	Circulating levels of tumor necrosis factor receptors are highly predictive of mortality in patients with rheumatoid arthritis. 2007 , 56, 3940-8	30
1124	Reverse epidemiology beyond dialysis patients: chronic heart failure, geriatrics, rheumatoid arthritis, COPD, and AIDS. 2007 , 20, 549-53	47
1123	Immune activation and inflammatory system in chronic heart failure: novel pathophysiological hypotheses generate new therapeutic options. 2007 , 61, 536-8	1
1122	Peroxisome proliferator-activated receptors and inflammation: take it to heart. 2007 , 191, 171-88	45

1121	Prenatal exposure to lipopolysaccharide results in increases in blood pressure and body weight in rats. 2007 , 28, 651-6	44
1120	Emerging role of anemia in heart failure. 2007 , 99, 15D-20D	33
1119	Impaired tissue responsiveness to organic nitrates and nitric oxide: a new therapeutic frontier?. 2007 , 116, 287-305	75
1118	Cardiac cachexia at a glance. 2007 , 22, 101-3	2
1117	Change in TNF-alpha receptor expression is a relevant event in doxorubicin-induced H9c2 cardiomyocyte cell death. 2007 , 27, 589-97	32
1116	Impact of adenosine receptor signaling and metabolism on pathophysiology in patients with chronic heart failure. 2007 , 30, 781-7	45
1115	Predicting survival in heart failure. 2007 , 9, 209-17	1
1114	Role of inflammation in the progression of heart failure. 2007 , 9, 236-41	139
1113	Expression of interferon-gamma and interleukin-4 production in CD4+ T cells in patients with chronic heart failure. 2007 , 22, 178-83	28
1112	P1 receptors and cytokine secretion. 2007 , 3, 13-25	50
1111	Autoimmunological features in inflammatory cardiomyopathy. 2007 , 96, 469-80	39
1110	Adenoviral beta-adrenergic receptor kinase inhibitor gene transfer improves exercise capacity, cardiac contractility, and systemic inflammation in a model of pressure overload hypertrophy. 2008 , 22, 373-81	4
1109	Lipopolysaccharide induces cellular hypertrophy through calcineurin/NFAT-3 signaling pathway in H9c2 myocardial cells. 2008 , 313, 167-78	43
1108	Should a statin be prescribed to every patient with heart failure?. 2008 , 13, 211-25	13
1107	Effects of exercise training on inflammatory markers in patients with heart failure. 2008 , 13, 39-49	38
1106	Exercise training in patients with heart failure: clinical outcomes, safety, and indications. 2008 , 13, 3-11	76
1105	Implications of chronic heart failure on peripheral vasculature and skeletal muscle before and after exercise training. 2008 , 13, 21-37	80
1104	Digoxin and digoxin-like immunoreactive factors (DLIF) modulate the release of pro-inflammatory cytokines. 2008 , 57, 519-23	17

1103	Immune modulation: role of the inflammatory cytokine cascade in the failing human heart. 2008 , 5, 69-74	55
1102	Malnutrition and chronic heart failure. 2008 , 1, 95-98	1
1101	Proinflammatory cytokines in acute myocardial infarction with and without cardiogenic shock. 2008 , 97, 298-305	73
1100	Adeno-associated virus vector-mediated systemic interleukin-10 expression ameliorates hypertensive organ damage in Dahl salt-sensitive rats. 2008 , 10, 368-74	30
1099	Thiazolidinediones as anti-inflammatory and anti-atherogenic agents. 2008 , 24, 14-26	77
1098	Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?. 2008 , 58, 667-77	166
1097	Ghrelin prevents doxorubicin-induced cardiotoxicity through TNF-alpha/NF-kappaB pathways and mitochondrial protective mechanisms. 2008 , 247, 133-8	92
1096	Biomarkers in heart failure. <i>New England Journal of Medicine</i> , 2008 , 358, 2148-59	59.2 923
1095	Down-regulation of MyoD gene expression in rat diaphragm muscle with heart failure. 2008 , 89, 216-22	16
1094	Genetics of humoral and cytokine activation in heart failure and its importance for risk stratification of patients. 2008 , 84, 251-5	2
1093	Nutritional and anti-inflammatory interventions in chronic heart failure. 2008 , 101, 89E-103E	117
1092	TNFalpha blockade in human diseases: an overview of efficacy and safety. 2008 , 126, 13-30	194
1091	Sleep-disordered breathing, cognitive functioning, and adherence in heart failure: linked through pathology?. 2008 , 23, 32-6	4
1090	Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. 2008 , 51, 415-26	125
1089	The Role of Central Melanocortins in Cachexia. 2007 , 59-68	
1088	Shock: Classification, Pathophysiology, and Approach to Management. 2008 , 379-422	2
1087	The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure. 2008 , 123, 102-7	52
1086	Cardioplegic ischemia or reperfusion: which is a main trigger for tumor necrosis factor production?. 2008 , 127, 186-91	10

1085	High impact of depression in heart failure: early diagnosis and treatment options. 2008 , 125, 220-31	35
1084	Hypothesis: myostatin is a mediator of cardiac cachexia. 2008 , 124, 131-3	13
1083	Fibrinogen synthesis is increased in cachectic patients with chronic heart failure. 2008 , 129, 363-7	16
1082	Prognostic value of pentraxin 3 in patients with chronic heart failure. 2008 , 130, 19-22	54
1081	Improved exercise capacity and reduced systemic inflammation after adenoviral-mediated SERCA-2a gene transfer. 2008 , 145, 257-65	8
1080	Albumin levels predict survival in patients with systolic heart failure. 2008 , 155, 883-9	261
1079	Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. 2008 , 156, 336-41	76
1078	Ultrafiltration for the management of acute decompensated heart failure. 2008 , 14, 754-9	12
1077	ARHGAP21 associates with FAK and PKCzeta and is redistributed after cardiac pressure overload. 2008 , 374, 641-6	18
1076	Cytokines, interstitial collagen and ventricular remodelling in dilated cardiomyopathy. 2008 , 124, 293-300	46
1075	Insulin resistance: a potential new target for therapy in patients with heart failure. 2008 , 26, 203-13	38
1074	The cholesterol paradox revisited: heart failure, systemic inflammation, and beyond. 2008 , 4, 141-51	20
1073	Pathological role of angiostatin in heart failure: an endogenous inhibitor of mesenchymal stem-cell activation. 2009 , 95, 283-9	7
1072	Interleukin-10 improves left ventricular function in rats with heart failure subsequent to myocardial infarction. 2008 , 10, 733-9	46
1071	A wearable hemofilter for continuous ambulatory ultrafiltration. 2008 , 73, 497-502	56
1070	Statins in heart failure. 2008 , 26, 573-87	4
1069	Tumor necrosis factor-alpha and mortality in heart failure: a community study. 2008 , 118, 625-31	116
1068	Platelets contribute to enhanced MCP-1 levels in patients with chronic heart failure. 2008 , 94, 65-9	12

1067	Lower levels of the host protective IL-10 in DCM--a feature of autoimmune pathogenesis?. 2008 , 41, 478-83	10
1066	Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure. 2008 , 4, 47-57	125
1065	Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. 2008 , 7, 617-32	35
1064	Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by peroxisome proliferator-activated receptors PPARalpha and PPARdelta. 2008 , 283, 29109-18	103
1063	Beneficial Actions of Polyunsaturated Fatty Acids in Cardiovascular Diseases: But, How and Why?. 2008 , 4, 2-31	10
1062	TNF-alpha gene promoter polymorphism at nucleotide -308 and the inflammatory response and oxidative stress induced by cardiac surgery: role of heart failure and medical treatment. 2008 , 34, 332-7	15
1061	Tumour necrosis factor alpha upregulates platelet CD40L in patients with heart failure. 2008 , 78, 515-22	24
1060	RAGE and modulation of ischemic injury in the diabetic myocardium. 2008 , 57, 1941-51	92
1059	Cardiac surgery as a cause of acute kidney injury: pathogenesis and potential therapies. 2008 , 23, 3-18	88
1058	Beta-blockade does not alter plasma cytokine concentrations and ventricular function in young adults with right ventricular dysfunction secondary to operated congenital heart disease. 2008 , 72, 747-52	15
1057	Leptin, a novel predictor of lung function in heart failure. 2008 , 134, 346-350	4
1056	Chronic heart failure and exercise intolerance: the hemodynamic paradox. 2008 , 4, 92-100	32
1055	Device-based nonspecific immunomodulation therapy (Celacade), and its potential role in the treatment of chronic heart failure. 2008 , 16, 280-7	6
1054	Evidence for activation of immune system in heart failure: is there a role for anti-inflammatory therapy?. 2008 , 23, 254-60	32
1053	Biologics and heart failure in rheumatoid arthritis: are we any wiser?. 2008 , 20, 327-33	26
1052	Cytokines and acute heart failure. 2008 , 36, S9-16	89
1051	Insulin inhibits tumor necrosis factor-alpha induction in myocardial ischemia/reperfusion: role of Akt and endothelial nitric oxide synthase phosphorylation. 2008 , 36, 1551-8	96
1050	Left ventricular assist device-induced molecular changes in the failing myocardium. 2008 , 23, 206-18	34

1049	Cardiotrophin-1 induces intercellular adhesion molecule-1 expression by nuclear factor B activation in human umbilical vein endothelial cells. 2008 , 121, 2592-2598	10
1048	Continuous Renal Replacement Therapy. 2008 , 301-326	
1047	Altered interleukin-1 receptor antagonist and interleukin-18 mRNA expression in myocardial tissues of patients with dilatated cardiomyopathy. 2008 , 14, 55-63	14
1046	Cytokine levels in pleural effusions of patients under intensive care. 2008 , 75, 262-8	4
1045	Malnutrition and chronic heart failure. 2008 , 1, 95-98	
1044	Characteristics and Causes of Immune Dysfunction Related to Uremia and Dialysis. 2008 , 28, 183-187	120
1043	N-terminal pro-B-type natriuretic Peptide in overweight and obese patients with and without diabetes: an analysis based on body mass index and left ventricular geometry. 2009 , 39, 538-44	11
1042	Efeito anti-inflamatório do treinamento físico na insuficiência cardíaca: papel do TNF- α e da IL-10. 2009 , 93, 692-700	7
1041	omega-3 polyunsaturated fatty acid supplementation for the treatment of heart failure: mechanisms and clinical potential. 2009 , 84, 33-41	79
1040	Oligonucleotide microarrays reveal regulated genes related to inward arterial remodeling induced by urokinase plasminogen activator. 2009 , 46, 177-87	13
1039	Leukocyte count and incidence of hospitalizations due to heart failure. 2009 , 2, 217-22	68
1038	N-terminal pro-brain natriuretic peptide independently predicts protein energy wasting and is associated with all-cause mortality in prevalent HD patients. 2009 , 29, 516-23	16
1037	IL-10 attenuates TNF-alpha-induced NF kappaB pathway activation and cardiomyocyte apoptosis. 2009 , 82, 59-66	128
1036	Anemia in heart failure: pathophysiologic insights and treatment options. 2009 , 5, 71-81	5
1035	Overview of emerging pharmacotherapy in chronic heart failure. 2009 , 10, 2055-74	4
1034	[Comorbidity: anemia and heart failure]. 2009 , 134, 825-30	8
1033	Von der Herzinsuffizienz zur kardialen Kachexie: Klinik und pathophysiologische Mechanismen. 2009 , 34, e1-e10	1
1032	AMPK and TNF-alpha at the crossroad of cell survival and death in ischaemic heart. 2009 , 84, 1-3	7

1031	Increased neutrophil lifespan in patients with congestive heart failure. 2009 , 11, 378-85	23
1030	Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. 2009 , 11, 444-52	114
1029	Adiponectin is increased in cardiac cachexia irrespective of body mass index. 2009 , 11, 567-72	37
1028	TNF-alpha inhibition attenuates adverse myocardial remodeling in a rat model of volume overload. 2009 , 297, H1462-8	53
1027	Evaluation of the sublingual microcirculation in cardiogenic shock. 2009 , 42, 141-8	43
1026	Immunological mechanisms of pentoxifylline in chronic heart failure. 2009 , 11, 113-8	48
1025	Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure. 2009 , 11, 1050-6	52
1024	Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction. 2009 , 81, 319-27	142
1023	Spinal cord stimulation improves ventricular function and reduces ventricular arrhythmias in a canine postinfarction heart failure model. 2009 , 120, 286-94	117
1022	Energy intake and expenditure profile in chronic peritoneal dialysis patients complicated with circulatory congestion. 2009 , 90, 1179-84	16
1021	Cardiac cachexia: a systematic overview. 2009 , 121, 227-52	244
1020	Association between cardiac function and metabolic factors including adiponectin in patients with acute myocardial infarction. 2009 , 53, 65-71	8
1019	PPAR gamma protects cardiomyocytes against oxidative stress and apoptosis via Bcl-2 upregulation. 2009 , 51, 169-74	68
1018	The nutrition implications of cardiac cachexia. 1994 , 52, 340-7	111
1017	ESPEN Guidelines on Parenteral Nutrition: on cardiology and pneumology. 2009 , 28, 455-60	41
1016	Roles and regulation of secretory and lysosomal acid sphingomyelinase. 2009 , 21, 836-46	212
1015	Glutamine preserves skeletal muscle force during an inflammatory insult. 2009 , 40, 1000-7	17
1014	Role of apoptosis in cardiovascular disease. 2009 , 14, 536-48	254

1013	Circulating proinflammatory cytokines and N-terminal pro-brain natriuretic peptide significantly decrease with recovery of left ventricular function in patients with dilated cardiomyopathy. 2009 , 324, 139-45	11
1012	Prognostic factors in chronic heart failure. A review of serum biomarkers, metabolic changes, symptoms, and scoring systems. 2009 , 34, 141-7	19
1011	[Percutaneous aortic valve replacement - pro]. 2009 , 34, 124-9	5
1010	Biomarkers in heart failure--better than history or echocardiography?. 2009 , 34, 581-8	8
1009	Biomarkers in inflammatory and noninflammatory cardiomyopathy. 2009 , 34, 614-23	5
1008	Chronic systemic inflammation accompanies impaired ventricular diastolic function, detected by Doppler imaging, in patients with newly diagnosed systolic heart failure (Hellenic Heart Failure Study). 2009 , 24, 22-6	49
1007	Plasma concentrations of TNF-alpha and its soluble receptors sTNFR1 and sTNFR2 in patients with coronary artery disease. 2009 , 74, 386-92	54
1006	Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders. 2009 , 5, 549-60	75
1005	Right ventricular beneficial effects of beta adrenergic receptor kinase inhibitor (betaARKct) gene transfer in a rat model of severe pressure overload. 2009 , 63, 331-6	7
1004	Tumor necrosis factor alpha -308 gene locus promoter polymorphism: an analysis of association with health and disease. 2009 , 1792, 163-72	152
1003	Gas6 evaluation in patients with acute dyspnea due to suspected pulmonary embolism. 2009 , 103, 589-94	17
1002	Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: Does it go beyond the RISK pathway?. 2009 , 47, 32-40	242
1001	A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. 2009 , 61, S1-S46	28
1000	PKC and MLCK-dependent, cytokine-induced rat coronary endothelial dysfunction. 2009 , 152, 76-83	29
999	Novel experimental model of pressure overload hypertrophy in rats. 2009 , 153, 287-94	15
998	Increased interleukin-13 levels in patients with chronic heart failure. 2009 , 131, 421-3	21
997	Does a low sodium diet modify heart rate variability? A randomised placebo-controlled double-blind trial. 2009 , 135, 390-3	2
996	Increased nitrotyrosine plasma levels in relation to systemic markers of inflammation and myeloperoxidase in chronic heart failure. 2009 , 135, 386-90	29

995	The interpretation of clinical trial data--wrongly ACCLAIM'ed?. 2009 , 158, 149-51	
994	B-type natriuretic peptide-guided management and outcome in patients with obesity and dyspnea--results from the BASEL study. 2009 , 158, 488-95	17
993	Red cell distribution width in heart failure: prediction of clinical events and relationship with markers of ineffective erythropoiesis, inflammation, renal function, and nutritional state. 2009 , 158, 659-66	398
992	The immune system and chronic heart failure: is the heart in control?. 2009 , 53, 1013-20	55
991	Effect of statin treatment on mortality in a large cohort of heart failure patients. 2009 , 62, 323-7	3
990	Role for TNF in atherosclerosis? Lessons from autoimmune disease. 2009 , 6, 410-7	208
989	Short term effects of milrinone on biomarkers of necrosis, apoptosis, and inflammation in patients with severe heart failure. 2009 , 7, 67	19
988	Regulation of arterial remodeling and angiogenesis by urokinase-type plasminogen activator. 2009 , 87, 231-51	44
987	Fatigue in cardiopulmonary disease. 2009 , 20, 389-404	9
986	Antioxidants in the prevention of myocardial ischemia/reperfusion injury. 2009 , 2, 673-95	17
985	Inflammation-sensitive plasma proteins are associated with increased incidence of heart failure: a population-based cohort study. 2009 , 202, 617-22	40
984	Prognostic value of high-sensitivity C-reactive protein in heart failure: a systematic review. 2009 , 15, 256-66	103
983	Sex-based cardiac physiology. 2009 , 71, 1-18	99
982	Efecto del tratamiento con estatinas en la mortalidad de una gran cohorte de pacientes con insuficiencia cardiaca. 2009 , 62, 323-327	3
981	Neuroendocrine effects on the heart and targets for therapeutic manipulation in heart failure. 2009 , 27, 187-93	30
980	Stress, depression and cardiovascular dysregulation: a review of neurobiological mechanisms and the integration of research from preclinical disease models. 2009 , 12, 1-21	300
979	What we may expect from biomarkers in heart failure. 2009 , 5, 463-70	11
978	Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. 2009 , 120, 2188-96	138

977	Impact of new technologies on metabolic care in the intensive care unit. 2009 , 12, 196-200	10
976	Cytokines and matrix metalloproteinases as potential biomarkers in chronic heart failure. 2009 , 3, 513-523	22
975	Nutrition in heart failure: an update. 2009 , 12, 384-91	34
974	The gut and intestinal bacteria in chronic heart failure. 2009 , 10, 22-8	56
973	Actions of Rho-Kinase Inhibitors in Cardiovascular Diseases. 2010 , 6, 11-18	1
972	The failure of immunomodulation therapy in heart failure: does the statins "paradigm" prove the rule?. 2010 , 8, 114-21	5
971	Inflammatory responses in embryonal cardiomyocytes exposed to LPS challenge: an in vitro model of deciphering the effects of LPS on the heart. 2010 , 16, 754-65	9
970	Pharmacological treatment of chronic systolic heart failure: are we scraping the bottom of the barrel?. 2010 , 11, 893-905	3
969	Tumor necrosis factor-alpha decreases sarcoplasmic reticulum Ca ²⁺ -ATPase expressions via the promoter methylation in cardiomyocytes. 2010 , 38, 217-22	107
968	Treatment of anemia in heart failure: potential risks and benefits of intravenous iron therapy in cardiovascular disease. 2010 , 18, 240-50	10
967	Ultrafiltration in the management of acute decompensated heart failure. 2010 , 25, 155-60	4
966	Iron regulatory hormone hepcidin decreases in chronic heart failure patients with anemia. 2010 , 74, 301-6	48
965	Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4. 2004 , 56, 757-68	34
964	Assessment of inflammation in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. 2010 , 37, 2079-85	43
963	Plasma levels of tumor necrosis factor-alpha and its receptors in patients with mitral stenosis and sinus rhythm undergoing percutaneous balloon valvuloplasty. 2010 , 25, 131-7	7
962	Short-term effect of levosimendan on free light chain kappa and lambda levels in patients with decompensated chronic heart failure. 2010 , 25, 392-9	12
961	Effects of telmisartan on markers of ventricular remodeling in patients with acute myocardial infarction: comparison with enalapril. 2010 , 25, 460-8	19
960	FGF-inducible 14-kDa protein (Fn14) is regulated via the RhoA/ROCK kinase pathway in cardiomyocytes and mediates nuclear factor-kappaB activation by TWEAK. 2010 , 105, 301-13	84

959	Direct relationship between levels of TNF-alpha expression and endothelial dysfunction in reperfusion injury. 2010 , 105, 453-64	51
958	Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. 2010 , 1, 9-21	166
957	Pathophysiology and treatment of inflammatory anorexia in chronic disease. 2010 , 1, 135-145	57
956	Biomarkers in heart failure: a clinical review. 2010 , 15, 251-73	19
955	Biomarkers of inflammation in heart failure. 2010 , 15, 331-41	153
954	Role and benefits of exercise in the management of patients with heart failure. 2010 , 15, 523-30	20
953	TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. 2010 , 127, 295-314	303
952	Microglia activation in the hypothalamic PVN following myocardial infarction. 2010 , 1326, 96-104	63
951	Impaired activation of IFN-gamma+CD4+ T cells in peripheral blood of patients with dilated cardiomyopathy. 2010 , 263, 224-9	8
950	Suppression of proinflammatory cytokine production by specific metabolites of Lactobacillus plantarum 10hk2 via inhibiting NF-B and p38 MAPK expressions. 2010 , 33, e41-9	36
949	Biomarkers in Heart Failure. 2010 , 27-43	
948	Left ventricular structure and function in patients with rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging. 2010 , 62, 940-51	86
947	Expression of the peptide hormone hepcidin increases in cardiomyocytes under myocarditis and myocardial infarction. 2010 , 21, 749-56	42
946	Regulation of cardiac angiotensin-converting enzyme and angiotensin AT1 receptor gene expression in Npr1 gene-disrupted mice. 2010 , 37, e70-7	7
945	Clinical Immunology. 2010 , 82-90	1
944	Systemic Circulation. 2010 , 91-116	
943	The beneficial effect of n-3 polyunsaturated fatty acids on doxorubicin-induced chronic heart failure in rats. 2010 , 38, 940-8	28
942	Minireview: Won't get fooled again: the nonmetabolic roles of peroxisome proliferator-activated receptors (PPARs) in the heart. 2010 , 24, 1111-9	30

941	Effects of free immunoglobulin light chains on viral myocarditis. 2010 , 106, 1533-40	23
940	The influence of diabetes on the relationship between N-terminal pro-B-type natriuretic peptide and body mass index. 2010 , 38, 1737-48	5
939	Roles of ghrelin in left-ventricular remodelling after acute myocardial infarction. 2010 , 2, 1-4	3
938	Heart Failure in Clinical Practice. 2010 ,	4
937	Serum resistin: physiology, pathophysiology and implications for heart failure. 2010 , 4, 445-52	11
936	Multiple cytokine biomarkers in heart failure. 2010 , 10, 147-57	16
935	Cardioprotective properties of bradykinin: role of the B(2) receptor. 2010 , 33, 772-7	36
934	Cardioprotective effects of a selective B(2) receptor agonist of bradykinin post-acute myocardial infarct. 2010 , 23, 562-8	37
933	Genetic regulation of endothelial inflammatory responses in baboons. 2010 , 30, 1628-33	15
932	Monocytes in heart failure: relationship to a deteriorating immune overreaction or a desperate attempt for tissue repair?. 2010 , 85, 649-60	57
931	Metabolic disorders in heart diseases with an inflammatory background. 2010 , 87, 403-5	1
930	The five most cited NDT articles from 1999 to 2004. 2010 , 25, 2818-24	1
929	Molecular determinants of the cardiometabolic phenotype. 2010 , 10, 109-23	4
928	Iron deficiency and heart disease: ironclad evidence?. 2010 , 2010, 348-50	5
927	Role of the hypothalamic PVN in the regulation of renal sympathetic nerve activity and blood flow during hyperthermia and in heart failure. 2010 , 298, F839-46	51
926	Use of biomarkers in evaluation of patients with heart failure. 2010 , 164, 88-117	2
925	Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. 2010 , CD007613	36
924	Endothelial dysfunction, measured by reactive hyperaemia using strain-gauge plethysmography, is an independent predictor of adverse outcome in heart failure. 2010 , 12, 477-83	40

923	Circulating cytokine levels in mice with heart failure are etiology dependent. 2010 , 108, 1357-64	38
922	Genetic and pharmacologic blockade of central melanocortin signaling attenuates cardiac cachexia in rodent models of heart failure. 2010 , 206, 121-30	41
921	The Effects and Safety of Exercise Training in Subjects With Chronic Heart Failure Do Elder Subjects Gain Similar Benefits?. 2010 , 4, 165-170	5
920	Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. 2010 , 55, 2129-37	284
919	Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. 2010 , 56, 1071-8	301
918	Hypothalamic mechanisms in cachexia. 2010 , 100, 478-89	103
917	New biomarkers in heart failure: applications in diagnosis, prognosis and guidance of therapy. 2010 , 63, 635-9	4
916	Innate inflammation in myocardial perfusion and its implication for heart failure. 2010 , 1207, 107-15	10
915	Current and potential roles of ghrelin in clinical practice. 2010 , 33, 823-38	20
914	Body mass, chronic heart failure, surgery and survival. 2010 , 29, 261-4	9
913	Anemia and renal failure as predictors of risk in a mainly non-ischemic heart failure population. 2010 , 141, 198-200	6
912	The relationship between tumor necrosis factor- β brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure. 2010 , 141, 39-43	51
911	Inflammation in right ventricular dysfunction due to thromboembolic pulmonary hypertension. 2010 , 144, 206-11	29
910	The cardiopulmonary continuum systemic inflammation as 'common soil' of heart and lung disease. 2010 , 145, 172-176	47
909	Serum interleukin-6 and C-reactive protein are markedly elevated in acute decompensated heart failure patients with left ventricular systolic dysfunction. 2010 , 49, 264-8	34
908	Differential regulation of TNF receptors by vagal nerve stimulation protects heart against acute ischemic injury. 2010 , 49, 234-44	36
907	Obesity and survival in patients with heart failure and preserved systolic function: a U-shaped relationship. 2010 , 159, 75-80	100
906	Serum albumin concentration and heart failure risk The Health, Aging, and Body Composition Study. 2010 , 160, 279-85	85

905	[Not Available]. 2010 , 63, 635-9	9
904	Ventricular assist devices today and tomorrow. 2010 , 24, 656-80	76
903	Early inflammatory response during the development of right ventricular heart failure in a rat model. 2010 , 12, 653-8	44
902	Biomarkers of Cardiac Injury. 2010 , 119-155	1
901	Statin treatment for patients with heart failure. 2010 , 7, 249-55	17
900	Diagnosing destabilized heart failure in the emergency setting: current and future biomarker tests. 2011 , 15, 327-40	
899	Direct comparison of serial B-type natriuretic peptide and NT-proBNP levels for prediction of short- and long-term outcome in acute decompensated heart failure. 2011 , 15, R1	71
898	Consequences of chronic inflammation in peritoneal dialysis. 2011 , 31, 159-71	27
897	Energy intake and energy expenditure profiles in peritoneal dialysis patients. 2011 , 21, 31-4	7
896	Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. 2011 , 14, 893-907	149
895	Regenerable electrochemical immunological sensing at DNA nanostructure-decorated gold surfaces. 2011 , 47, 6254-6	90
894	Nutritional considerations in adult cardiothoracic surgical patients. 2011 , 91, 857-75, ix	26
893	Fish oil decreases inflammation and reduces cardiac remodeling in rosiglitazone treated aging mice. 2011 , 63, 300-7	8
892	Inflammatory markers as related to disease severity in patients with chronic heart failure: limited effects of exercise training. 2011 , 71, 598-605	18
891	The Use of Biomarkers in the Evaluation of Heart Failure. 2011 , 545-559	1
890	Toll-like receptors: new players in myocardial ischemia/reperfusion injury. 2011 , 15, 1875-93	84
889	Serum interleukin-6 concentration reflects the extent of asymptomatic left ventricular dysfunction and predicts progression to heart failure in patients with stable coronary artery disease. 2011 , 54, 266-71	16
888	Antiinflammatory autoimmune cellular responses to cardiac troponin I in idiopathic dilated cardiomyopathy. 2011 , 17, 359-65	6

887	Dynamics in insulin resistance and plasma levels of adipokines in patients with acute decompensated and chronic stable heart failure. 2011 , 17, 1004-11	31
886	Respiratory muscle dysfunction and training in chronic heart failure. 2011 , 20, 289-94	35
885	Nutritional markers and prognosis in cardiac cachexia. 2011 , 146, 359-63	46
884	Ghrelin and cachexia: will treatment with GHSR-1a agonists make a difference for patients suffering from chronic wasting syndromes?. 2011 , 340, 97-105	38
883	Safety of biologic therapy in rheumatoid arthritis. 2011 , 7, 639-52	50
882	Serum C-reactive protein levels and death and cardiovascular events in mild to moderate chronic kidney disease. 2011 , 52, 180-4	7
881	Biomarkers of Heart Failure in Myocarditis and Dilated Cardiomyopathy. 2011 ,	2
880	Age Dependent Efficacy of Ace Inhibitors Among Chinese Cardiovascular Patients During Hospitalization Phase. 2011 , 1, 59-63	
879	Molecular Basis for Heart Failure. 2011 , 7-31	1
878	The Prognosis of Heart Failure. 2011 , 501-510	1
877	Activation of Inflammatory Mediators in Heart Failure. 2011 , 163-184	1
876	Alterations in Nutrition and Body Mass in Heart Failure. 2011 , 330-345	
875	Akt regulates IL-10 mediated suppression of TNF α induced cardiomyocyte apoptosis by upregulating Stat3 phosphorylation. 2011 , 6, e25009	46
874	Gender specific aspects of cell death in the cardiovascular system. 2011 , 17, 1046-55	14
873	Medical therapy of aortic aneurysms: a pathophysiology-based approach. 2011 , 9, 572-84	3
872	Stem cells in cardiovascular regeneration: from preservation of endogenous repair to future cardiovascular therapies. 2011 , 17, 3280-94	11
871	Role of toll-like receptors in cardiovascular diseases. 2011 , 121, 1-10	70
870	Targeting inflammation in heart failure with histone deacetylase inhibitors. 2011 , 17, 434-41	75

869	Tumour necrosis factor- α and its receptors in the beneficial effects of vagal stimulation after myocardial infarction in rats. 2011 , 38, 300-6	30
868	The Utility of Animal Models in Understanding Links between Psychosocial Processes and Cardiovascular Health. 2011 , 5, 164-179	20
867	Type-specific dysregulation of matrix metalloproteinases and their tissue inhibitors in end-stage heart failure patients: relationship between MMP-10 and LV remodelling. 2011 , 15, 773-82	17
866	Nox2 and Nox4 mediate tumour necrosis factor- α -induced ventricular remodelling in mice. 2011 , 15, 2601-13	19
865	Exercise training in congestive heart failure: risks and benefits. 2011 , 53, 419-28	46
864	Current perspectives on diagnosis of heart failure in long-term dialysis patients. 2011 , 57, 308-19	22
863	Testosterone modulation of cardiac β -adrenergic signals in a rat model of heart failure. 2011 , 172, 518-25	23
862	Cardiovascular safety of anti-TNF- α therapies: facts and unsettled issues. 2011 , 10, 631-5	36
861	Effects of statin treatment on cardiac function in patients with chronic heart failure: a meta-analysis of randomized controlled trials. 2011 , 34, 117-23	28
860	A review of causes and systemic approach to cardiac troponin elevation. 2011 , 34, 723-8	24
859	TNF α in myocardial ischemia/reperfusion, remodeling and heart failure. 2011 , 16, 49-69	175
858	Effect of TNF- α and IL-1 β genetic variants on the development of myocardial infarction in Turkish population. 2011 , 38, 5453-7	16
857	Serum soluble E-selectin and NT-proBNP levels additively predict mortality in diabetic patients with chronic heart failure. 2011 , 100, 587-94	10
856	A novel phenylpyridazinone, T-3999, reduces the progression of autoimmune myocarditis to dilated cardiomyopathy. 2011 , 26, 81-90	21
855	Significance of circulating hepatocyte growth factor in protein-losing enteropathy after Fontan operation. 2011 , 32, 917-23	1
854	Cachexia in heart disease: highlights from the ESC 2010. 2011 , 2, 63-69	22
853	Cardio-renal cachexia syndromes (CRCS): pathophysiological foundations of a vicious pathological circle. 2011 , 2, 135-142	24
852	Mechanistic clues in the cardioprotective effect of Terminalia arjuna bark extract in isoproterenol-induced chronic heart failure in rats. 2011 , 11, 48-57	38

851	Immune modulation in heart failure: past challenges and future hopes. 2011 , 8, 28-37	20
850	Increase of plasma IL-9 and decrease of plasma IL-5, IL-7, and IFN- γ in patients with chronic heart failure. 2011 , 9, 28	51
849	Cardiomyopathy in ankylosing spondylitis. 2011 , 63, 564-9	8
848	Biomarkers in pediatric heart failure: Their role in diagnosis and evaluating disease progression. 2011 , 31, 53-57	7
847	The role of monocytes and inflammation in the pathophysiology of heart failure. 2011 , 13, 1161-71	126
846	Follistatin-like 1 in chronic systolic heart failure: a marker of left ventricular remodeling. 2011 , 4, 621-7	50
845	Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction. 2011 , 57, 874-82	68
844	Sirt1 acts in association with PPAR α to protect the heart from hypertrophy, metabolic dysregulation, and inflammation. 2011 , 90, 276-84	202
843	Insulin says NO to cardiovascular disease. 2011 , 89, 516-24	118
842	Reversible heart failure: the role of inflammatory activation. 2011 , 87, 110-5	11
841	When are pro-inflammatory cytokines SAFE in heart failure?. 2011 , 32, 680-5	51
840	Modulation of novel cardiorenal and inflammatory biomarkers by intravenous nitroglycerin and nesiritide in acute decompensated heart failure: an exploratory study. 2011 , 4, 450-5	19
839	Increased inflammatory response in patients with dilated cardiomyopathy is associated with dyslipidemia: Effects of statin therapy. 2011 , 62, 55-61	0
838	Neurohormonal activation in acute heart failure: results from VERITAS. 2011 , 119, 96-105	44
837	Mechanisms involved in increased plasma brain natriuretic peptide after heart transplantation. 2011 , 89, 273-81	21
836	Lipotab, a polyherbal formulation, attenuates isoprenaline-induced left ventricular remodeling and heart failure in rats. 2011 , 30, 1000-8	4
835	Does Vitamin E and C Supplementation Improve the Recovery From Anterior Cruciate Ligament Surgery?. 2011 , 16, 114-128	0
834	Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting. 2011 , 300, H1973-82	83

833	New Treatment Alternatives in the Management of Non-infectious Intraocular Inflammations: Biologic Agents. 2011 , 41, 243-255	
832	Ambient temperature and biomarkers of heart failure: a repeated measures analysis. 2012 , 120, 1083-7	39
831	Septic cardiomyopathy. 2012 , 50, 187-201	4
830	Muscle oxygen transport and utilization in heart failure: implications for exercise (in)tolerance. 2012 , 302, H1050-63	197
829	Exercise training leads to a reduction of elevated myostatin levels in patients with chronic heart failure. 2012 , 19, 404-11	86
828	Mathematical modeling mechanisms of arrhythmias in transgenic mouse heart overexpressing TNF- α . 2012 , 302, H934-52	20
827	Leptin in anorexia and cachexia syndrome. 2012 , 2012, 287457	38
826	Slow Continuous Isolated Ultrafiltration as Nonpharmacological Therapy for Congestive Heart Failure: Facts and Perspectives. 2012 , 441-455	1
825	Differential white blood cell count and incident heart failure in men and women in the EPIC-Norfolk study. 2012 , 33, 523-30	37
824	The expanding role of epigenetics. 2012 , 2012, 7	9
823	New insights into HLA-G and inflammatory diseases. 2012 , 11, 448-63	31
822	The use of ghrelin and ghrelin receptor agonists as a treatment for animal models of disease: efficacy and mechanism. 2012 , 18, 4779-99	17
821	Chronic intermittent hypoxia exposure improves left ventricular contractility in transgenic mice with heart failure. 2012 , 113, 791-8	21
820	Cardiac intercellular communication: are myocytes and fibroblasts fair-weather friends?. 2012 , 5, 768-82	40
819	Adipose tissue inflammation and adiponectin resistance in patients with advanced heart failure: correction after ventricular assist device implantation. 2012 , 5, 340-8	69
818	Assessing the safety of biologic agents in patients with rheumatoid arthritis. 2012 , 51 Suppl 5, v38-47	99
817	Cachexia and sarcopenia: emerging syndromes of importance in dogs and cats. 2012 , 26, 3-17	106
816	Influence of Obesity and Malnutrition on Acute Heart Failure. 2012 , 65, 421-426	5

815	Tibolone has anti-inflammatory effects in estrogen-deficient female rats on the natriuretic peptide system and TNF-alpha. 2012 , 179, 55-60	16
814	Dilated cardiomyopathy and mitochondrial dysfunction in Sirt1-deficient mice: a role for Sirt1-Mef2 in adult heart. 2012 , 53, 521-31	60
813	Mechanism of TNF- α autocrine effects in hypoxic cardiomyocytes: initiated by hypoxia inducible factor 1 β presented by exosomes. 2012 , 53, 848-57	143
812	Cardiovascular safety of biologic therapies for the treatment of RA. 2011 , 8, 13-21	33
811	Etanercept: efficacy and safety for approved indications. 2012 , 11, 121-39	55
810	Influence of obesity and malnutrition on acute heart failure. 2012 , 65, 421-6	24
809	Lack of association between polymorphisms in the interleukin-1 gene cluster and familial thrombophilia. 2012 , 129, 629-34	
808	Chronic inflammatory cardiomyopathy of interferon β overexpressing transgenic mice is mediated by tumor necrosis factor- α . 2012 , 180, 73-81	18
807	S100A8/A9 complex as a new biomarker in prediction of mortality in elderly patients with severe heart failure. 2012 , 155, 26-32	29
806	The Role of Proinflammatory Cytokines in Regulation of Cardiac Bioelectrical Activity: Link to Mechanoelectrical Feedback. 2012 , 107-153	2
805	β 1-adrenergic receptor autoantibodies from heart failure patients enhanced TNF- α secretion in RAW264.7 macrophages in a largely PKA-dependent fashion. 2012 , 113, 3218-28	11
804	Skeletal muscle weakness caused by carrageenan-induced inflammation. 2012 , 46, 413-20	12
803	Effects of fish oil supplementation on inflammatory markers in chronic heart failure: a meta-analysis of randomized controlled trials. 2012 , 12, 77	35
802	Cardiac cachexia and the aged: death by water, wind, earth, and fire. 2012 , 60, 1999-2000	
801	Calpains, mitochondria, and apoptosis. 2012 , 96, 32-7	166
800	The role of red blood cell distribution width in cardiovascular and thrombotic disorders. 2011 , 50, 635-41	135
799	Systemic Disease and the Gastrointestinal Tract. 2012 , 839-843	
798	Thrombospondin-4, tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor Fn14: novel extracellular matrix modulating factors in cardiac remodelling. 2012 , 44, 793-804	16

797	Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. 2012 , 60, 1031-42	268
796	The influence of a biologically relevant substratum topography on human aortic and umbilical vein endothelial cells. 2012 , 102, 1224-33	26
795	Acute Kidney Injury Associated with Cardiac Surgery. 2012 , 37-52	2
794	The role of inflammation in the cardio-renal syndrome: a focus on cytokines and inflammatory mediators. 2012 , 32, 70-8	61
793	Effects of tetramethylpyrazine on cardiac function and mortality rate in septic rats. 2012 , 18, 610-5	4
792	Biomarkers. 2012 , 8, 207-24	7
791	Mechanical Stretch and Cytokines. 2012 ,	4
790	Acute myocardial infarction and cardiogenic shock: prognostic impact of cytokines: INF- α /TNF- α /MIP-1 β /G-CSF, and MCP-1 β 2012 , 107, 476-84	34
789	Relation between red cell distribution width and clinical outcome after surgery for congenital heart disease in children. 2012 , 33, 1021-5	11
788	A20 (TNFAIP3) alleviates CVB3-induced myocarditis via inhibiting NF- κ B signaling. 2012 , 7, e46515	50
787	Acute kidney injury and extrarenal organ dysfunction: new concepts and experimental evidence. 2012 , 116, 1139-48	129
786	Regulation of inflammatory cytokines in lipopolysaccharide-stimulated RAW 264.7 murine macrophage by 7-O-methyl-naringenin. 2012 , 17, 3574-85	78
785	Proinflammatory cytokine activation is linked to apoptotic mediator, soluble Fas level in patients with chronic heart failure. 2012 , 53, 182-6	22
784	. 2012 ,	13
783	Effects of levosimendan on TNF-alpha, BNP and MMP-1 in patients with heart failure with anemia. 2012 , 99, 659-64	1
782	Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. 2012 , 119, 651-65	463
781	Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. 2012 , 17, 325-44	240
780	Animal models of cardiorenal syndrome: a review. 2012 , 17, 411-20	26

779	TNF revisited: osteoprotegerin and TNF-related molecules in heart failure. 2012 , 9, 92-100	22
778	Leptin, leptin gene and leptin receptor gene polymorphism in heart failure with preserved ejection fraction. 2012 , 27, 271-9	15
777	Hypertension favors the inflammatory process in rats with experimentally induced periodontitis. 2012 , 47, 783-92	20
776	Inflammatory activation and carbohydrate antigen-125 levels in subjects with atrial fibrillation. 2012 , 42, 371-5	28
775	The effects of endothelial lipase gene (LIPG) variants on inflammation marker levels and atherosclerosis development. 2013 , 40, 5143-9	5
774	Relationships between right ventricular function, body composition, and prognosis in advanced heart failure. 2013 , 62, 1660-1670	99
773	Inflammatory Response in Cardiovascular Surgery. 2013 ,	2
772	Persistence of apoptosis and inflammatory responses in the heart and bone marrow of mice following whole-body exposure to silicon (Si) ions. 2013 , 52, 339-50	42
771	Cachexia in chronic heart failure: endocrine determinants and treatment perspectives. 2013 , 43, 253-65	15
770	Cardiac surgery-associated acute kidney injury. 2013 , 27, 433-46	34
769	Mechanisms for cachexia in heart failure. 2013 , 10, 307-14	32
768	Acute heart failure: patient characteristics and pathophysiology. 2013 , 10, 427-33	21
767	Positioning of inflammatory biomarkers in the heart failure landscape. 2013 , 6, 485-92	53
766	New and emerging biomarkers in left ventricular systolic dysfunction--insight into dilated cardiomyopathy. 2013 , 6, 516-27	24
765	Attenuation of monocyte chemotaxis--a novel anti-inflammatory mechanism of action for the cardio-protective hormone B-type natriuretic peptide. 2013 , 6, 545-57	18
764	Obesity in heart failure: impact on survival and treatment modalities. 2013 , 11, 1141-53	1
763	Hyperthermia by bathing in a hot spring improves cardiovascular functions and reduces the production of inflammatory cytokines in patients with chronic heart failure. 2013 , 28, 173-8	24
762	[Obesity and cardiac cachexia in chronic heart failure]. 2013 , 38, 610-7	3

761	Liver dysfunction and its nutritional implications in heart failure. 2013 , 29, 370-8	29
760	Angiotensin-converting enzyme and the tumor microenvironment: mechanisms beyond angiogenesis. 2013 , 305, R205-15	23
759	Anti-oxidative and cholesterol efflux capacities of high-density lipoprotein are reduced in ischaemic cardiomyopathy. 2013 , 15, 1215-9	42
758	Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study. 2013 , 163, 320-325	59
757	Is tumor necrosis factor-Friend or foe for chronic heart failure?. 2013 , 113, 492-4	22
756	Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist. 2013 , 72, 1813-8	43
755	Association between serum adipocyte fatty-acid binding protein concentrations, left ventricular function and myocardial perfusion abnormalities in patients with coronary artery disease. 2013 , 12, 105	23
754	The immunological axis in heart failure: importance of the leukocyte differential. 2013 , 18, 835-45	40
753	Heart failure and anti tumor necrosis factor-alpha in systemic chronic inflammatory diseases. 2013 , 24, 385-92	54
752	CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trials. 2013 , 15, 747-55	9
751	Treatment of cachexia: melanocortin and ghrelin interventions. 2013 , 92, 197-242	12
750	Viral kinetics are associated with changes in cytokines and chemokines in serum and target organs of SSM-CVB3-infected macaques. 2013 , 94, 174-81	6
749	Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. 2013 , 167, 1772-82	53
748	Mechanism and novel therapeutic approaches to wasting in chronic disease. 2013 , 75, 199-206	36
747	The WAP four-disulfide core domain protein HE4: a novel biomarker for heart failure. 2013 , 1, 164-9	29
746	Coronary microvascular dysfunction and diastolic load correlate with cardiac troponin T release measured by a highly sensitive assay in patients with nonischemic heart failure. 2013 , 62, 632-40	60
745	Therapeutic potential of tumour necrosis factor-alpha antagonists in patients with chronic heart failure. 2013 , 22, 323-7	30
744	An inverse correlation between TNF alpha serum levels and heart rate variability in patients with heart failure. 2013 , 62, 37-43	25

- 743 The prognostic implication of high-sensitivity C-reactive protein in patients with established cardiomyopathy. **2013**, 165, e17
- 742 Ivabradine inhibits the production of proinflammatory cytokines and inducible nitric oxide synthase in acute coxsackievirus B3-induced myocarditis. **2013**, 431, 450-5 18
- 741 Troponin leak in heart failure: moving forward to arrest cardiomyocyte attrition and promote myocardial regeneration. **2013**, 162, 137-9 3
- 740 Prealbumin improves death risk prediction of BNP-added Seattle Heart Failure Model: results from a pilot study in elderly chronic heart failure patients. **2013**, 168, 3334-9 25
- 739 Thrombospondins, potential drug targets for cardiovascular diseases. **2013**, 112, 4-12 28
- 738 Genetic prediction of heart failure incidence, prognosis and beta-blocker response. **2013**, 17, 205-19 4
- 737 Cardiorenal syndrome: pathophysiology and potential targets for clinical management. **2013**, 9, 99-111 99
- 736 Contributions of cardiomyocyte-cardiac fibroblast-immune cell interactions in heart failure development. **2013**, 108, 357 47
- 735 Is there a rationale for antiplatelet therapy in acute heart failure?. **2013**, 6, 869-76 4
- 734 Direct effects of TNF- α on local fuel metabolism and cytokine levels in the placebo-controlled, bilaterally infused human leg: increased insulin sensitivity, increased net protein breakdown, and increased IL-6 release. **2013**, 62, 4023-9 39
- 733 Tumor necrosis factor- α antagonists: Side effects and their management. **2013**, 79 Suppl 7, S35-46 18
- 732 Rheumatoid arthritis and cardiovascular disease: an update on treatment issues. **2013**, 25, 317-24 31
- 731 Cardiogenic Shock and the ICU Patient. **2013**, 14, 235-243
- 730 Baseline and 6-Week follow-up levels of PAF and activity of its metabolic enzymes in patients with heart failure and healthy volunteers--a pilot study. **2013**, 64, 522-8 3
- 729 Psychophysiological Remodeling of the Failing Human Heart. **2013**, 41, 7-12 9
- 728 Immunomodulatory effects of mesenchymal stromal cells revisited in the context of inflammatory cardiomyopathy. **2013**, 2013, 353097 12
- 727 Inflammatory markers are associated with left ventricular hypertrophy and diastolic dysfunction in a population-based sample of elderly men and women. **2013**, 27, 13-7 54
- 726 TNF, acting through inducibly expressed TNFR2, drives activation and cell cycle entry of c-Kit+ cardiac stem cells in ischemic heart disease. **2013**, 31, 1881-92 19

725	Evaluating Chagas disease progression and cure through blood-derived biomarkers: a systematic review. 2013 , 11, 957-76	36
724	Exercise intolerance in chronic heart failure--skeletal muscle dysfunction and potential therapies. 2013 , 77, 293-300	77
723	Inflammatory markers in heart failure: hype or hope?. 2013 , 14, 342-50	4
722	Obesity, brain natriuretic peptide levels and mortality in patients hospitalized with heart failure and preserved left ventricular systolic function. 2013 , 345, 211-7	19
721	Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure. 2013 , 14, 49-56	4
720	Nutritional Management of Cardiovascular Diseases. 2013 , 301-313	1
719	Relationship between the red cell distribution width and the one-year outcomes in Chinese patients with stable angina pectoris. 2013 , 52, 1769-74	17
718	Physiological regulation of pro-inflammatory cytokines expression in rat cardiovascular tissues by sympathetic nervous system and angiotensin II. 2013 , 32, 569-75	5
717	Statins in heart failure: do we need another trial?. 2013 , 9, 303-19	22
716	Mind and body: how the health of the body impacts on neuropsychiatry. 2013 , 4, 158	32
715	Sarcopenia, cachexia and congestive heart failure in the elderly. 2013 , 13, 58-67	35
714	Neuroimmune activation in chronic heart failure. 2013 , 13, 68-75	5
713	Association of interleukin 8 and myocardial recovery in patients with ST-elevation myocardial infarction complicated by acute heart failure. 2014 , 9, e112359	26
712	Inflammation and prolonged QT time: results from the Cardiovascular Disease, Living and Ageing in Halle (CARLA) study. 2014 , 9, e95994	24
711	Aerobic exercise training prevents heart failure-induced skeletal muscle atrophy by anti-catabolic, but not anabolic actions. 2014 , 9, e110020	38
710	Red cell distribution width and other red blood cell parameters in patients with cancer: association with risk of venous thromboembolism and mortality. 2014 , 9, e111440	50
709	Cardiac cachexia and muscle wasting: definition, physiopathology, and clinical consequences. 2014 , 319	1
708	NEW EMPHASES ON THE STUDY OF THE PATHOGENESIS OF CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION: FOCUS ON INFLAMMATORY MARKERS. 2014 , 10, 317-321	7

707	Cholinergic activity as a new target in diseases of the heart. 2015 , 20, 527-37	47
706	Interleukin-1 β reduces L-type Ca ²⁺ current through protein kinase C γ activation in mouse heart. 2014 , 289, 21896-908	36
705	The Pathophysiology of Cardiac Hypertrophy and Heart Failure. 2014 , 51-78	13
704	Soluble tumor necrosis factor receptors and heart failure risk in older adults: Health, Aging, and Body Composition (Health ABC) Study. 2014 , 7, 5-11	30
703	Rheumatoid arthritis and cardiac disease. 2014 , 9, 457-473	
702	CA 125 levels and left ventricular function in patients with end-stage renal disease on maintenance hemodialysis. 2014 , 36, 210-6	3
701	A meta-analysis of proinflammatory cytokines in chronic heart failure. 2014 , 6, 130-6	21
700	Oxidative stress markers and C-reactive protein are related to severity of heart failure in patients with dilated cardiomyopathy. 2014 , 2014, 147040	27
699	Urinary creatinine excretion, bioelectrical impedance analysis, and clinical outcomes in patients with CKD: the CRIC study. 2014 , 9, 2095-103	49
698	TNF-like weak inducer of apoptosis aggravates left ventricular dysfunction after myocardial infarction in mice. 2014 , 2014, 131950	15
697	Neopterin and beta-2 microglobulin relations to immunity and inflammatory status in nonischemic dilated cardiomyopathy patients. 2014 , 2014, 585067	4
696	Galectin-3 and plasma cytokines in patients with acute myocardial infarction. 2014 , 45, 336-41	9
695	Myocyte signalling in leucocyte recruitment to the heart. 2014 , 102, 270-80	42
694	Prognostic impact of systemic inflammatory diseases in elderly patients with congestive heart failure. 2014 , 107, 131-8	5
693	Association of nutritional risk index with metabolic biomarkers, appetite-regulatory hormones and inflammatory biomarkers and outcome in patients with chronic heart failure. 2014 , 68, 1293-300	15
692	Effect of hemodiafiltration with endogenous reinfusion on overt idiopathic chronic inflammation in maintenance hemodialysis patients: a multicenter longitudinal study. 2014 , 18, 758-66	7
691	Save life and improve quality: report from the 5th Congress of International Society for Hemodialysis. 2014 , 18, 163-71	2
690	Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation. 2014 , 16, 377-83	36

689	Pulmonary venous hypertension and mechanical strain stimulate monocyte chemoattractant protein-1 release and structural remodelling of the lung in human and rodent chronic heart failure models. 2014 , 69, 1120-7	12
688	Genetically altered mutant mouse models of guanylyl cyclase/natriuretic peptide receptor-A exhibit the cardiac expression of proinflammatory mediators in a gene-dose-dependent manner. 2014 , 155, 1045-56	22
687	Cardiovascular risk and the use of biologic agents in rheumatoid arthritis. 2014 , 16, 459	8
686	Statin-mediated low-density lipoprotein lowering in chronic congestive heart failure. 2014 , 347, 14-22	4
685	TWEAK-Fn14 Cytokine-Receptor Axis: A New Player of Myocardial Remodeling and Cardiac Failure. 2014 , 5, 50	29
684	Prostaglandin E2 does not attenuate adrenergic-induced cardiac contractile response. 2014 , 387, 963-8	1
683	The Immunoregulatory Role of Cytokines in Congestive Heart Failure. 2014 , 01,	
682	Role of platelets in NOX2 activation mediated by TNF α in heart failure. 2014 , 9, 179-85	15
681	Prognostic value of C-reactive protein as an inflammatory and N-terminal probrain natriuretic peptide as a neurohumoral marker in acute heart failure (from the Korean Heart Failure registry). 2014 , 113, 511-7	29
680	Colchicine and the failing heart: a "FINER" anti-inflammatory agent?. 2014 , 2, 138-40	1
679	Immunosenescence and inflammation characterize chronic heart failure patients with more advanced disease. 2014 , 174, 590-9	40
678	Possible synergism of physical exercise and ghrelin-agonists in patients with cachexia associated with chronic heart failure. 2014 , 26, 341-51	14
677	Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives. 2014 , 2, 1-14	40
676	Could interferon-gamma be a therapeutic target for treating heart failure?. 2014 , 19, 227-36	46
675	Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure. 2014 , 11, 146-55	37
674	Pediatric Critical Care Medicine. 2014 ,	
673	Oral budesonide as a therapy for protein-losing enteropathy in children after the Fontan operation. 2014 , 29, 712-6	12
672	Review article: elevated troponin: diagnostic gold or fool's gold?. 2014 , 26, 125-30	14

671	Ultrafiltration veineuse isolée dans la prise en charge de l'insuffisance cardiaque congestive et du syndrome cardio-renal. 2014 , 23, 603-617	
670	The case for treating refractory congestive heart failure with ultrafiltration. 2014 , 37 Suppl 2, 51-60	3
669	[Organ damage and cardiorenal syndrome in acute heart failure]. 2014 , 142 Suppl 1, 26-31	9
668	Depressive symptoms and the relationship of inflammation to physical signs and symptoms in heart failure patients. 2014 , 23, 404-13	14
667	Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population. 2014 , 13, 126	57
666	Cardiac biomarkers in heart failure. 2014 , 47, 327-37	39
665	Preventing Heart Failure in Inflammatory and Immune Disorders. 2014 , 8, 1	5
664	Core Knowledge in Critical Care Medicine. 2014 ,	
663	Cardiovascular disease in rheumatoid arthritis. 2014 , 40, 27-49	27
662	Mitochondrial protein synthesis is increased in oxidative skeletal muscles of rats with cardiac cachexia. 2014 , 34, 250-7	4
661	The effects of high thoracic epidural anesthesia on sympathetic activity and apoptosis in experimentally induced congestive heart failure. 2014 , 28, 317-22	6
660	Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target. 2014 , 19, 681-94	104
659	Recent insights on the molecular mechanisms and therapeutic approaches for cardiac cachexia. 2014 , 47, 8-15	31
658	Relationships between the serum cholesterol levels, production of monocyte proinflammatory cytokines and long-term prognosis in patients with chronic heart failure. 2014 , 53, 2415-24	15
657	Relationship between red blood cell distribution width and early-stage renal function damage in patients with essential hypertension. 2014 , 32, 2450-5; discussion 2456	20
656	Cardiac cachexia remains a clinical challenge. 2014 , 68, 1284-5	1
655	Diagnostic markers of acute myocardial infarction. 2015 , 3, 743-748	127
654	Immunopathogenesis of Myocarditis: The Interplay Between Cardiac Fibroblast Cells, Dendritic Cells, Macrophages and CD4+ T Cells. 2015 , 82, 1-9	21

653	Upregulated microRNA-214 enhances cardiac injury by targeting ITCH during coxsackievirus infection. 2015 , 12, 1258-64	20
652	Frailty in Advanced Heart Failure: A Consequence of Aging or a Separate Entity?. 2015 , 9, 39-46	24
651	Microparticles from apoptotic RAW 264.7 macrophage cells carry tumour necrosis factor- β functionally active on cardiomyocytes from adult mice. 2015 , 4, 28621	14
650	Effects of Statin Treatment on Inflammation and Cardiac Function in Heart Failure: An Adjusted Indirect Comparison Meta-Analysis of Randomized Trials. 2015 , 33, 338-46	35
649	Delayed administration of allogeneic cardiac stem cell therapy for acute myocardial infarction could ameliorate adverse remodeling: experimental study in swine. 2015 , 13, 156	31
648	Xenon triggers pro-inflammatory effects and suppresses the anti-inflammatory response compared to sevoflurane in patients undergoing cardiac surgery. 2015 , 19, 365	8
647	Tumor Necrosis Factor Related Apoptosis Inducing Ligand (Trail) in endothelial response to biomechanical and biochemical stresses in arteries. 2015 , 116, 2427-34	8
646	Reverse Signaling Contributes to Control of Chronic Inflammation by Anti-TNF Therapeutics. 2015 , 4, 123-140	4
645	Animal Models to Study Links between Cardiovascular Disease and Renal Failure and Their Relevance to Human Pathology. 2015 , 6, 465	29
644	TLR4 Expression Is Associated with Left Ventricular Dysfunction in Patients Undergoing Coronary Artery Bypass Surgery. 2015 , 10, e0120175	19
643	Serum Angiotensin-Like Protein 2 Concentrations Are Independently Associated with Heart Failure. 2015 , 10, e0138678	20
642	Left Ventricular Dysfunction and CXCR3 Ligands in Hypertension: From Animal Experiments to a Population-Based Pilot Study. 2015 , 10, e0141394	27
641	The case for inhibiting p38 mitogen-activated protein kinase in heart failure. 2015 , 6, 102	44
640	Validity of Oxygen-Ozone Therapy as Integrated Medication Form in Chronic Inflammatory Diseases. 2015 , 15, 127-38	19
639	Cardiac oxidative stress and inflammatory cytokines response after myocardial infarction. 2015 , 13, 26-36	153
638	Inflammatory Biomarkers in Refractory Congestive Heart Failure Patients Treated with Peritoneal Dialysis. 2015 , 2015, 590851	6
637	Malnutrition and Gut Flora Dysbiosis: Specific Therapies for Emerging Comorbidities in Heart Failure. 2015 , 2015, 382585	5
636	Vitamin D deficiency contributes to the reduction and impaired function of naïve CD45RA ⁺ regulatory T cell in chronic heart failure. 2015 , 2015, 547697	11

635	The Role of Cytokines in Clinical Heart Failure. 2015 , 191-203	
634	Left Ventricular T-Cell Recruitment Contributes to the Pathogenesis of Heart Failure. 2015 , 8, 776-87	140
633	Regulation of cardiac microRNAs induced by aerobic exercise training during heart failure. 2015 , 309, H1629-41	27
632	Cardiac cachexia: hic et nunc: "hic et nunc" - here and now. 2015 , 201, e1-12	15
631	Acetylcholine Attenuated TNF- β -Induced Apoptosis in H9c2 Cells: Role of Calpain and the p38-MAPK Pathway. 2015 , 36, 1877-89	16
630	Mechanisms and clinical consequences of untreated central sleep apnea in heart failure. 2015 , 65, 72-84	86
629	Inflammatory Biomarkers in Post-infarction Heart Failure and Cardiac Remodeling. 2015 , 105-116	
628	The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. 2015 , 74, 480-9	477
627	The inflammasome in myocardial injury and cardiac remodeling. 2015 , 22, 1146-61	100
626	Inflammatory cytokines as biomarkers in heart failure. 2015 , 443, 71-7	68
625	The role of neutrophil gelatinase associated lipocalin (NGAL) as biological constituent linking depression and cardiovascular disease. 2015 , 46, 23-32	28
624	Cancer antigen 125 levels and increased risk of new-onset atrial fibrillation. 2015 , 40 Suppl 2, 119-24	15
623	Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. 2015 , 89, 1401-38	337
622	Association between red blood cell distribution and renal function in patients with untreated type 2 diabetes mellitus. 2015 , 37, 659-63	18
621	Quality control systems in cardiac aging. 2015 , 23, 101-15	24
620	Differential effects of self-reported lifetime marijuana use on interleukin-1 alpha and tumor necrosis factor in African American adults. 2015 , 38, 527-34	11
619	Tanshinone IIA attenuates cardiac dysfunction in endotoxin-induced septic mice via inhibition of NADPH oxidase 2-related signaling pathway. 2015 , 28, 444-9	18
618	[Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritis]. 2015 , 55, 281-309	12

617	Left ventricular vs. biventricular mechanical support: Decision making and strategies for avoidance of right heart failure after left ventricular assist device implantation. 2015 , 198, 241-50	52
616	The duality of chemokines in heart failure. 2015 , 11, 523-36	1
615	Immunologic Network and Response to Intramyocardial CD34+ Stem Cell Therapy in Patients With Dilated Cardiomyopathy. 2015 , 21, 572-82	9
614	miRNA208/Mef2 and TNF- α in right ventricular dysfunction: the transition from hypertrophy to failure. 2015 , 116, 6-8	5
613	Tumor necrosis factor alpha stimulates p62 accumulation and enhances proteasome activity independently of ROS. 2015 , 31, 83-94	19
612	Vitamin D attenuates pro-inflammatory TNF- α cytokine expression by inhibiting NF- κ B/p65 signaling in hypertrophied rat hearts. 2015 , 71, 289-99	35
611	Innate immunity and the failing heart: the cytokine hypothesis revisited. 2015 , 116, 1254-68	375
610	Prognostic Value of Osteoprotegerin in Acute Heart Failure. 2015 , 31, 1266-71	7
609	Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. 2015 , 115, 1428-34	242
608	Intersections Between Microbiome and Heart Failure: Revisiting the Gut Hypothesis. 2015 , 21, 973-80	118
607	Tumor necrosis factor- β confers cardioprotection through ectopic expression of keratins K8 and K18. 2015 , 21, 1076-84	69
606	Supplementation of l-Alanyl-l-Glutamine and Fish Oil Improves Body Composition and Quality of Life in Patients With Chronic Heart Failure. 2015 , 8, 1077-87	26
605	Inhibition of Histone Deacetylase Activity Aggravates Coxsackievirus B3-Induced Myocarditis by Promoting Viral Replication and Myocardial Apoptosis. 2015 , 89, 10512-23	25
604	Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritis. 2015 , 55, 281-309	1
603	Markers of fibrosis, inflammation, and remodeling pathways in heart failure. 2015 , 443, 29-38	58
602	Serum cholinesterase is an important prognostic factor in chronic heart failure. 2015 , 30, 204-10	26
601	Association between serum total antioxidant status and coronary microvascular function in idiopathic dilated cardiomyopathy. 2015 , 40, 487-94	2
600	Psoriasis comorbidities: complications and benefits of immunobiological treatment. 2016 , 91, 781-789	21

599	Prevalence and Prognosis of Anemia in Dogs with Degenerative Mitral Valve Disease. 2016 , 2016, 4727054	9
598	Nutritional Status is Associated with Inflammation and Predicts a Poor Outcome in Patients with Chronic Heart Failure. 2016 , 23, 713-27	69
597	Decreased Peripheral Mitochondrial DNA Copy Number is Associated with the Risk of Heart Failure and Long-term Outcomes. 2016 , 95, e3323	39
596	Ghrelin and the Cardiovascular System. 2016 , 24, 288-297	32
595	Anticoagulation Therapy and NOACs in Heart Failure. 2017 , 243, 515-535	4
594	Mitogen-activated protein kinase p38 target regenerating islet-derived 3 β expression is upregulated in cardiac inflammatory response in the rat heart. 2016 , 4, e12996	5
593	Cyanotoxins at low doses induce apoptosis and inflammatory effects in murine brain cells: Potential implications for neurodegenerative diseases. 2016 , 3, 180-189	37
592	Dialysis modality and nutritional status are associated with variability of inflammatory markers. 2016 , 31, 1320-7	30
591	Heart Failure and Inflammatory Arthritis: the Relationship of Systemic Inflammation. 2016 , 10, 1	
590	Is There a Need for Early Seizure Prophylaxis After Traumatic Brain Injury?. 2016 , 8, 169-75	1
589	Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle Disorders. 2016 , 68, 476-532	233
588	Gastrointestinal and Liver Issues in Heart Failure. 2016 , 133, 1696-703	79
587	Molecular Mechanisms and New Treatment Paradigm for Atrial Fibrillation. 2016 , 9,	31
586	Predictive Cardiac Hypertrophy Biomarkers in Nonclinical Studies. 2016 , 385-396	
585	Transcriptional patterns of reverse remodeling with left ventricular assist devices: a consistent signature. 2016 , 13, 1029-1034	5
584	Serum Concentrations of Leptin and Adiponectin in Dogs with Myxomatous Mitral Valve Disease. 2016 , 30, 1589-1600	11
583	VCP746, a novel A1 adenosine receptor biased agonist, reduces hypertrophy in a rat neonatal cardiac myocyte model. 2016 , 43, 976-82	15
582	Cardiac Troponins in Dogs and Cats. 2016 , 30, 36-50	58

581	Cardiac cachexia: hic et nunc. 2016 , 7, 246-60	74
580	Emerging importance of chemokine receptor CXCR3 and its ligands in cardiovascular diseases. 2016 , 130, 463-78	42
579	Mesenchymal stem cells attenuate inflammatory processes in the heart and lung via inhibition of TNF signaling. 2016 , 111, 54	28
578	Proliferation and Recruitment Contribute to Myocardial Macrophage Expansion in Chronic Heart Failure. 2016 , 119, 853-64	210
577	Current and future developments in the field of central sleep apnoea. 2016 , 18, 1123-34	16
576	Chronic Osteomyelitis and Atrial Fibrillation: Revisiting the Link Between Inflammation Burden and Arrhythmia. 2016 , 32, 1366-1368	
575	The Effect of TNF Inhibitors on Cardiovascular Events in Psoriasis and Psoriatic Arthritis: an Updated Meta-Analysis. 2016 , 51, 240-7	55
574	Timing of Haemophilus influenzae type b vaccination after cardiac surgery. 2016 , 58, 691-7	5
573	Malnutrition and Cachexia in Heart Failure. 2016 , 40, 475-86	109
572	Altered Cholesterol Metabolism and Hypocholesterolemia in Patients with Single Ventricle following Fontan Palliation. 2016 , 171, 73-7	9
571	The Role of Congestion in Cardiorenal Syndrome Type 2: New Pathophysiological Insights into an Experimental Model of Heart Failure. 2015 , 6, 61-72	24
570	Knockdown of TNF- α by DNAzyme gold nanoparticles as an anti-inflammatory therapy for myocardial infarction. 2016 , 83, 12-22	62
569	Gene expression analysis during recovery process indicates the mechanism for innate immune injury and repair from Coxsackievirus B3-induced myocarditis. 2016 , 213, 314-321	6
568	mTOR, cardiomyocytes and inflammation in cardiac hypertrophy. 2016 , 1863, 1894-903	65
567	Pathogenic Gut Flora in Patients With Chronic Heart Failure. 2016 , 4, 220-7	166
566	The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure. 2016 , 21, 169-76	92
565	The fibrosis-cell death axis in heart failure. 2016 , 21, 199-211	144
564	Exploring the Microbiome in Heart Failure. 2016 , 13, 103-9	48

563	Cytokine expression in peripheral blood mononuclear cells of dogs with mitral valve disease. 2016 , 211, 45-51	8
562	Erectile dysfunction in heart failure rats is associated with increased neurogenic contractions in cavernous tissue and internal pudendal artery. 2016 , 145, 9-18	10
561	Vagal Stimulation in Heart Failure: An Anti-inflammatory Intervention?. 2016 , 165-182	1
560	Heart Failure Management: The Neural Pathways. 2016 ,	
559	The central role of hypothalamic inflammation in the acute illness response and cachexia. 2016 , 54, 42-52	76
558	Red Cell Distribution Width and the Risk of Mortality in Patients With Acute Heart Failure With or Without Cardiorenal Anemia Syndrome. 2016 , 117, 399-403	8
557	Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk. 2017 , 37, 151-167	32
556	Molecular mechanism of sarcopenia and cachexia: recent research advances. 2017 , 469, 573-591	75
555	Cardiometabolic biomarkers are predictors of readmission and death in patients hospitalized for acute dyspnea. 2017 , 35, 610-614	3
554	Can Vaccinations Improve Heart Failure Outcomes?: Contemporary Data and Future Directions. 2017 , 5, 194-203	35
553	Serum IL-8 is a marker of white-matter hyperintensities in patients with Alzheimer's disease. 2017 , 7, 41-47	19
552	Prognostic value of simple frailty and malnutrition screening tools in patients with acute heart failure due to left ventricular systolic dysfunction. 2017 , 106, 533-541	59
551	BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study. 2017 , 233, 61-66	24
550	Inflammation and metabolic cardiomyopathy. 2017 , 113, 389-398	124
549	Metabolites of Hypoxic Cardiomyocytes Induce the Migration of Cardiac Fibroblasts. 2017 , 41, 413-421	16
548	Role of Inflammation in Heart Failure. 2017 , 19, 27	129
547	Muscle wasting and cachexia in heart failure: mechanisms and therapies. 2017 , 14, 323-341	160
546	Use of Tumor Necrosis Factor Alpha Inhibitors for Inflammatory Bowel Disease Patients with Concurrent Heart Failure. 2017 , 62, 1597-1606	3

545	Do We Really Need Another Biomarker for Heart Failure?. 2017 , 23, 433	
544	Orosomucoid as prognosis factor associated with inflammation in acute or nutritional status in chronic heart failure. 2017 , 228, 488-494	9
543	Autoantibody profiling on a plasmonic nano-gold chip for the early detection of hypertensive heart disease. 2017 , 114, 7089-7094	22
542	Electrochemical biosensor platform for TNF- α cytokines detection in both artificial and human saliva: Heart failure. 2017 , 251, 1026-1033	57
541	Heart Failure. 2017 ,	4
540	Facile endothelium protection from TNF- α inflammatory insult with surface topography. 2017 , 138, 131-141	8
539	The impact of obesity on heart failure. 2017 , 32, 196-202	19
538	Cellular interplay via cytokine hierarchy causes pathological cardiac hypertrophy in RAF1-mutant Noonan syndrome. 2017 , 8, 15518	15
537	The selective estrogen receptor modulators (SERMs) raloxifene and tamoxifen improve ANP levels and decrease nuclear translocation of NF- κ B in estrogen-deficient rats. 2017 , 69, 798-805	7
536	ERBB signaling attenuates proinflammatory activation of nonclassical monocytes. 2017 , 312, H907-H918	27
535	Prognostic value of malnutrition assessed by Controlling Nutritional Status score for long-term mortality in patients with acute heart failure. 2017 , 230, 529-536	73
534	Beyond Natriuretic Peptides for Diagnosis and Management of Heart Failure. 2017 , 63, 211-222	25
533	Skeletal muscle alterations in HFrEF vs. HFpEF. 2017 , 14, 489-497	19
532	Immunity, Inflammation, and Oxidative Stress in Heart Failure: Emerging Molecular Targets. 2017 , 31, 593-608	52
531	Comparison of In-Hospital Outcomes After Percutaneous Revascularization for Peripheral Arterial Disease in Patients With a Body Mass Index of >30 kg/m Versus ≤ 30 kg/m (from the National Inpatient Sample). 2017 , 120, 1648-1652	15
530	Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study). 2017 , 121, 1279-1290	105
529	The role of procalcitonin in acute heart failure patients. 2017 , 4, 203-208	18
528	Sex Differences in Muscle Wasting. 2017 , 1043, 153-197	80

527	TNFR2 Stimulation Promotes Mitochondrial Fusion via Stat3- and NF- κ B-Dependent Activation of OPA1 Expression. 2017 , 121, 392-410	47
526	Proinflammatory Cytokines Mediate GPCR Dysfunction. 2017 , 70, 61-73	8
525	The Immunology of Cardiovascular Homeostasis and Pathology. 2017 ,	7
524	Immune-Mediated Heart Disease. 2017 , 1003, 145-171	9
523	Association between the body mass index and the clinical findings in patients with acute heart failure: evaluation of the obesity paradox in patients with severely decompensated acute heart failure. 2017 , 32, 600-608	21
522	Activation of GPER ameliorates experimental pulmonary hypertension in male rats. 2017 , 97, 208-217	20
521	A U-shaped association of body mass index and all-cause mortality in heart failure patients: A dose-response meta-analysis of prospective cohort studies. 2017 , 35, e12232	17
520	Inflammation versus mechanical stretch biomarkers over time in acutely decompensated heart failure with reduced ejection fraction. 2017 , 226, 53-59	41
519	Molecular mechanisms of cardiac electromechanical remodeling during Chagas disease: Role of TNF and TGF- β 2017 , 27, 81-91	15
518	Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure. 2017 , 183, 35-39	5
517	Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial. 2017 , 69, 526-537	218
516	Hemographic indices are associated with mortality in acute heart failure. 2017 , 7, 17828	8
515	Cardiovascular Immunology Research in Wuhan Union Hospital: Over the Past 25 years. 2017 , 2, 147-154	
514	Novel Concept of a Heart-Gut Axis in the Pathophysiology of Heart Failure. 2017 , 47, 663-669	30
513	Insights from Second-Line Treatments for Idiopathic Dilated Cardiomyopathy. 2017 , 4,	2
512	Metabolic and Biochemical Stressors in Diabetic Cardiomyopathy. 2017 , 4, 31	13
511	The Roles of Hypoxia Signaling in the Pathogenesis of Cardiovascular Diseases. 2017 , 24, 884-894	84
510	Integrative model of leukocyte genomics and organ dysfunction in heart failure patients requiring mechanical circulatory support: a prospective observational study. 2017 , 10, 52	4

509	Sterile Inflammation and Degradation Systems in Heart Failure. 2017 , 81, 622-628	13
508	TNF Receptor 1/2 Predict Heart Failure Risk in Type 2 Diabetes Mellitus Patients. 2017 , 58, 245-249	13
507	Interaction between interleukin-6 and angiotensin II receptor 1 in the hypothalamic paraventricular nucleus contributes to progression of heart failure. 2017 , 15, 4259-4265	1
506	Tumor Necrosis Factor-Alpha and Inflammation-Mediated Cardiac Injury. 2017 , 08,	2
505	[Epidemiological features of cardiorenal syndrome: a study of 36 cases in the Cardiology Department in Dakar]. 2017 , 28, 58	2
504	Neutrophil counts and their potential prognostic value in cardiovascular diseases. 2017 , 2, 30-30	3
503	Cardiac eccentric remodeling in patients with rheumatoid arthritis. 2018 , 8, 5867	5
502	Absence of Fibrosis and Inflammation by Cardiac Magnetic Resonance Imaging in Rheumatoid Arthritis Patients with Low to Moderate Disease Activity. 2018 , 45, 1078-1084	10
501	Leptin-Aldosterone-Nepriylsin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity. 2018 , 137, 1614-1631	105
500	Pro-Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction. 2018 , 7,	22
499	Effect of aerobic and resistance training on inflammatory markers in heart failure patients: systematic review and meta-analysis. 2018 , 23, 209-223	17
498	Effect of sodium salicylate on COX-2 expression in neonatal rat cardiomyocytes. 2018 , 14, 87-92	1
497	Are pathogenic intestinal bacteria present in stool specimens from patients with chronic heart failure?. 2018 , 91, 141-143	2
496	Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. 2018 , 131, 1568-1575	35
495	The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC. 2018 , 20, 445-459	67
494	Immunotherapy for cardiovascular disease. 2018 , 103, 493-500	6
493	Troponin in Heart Failure. 2018 , 14, 57-64	12
492	Neuroimmune Mechanisms of Depression in Adults with Heart Failure. 2018 , 1781, 145-169	1

491	A novel chronoamperometric immunosensor for rapid detection of TNF- α in human saliva. 2018 , 266, 477-484	38
490	High-sensitivity cardiac troponin I is a biomarker for occult coronary plaque burden and cardiovascular events in patients with rheumatoid arthritis. 2018 , 57, 1080-1088	12
489	Immune Modulation in Heart Failure: the Promise of Novel Biologics. 2018 , 20, 26	10
488	MicroRNA-34a protects myocardial cells against ischemia-reperfusion injury through inhibiting autophagy via regulating TNF α expression. 2018 , 96, 349-354	30
487	Proteomic Biomarkers of Heart Failure. 2018 , 14, 93-107	16
486	Thyroid hormones decrease the proinflammatory TLR4/NF- κ B pathway and improve functional parameters of the left ventricle of infarcted rats. 2018 , 461, 132-142	11
485	Gene expression and levels of IL-6 and TNF α in PBMCs correlate with severity and functional class in patients with chronic heart failure. 2018 , 187, 359-368	24
484	Novel applications for serum procalcitonin testing in clinical practice. 2018 , 18, 27-34	25
483	Treatment of Inflammatory Bowel Disease with Biologics. 2018 ,	1
482	Noninfectious and Nonmalignant Complications of Anti-TNF Therapy. 2018 , 231-260	
481	OBSOLETE: Stage B Heart Failure. 2018 ,	
480	The Impact of Obesity on the Cardiovascular System. 2018 , 2018, 3407306	146
479	Temporal Frame of Immune Cell Infiltration during Heart Failure Establishment: Lessons from Animal Models. 2018 , 19,	9
478	Therapeutic Approaches Targeting Inflammation in Cardiovascular Disorders. 2018 , 7,	15
477	Beneficial Effects of Vaccination on Cardiovascular Events: Myocardial Infarction, Stroke, Heart Failure. 2018 , 141, 98-106	24
476	Macrophages and Cardiovascular Health. 2018 , 98, 2523-2569	39
475	Heart Under Attack: Cardiac Manifestations of Inflammatory Bowel Disease. 2018 , 24, 2322-2326	17
474	Does Inflammation Link Clinical Depression and Coronary Artery Disease?. 2018 , 393-409	

473	The Role of Toll-Like Receptor Signaling in the Progression of Heart Failure. 2018 , 2018, 9874109	52
472	Inflammatory Mediators in Heart Failure. 2018 , 33-50	
471	Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. 2018 , 15, 505-522	802
470	Comparison of Mesenchymal Stem Cell Efficacy in Ischemic Versus Nonischemic Dilated Cardiomyopathy. 2018 , 7,	17
469	The effect of emphysema on readmission and survival among smokers with heart failure. 2018 , 13, e0201376	3
468	Deficiency of NOD1 Improves the β -Adrenergic Modulation of Ca Handling in a Mouse Model of Heart Failure. 2018 , 9, 702	5
467	Exposure to an unpredictable and competitive social environment affects behavior and health of transition dairy cows. 2018 , 101, 9309-9320	10
466	Bimodal Function of Anti-TNF Treatment: Shall We Be Concerned about Anti-TNF Treatment in Patients with Rheumatoid Arthritis and Heart Failure?. 2018 , 19,	18
465	Quantitative temporal analysis of protein dynamics in cardiac remodeling. 2018 , 121, 163-172	16
464	A peripheral blood transcriptome biomarker test to diagnose functional recovery potential in advanced heart failure. 2018 , 12, 619-635	7
463	HIF Activation Against CVD in CKD: Novel Treatment Opportunities. 2018 , 38, 267-276	22
462	Current indications for transplantation: stratification of severe heart failure and shared decision-making. 2018 , 7, 56-66	11
461	Role of cytokines and inflammation in heart function during health and disease. 2018 , 23, 733-758	109
460	Muscle Mass and Mortality After Cardiac Transplantation. 2018 , 102, 2101-2107	14
459	Pathological presentation of cardiac mitochondria in a rat model for chronic kidney disease. 2018 , 13, e0198196	9
458	Examining the Associations among Fibrocystic Breast Change, Total Lean Mass, and Percent Body Fat. 2018 , 8, 9180	5
457	The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. 2019 , 58, e3-e42	49
456	A reduction of BMI predicts the risk of rehospitalization and cardiac death in non-obese patients with heart failure. 2019 , 276, 166-170	7

455	Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure. 2019 , 125, 265-281	29
454	High red blood cell distribution width is closely associated with in-stent restenosis in patients with unstable angina pectoris. 2019 , 19, 175	6
453	Macrophage hypoxia signaling regulates cardiac fibrosis via Oncostatin M. 2019 , 10, 2824	45
452	Effects of interval training on inflammatory biomarkers in patients with ischemic heart failure. 2019 , 53, 213-219	4
451	The Quest for Antiinflammatory and Immunomodulatory Strategies in Heart Failure. 2019 , 106, 1198-1208	9
450	Cytokines in heart failure. 2019 , 93, 63-113	8
449	A Review of Cardiovascular Toxicity of Microcystins. 2019 , 11,	24
448	Increased frequency of CD4CD57 senescent T cells in patients with newly diagnosed acute heart failure: exploring new pathogenic mechanisms with clinical relevance. 2019 , 9, 12887	15
447	Targeting Regulatory T Cells by Addressing Tumor Necrosis Factor and Its Receptors in Allogeneic Hematopoietic Cell Transplantation and Cancer. 2019 , 10, 2040	14
446	Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis. 2019 , 124, 437-450	104
445	Leveraging Signaling Pathways to Treat Heart Failure With Reduced Ejection Fraction. 2019 , 124, 1618-1632	21
444	Bidirectional Relationship Between Cancer and Heart Failure: Old and New Issues in Cardio-oncology. 2019 , 5, 106-111	17
443	Prognostic significance of serum cholinesterase in patients with acute decompensated heart failure: a prospective comparative study with other nutritional indices. 2019 , 110, 330-339	12
442	Brain TACE (Tumor Necrosis Factor- α -Converting Enzyme) Contributes to Sympathetic Excitation in Heart Failure Rats. 2019 , 74, 63-72	12
441	Heart failure risk in systemic lupus erythematosus compared to diabetes mellitus and general medicaid patients. 2019 , 49, 389-395	11
440	T-cell recruitment to the heart: friendly guests or unwelcome visitors?. 2019 , 317, H124-H140	42
439	Identification of time-series differentially expressed genes and pathways associated with heart failure post-myocardial infarction using integrated bioinformatics analysis. 2019 , 19, 5281-5290	2
438	Association between C-reactive protein levels at hospital admission and long-term mortality in patients with acute decompensated heart failure. 2019 , 34, 1961-1968	23

437	Chlorogenic acid: A potent molecule that protects cardiomyocytes from TNF- α -induced injury via inhibiting NF- κ B and JNK signals. 2019 , 23, 4666-4678	23
436	Increased risk of cancer death in patients with chronic heart failure with a special reference to inflammation-A report from the CHART-2 Study. 2019 , 290, 106-112	9
435	Primary graft dysfunction after heart transplantation: a thorn amongst the roses. 2019 , 24, 805-820	30
434	Tumor Necrosis Factor- α Gene Polymorphism (G-308A) and Dilated Cardiomyopathy. 2019 , 60, 656-664	2
433	Heart Failure, the Inflammasome, and Interleukin-1 β Prognostic and Therapeutic?. 2019 , 73, 1026-1028	4
432	Pathophysiology and imaging of heart failure in women with autoimmune rheumatic diseases. 2019 , 24, 489-498	4
431	Tumor necrosis factor receptor-2 (TNFR2): an overview of an emerging drug target. 2019 , 23, 295-307	57
430	Biological evidence of the relationship between Helicobacter pylori and associated extragastric diseases. 2019 , 120, 12128-12140	5
429	Cardiorenal Syndrome and Heart Failure-Challenges and Opportunities. 2019 , 35, 1208-1219	21
428	Diabetic cardiomyopathy - A comprehensive updated review. 2019 , 62, 315-326	72
427	TNF receptor type 1 and TNF receptor type 2 mRNA expression was not associated with coronary artery disease in a group of Iranian Turks. 2019 , 120, 144-147	
426	Inflammation and Innate Immunity. 2019 , 57-59	
425	Sympathoexcitation in response to cardiac and pulmonary afferent stimulation of TRPA1 channels is attenuated in rats with chronic heart failure. 2019 , 316, H862-H872	4
424	Delayed febrile response with bloodstream infections in patients with continuous-flow left ventricular assist devices. 2019 , 67, 653-658	2
423	Relationships Between Ion Channels, Mitochondrial Functions and Inflammation in Human Aging. 2019 , 10, 158	24
422	Heart Failure. 2019 ,	
421	Heart-Kidney Cross-Talk. 2019 , 664-670.e3	1
420	JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure - Digest Version. 2019 , 83, 2084-2184	228

419	Assessment of therapeutic effects of statin on cardiac sympathetic nerve activity and cardiac events in patients with ischemic cardiomyopathy and mild to moderate heart failure. 2019 , 40, 159-168	5
418	Cardiac Injury, Maladaptation, and Heart Failure Incidence. 2019 , 81-96	1
417	Myocardial Inflammation, Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography With Computed Tomography, Is Associated With Disease Activity in Rheumatoid Arthritis. 2019 , 71, 496-506	13
416	Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept. 2019 , 39, 239-243	12
415	Stem cells transplantation positively modulates the heart-kidney cross talk in cardiorenal syndrome type II. 2019 , 275, 136-144	5
414	Risk factors for ileus after hip and knee arthroplasty. 2019 , 34, 261-267	3
413	Hypothalamic Inflammation at a Crossroad of Somatic Diseases. 2019 , 39, 11-29	12
412	Innate immune response in the pathogenesis of heart failure in survivors of myocardial infarction. 2019 , 316, H435-H445	12
411	Vagus Nerve Stimulation and the Cardiovascular System. 2020 , 10,	11
410	Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions. 2020 , 41, 1764-1774	7
409	Effects of carvedilol vs bisoprolol on inflammation and oxidative stress in patients with chronic heart failure. 2020 , 75, 140-147	9
408	Inflammatory bowel disease and the risk for cardiovascular disease: Does all inflammation lead to heart disease?. 2020 , 30, 463-469	18
407	Capacitance electrochemical biosensor based on silicon nitride transducer for TNF- α cytokine detection in artificial human saliva: Heart failure (HF). 2020 , 209, 120501	15
406	Molecular Basis of Heart Failure. 2020 , 1-27.e3	
405	Role of Innate Immunity in Heart Failure. 2020 , 103-114.e2	
404	Alterations in the Peripheral Circulation in Heart Failure. 2020 , 201-213.e6	
403	Mechanisms underlying the cross-talk between heart and cancer. 2020 , 598, 3015-3027	8
402	Residual inflammatory risk in coronary heart disease: incidence of elevated high-sensitive CRP in a real-world cohort. 2020 , 109, 315-323	19

401	Crohn's disease and ulcerative colitis are associated with different lipid profile disorders: a nationwide population-based study. 2020 , 51, 446-456	7
400	Neurohormones, inflammatory mediators, and cardiovascular injury in the setting of heart failure. 2020 , 25, 685-701	6
399	Chemokines profile in patients with chronic heart failure treated with cardiac resynchronization therapy. 2020 , 65, 102-110	0
398	Reappraisal of Inflammatory Biomarkers in Heart Failure. 2020 , 17, 9-19	9
397	Prognostic Significance of Serum Cholinesterase Level in Patients With Acute Decompensated Heart Failure With Preserved Ejection Fraction: Insights From the PURSUIT-HFpEF Registry. 2020 , 9, e014100	20
396	Translational research from animal models. 2020 , 35-60	
395	Sympathetic overactivation predicts body weight loss in patients with heart failure. 2020 , 223, 102625	0
394	Budesonide for Protein Losing Enteropathy in Patients with Fontan Circulation: A Systematic Review and Meta-Analysis. 2020 , 11, 85-91	6
393	Mechanisms for the transition from physiological to pathological cardiac hypertrophy. 2020 , 98, 74-84	28
392	Advanced Heart Failure and Cardiogenic Shock. 2020 , 9-17	
391	TNF-alpha inhibition for the treatment of cardiac sarcoidosis. 2020 , 50, 546-552	12
390	Using Global Criteria to Detect Malnutrition: Application in Disease States. 2020 , 35, 85-97	5
389	Sarcopenia and Cardiac Dysfunction. 2020 , 28, 197-202	1
388	Signaling via the Interleukin-10 Receptor Attenuates Cardiac Hypertrophy in Mice During Pressure Overload, but not Isoproterenol Infusion. 2020 , 11, 559220	4
387	Exercise as a Therapeutic Strategy for Sarcopenia in Heart Failure: Insights into Underlying Mechanisms. 2020 , 9,	14
386	Nutrition for the Hospitalized Patient and the Importance of Nutritional Assessment in Critical Care. 2020 , 1, 207-225	0
385	Solvent-free Synthesis of Halogenated Furo[2,3-d] pyrimidines and Their Cytotoxic Activity on the T47D Breast Cancer Cell Line. 2020 , 52, 374-380	1
384	Guanxinshutong capsule ameliorates cardiac function and architecture following myocardial injury by modulating ventricular remodeling in rats. 2020 , 130, 110527	2

383	The role of interferon- γ in cardiovascular disease: an update. 2020 , 69, 975-988	10
382	Heart Failure-Induced Skeletal Muscle Wasting. 2020 , 17, 299-308	4
381	Cardiovascular Risk Assessment and Impact of Medications on Cardiovascular Disease in Inflammatory Bowel Disease. 2021 , 27, 1107-1115	5
380	Remembering Beth Levine [The autophagy pioneer and woman extraordinaire. 2020 , 287, 4314-4321	
379	Increased red blood cell distribution width might predict left ventricular hypertrophy in patients with atrial fibrillation. 2020 , 99, e22119	0
378	Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart Failure. 2020 , 34, 849-863	47
377	Pathophysiological implications of hypoxia in human diseases. 2020 , 27, 63	39
376	Immunoglobulin free light chains as an inflammatory biomarker of heart failure with myocarditis. 2020 , 217, 108455	3
375	Targeted anti-inflammatory therapy is a new insight for reducing cardiovascular events: A review from physiology to the clinic. 2020 , 253, 117720	1
374	Low Insulin Is an Independent Predictor of All-Cause and Cardiovascular Death in Acute Decompensated Heart Failure Patients Without Diabetes Mellitus. 2020 , 9, e015393	2
373	An evidence of brain-heart disorder: mental stress-induced myocardial ischemia regulated by inflammatory cytokines. 2020 , 42, 670-675	4
372	Postcardiac injury syndrome after cardiac implantable electronic device implantation. 2020 , 45, 696-702	2
371	Association of soluble interleukin-2 receptor β and tumour necrosis factor receptor 1 with heart failure: The Multi-Ethnic Study of Atherosclerosis. 2020 , 7, 639-644	4
370	Gut microbiota, endotoxemia, inflammation, and oxidative stress in patients with heart failure, left ventricular assist device, and transplant. 2020 , 39, 880-890	17
369	Distinctive patterns of inflammation across the heart failure syndrome. 2021 , 26, 1333-1344	19
368	Gut dysbiosis and heart failure: navigating the universe within. 2020 , 22, 629-637	9
367	Canine Traditional Laboratory Tests and Cardiac Biomarkers. 2020 , 7, 320	0
366	FULL ISSUE PDF. 2020 , 5, I-CIV	

365	Characteristics of Patients with an Abnormally Decreased Plasma Xanthine Oxidoreductase Activity in Acute Heart Failure Who Visited the Emergency Department. 2020 , 145, 473-480	4
364	Association of Controlling Nutritional Status Score With 2-Year Clinical Outcomes in Patients With ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. 2020 , 29, 1758-1765	5
363	Impact of changes in body mass index after percutaneous coronary intervention on long-term outcomes in patients with coronary artery disease. 2020 , 35, 1657-1663	3
362	Diaphragm weakness and proteomics (global and redox) modifications in heart failure with reduced ejection fraction in rats. 2020 , 139, 238-249	3
361	Clonal Hematopoiesis: A New Step Linking Inflammation to Heart Failure. 2020 , 5, 196-207	12
360	Novel Basic Science Insights to Improve the Management of Heart Failure: Review of the Working Group on Cellular and Molecular Biology of the Heart of the Italian Society of Cardiology. 2020 , 21,	4
359	Reappraising the role of inflammation in heart failure. 2020 , 17, 269-285	138
358	Macrophage Activities in Myocardial Infarction and Heart Failure. 2020 , 2020, 4375127	13
357	Systems and Synthetic Immunology. 2020 ,	
356	Right Heart Failure and Cardiorenal Syndrome. 2020 , 38, 185-202	7
355	Energy Metabolism and Nutritional Status in Hospitalized Patients with Chronic Heart Failure. 2020 , 76, 129-139	3
354	History of Serious Mental Illness Is a Predictor of Morbidity and Mortality in Cardiac Surgery. 2021 , 111, 109-116	2
353	The Face Is the Mirror of the Soul. The Cardiovascular Physical Exam Is Not Yet Dead!. 2021 , 46, 100644	0
352	Clinical and Imaging Response to Tumor Necrosis Factor Alpha Inhibitors in Treatment of Cardiac Sarcoidosis: A Multicenter Experience. 2021 , 27, 83-91	12
351	Heal the heart through gut (hormone) ghrelin: a potential player to combat heart failure. 2021 , 26, 417-435	2
350	Myeloid differentiation factor 2 in the heart: Bench to bedside evidence for potential clinical benefits?. 2021 , 163, 105239	5
349	Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations. 2021 , 42, 257-265	19
348	Cancer Risk in the Heart Failure Population: Epidemiology, Mechanisms, and Clinical Implications. 2020 , 23, 7	6

347	Sacubitril-valsartan improves conduit vessel function and functional capacity and reduces inflammation in heart failure with reduced ejection fraction. 2021 , 130, 256-268	4
346	Factors associated with elevated plasma phenylalanine in patients with heart failure. 2021 , 53, 149-157	1
345	Dysphagia of cachexia and sarcopenia. 2021 , 267-293	0
344	Long term prognostic value of suPAR in chronic heart failure: reclassification of patients with low MAGGIC score. 2021 , 59, 1299-1306	2
343	Quercetin Efficiently Alleviates TNF- α -stimulated Injury by Signal Transducer and Activator of Transcription 1 and Mitogen-Activated Protein Kinase Pathway in H9c2 Cells: A Protective Role of Quercetin in Myocarditis. 2021 , 77, 570-577	1
342	Pulmonary vasodilator use in continuous-flow left ventricular assist device management. 2021 , 9, 522	
341	The adipokine Retnla deficiency increases responsiveness to cardiac repair through adiponectin-rich bone marrow cells. 2021 , 12, 307	1
340	Effects of selective TNFR1 inhibition or TNFR2 stimulation, compared to non-selective TNF inhibition, on (neuro)inflammation and behavior after myocardial infarction in male mice. 2021 , 93, 156-171	7
339	Exercise Therapy for Patients with Heart Failure: Focusing on the Pathophysiology of Skeletal Muscle.	
338	Importance of clonal hematopoiesis in heart failure. 2021 ,	1
337	Circulating TNFR1 levels predict incidence of ischemic heart disease and total mortality, independently of intima media thickness and pulse wave velocity in male with type 2 diabetes. 2021 , 36, 1591-1596	
336	Coronary stent technology and the role of inflammation in the atherogenesis: problems and prospects. 2021 , 20, 200-212	
335	RhoA: a dubious molecule in cardiac pathophysiology. 2021 , 28, 33	6
334	Altered Amino Acid Metabolism in Patients with Cardiorenal Syndrome Type 2: Is It a Problem for Protein and Exercise Prescriptions?. 2021 , 13,	0
333	Emerging role of interleukin-13 in cardiovascular diseases: A ray of hope. 2021 , 25, 5351-5357	5
332	Immune Cells and Immunotherapy for Cardiac Injury and Repair. 2021 , 128, 1766-1779	17
331	Salivary Biomarkers for Diagnosis and Therapy Monitoring in Patients with Heart Failure. A Systematic Review. 2021 , 11,	1
330	Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction. 2021 , 8, 3168-3179	5

329	Tenascin-C in Heart Diseases-The Role of Inflammation. 2021 , 22,	4
328	Upregulation of COX-2 and PGE Induced by TNF- α Mediated Through TNFR1/MitoROS/PKC β /MAPK, JNK1/2/FoxO1 Cascade in Human Cardiac Fibroblasts. 2021 , 14, 2807-2824	3
327	Levels of Trimethylamine N-Oxide Remain Elevated Long Term After Left Ventricular Assist Device and Heart Transplantation and Are Independent From Measures of Inflammation and Gut Dysbiosis. 2021 , 14, e007909	2
326	Immunotherapy and cardiovascular diseases (CVD): novel avenues for immunotherapeutic approaches. 2021 ,	1
325	Effects of intravenous furosemide plus small-volume hypertonic saline solutions on markers of heart failure. 2021 , 8, 4174-4186	1
324	Role of the cardiac extracellular matrix in the onset and progression of heart failure. 2021 , 26, 4362	0
323	RhoA Signaling in Immune Cell Response and Cardiac Disease. 2021 , 10,	1
322	Primary Graft Dysfunction after Heart Transplantation - Unravelling the Enigma. 2021 , 100941	0
321	Inflammation-based assessment for the risk stratification of mortality in patients with heart failure. 2021 , 11, 14989	1
320	WBC count predicts heart failure in diabetes and coronary artery disease patients: a retrospective cohort study. 2021 , 8, 3748-3759	3
319	CMV Infection Is Directly Related to the Inflammatory Status in Chronic Heart Failure Patients. 2021 , 12, 687582	2
318	Knockdown circ_0040414 inhibits inflammation, apoptosis and promotes the proliferation of cardiomyocytes via miR-186-5p/PTEN/AKT axis in chronic heart failure. 2021 , 45, 2304-2315	0
317	Age, sex, and inflammatory markers predict chronic conditions, cardiac disease, and mortality among captive western lowland gorillas (<i>Gorilla gorilla gorilla</i>). 2021 , 62, 931-943	1
316	Heart Failure Syndrome With Preserved Ejection Fraction Is a Metabolic Cluster of Non-resolving Inflammation in Obesity. 2021 , 8, 695952	4
315	Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus. 2021 , 1867, 166148	4
314	Clonal Hematopoiesis and Cardiovascular Diseases: The Connection. 2021 , 100962	2
313	Voltage-gated potassium channel dysfunction in dorsal root ganglia contributes to the exaggerated exercise pressor reflex in rats with chronic heart failure. 2021 , 321, H461-H474	1
312	Effect of heart failure and malnutrition, alone and in combination, on rehabilitation effectiveness in patients with hip fracture. 2021 , 44, 356-366	1

311	Effect of N-terminal region of human parvovirus B19-VP1 unique region on cardiac injury in naïve mice. 2021 , 24,	0
310	Serum Soluble Tumor Necrosis Factor Receptors 1 and 2 Are Early Prognosis Markers After ST-Segment Elevation Myocardial Infarction. 2021 , 12, 656928	0
309	Impact of Protein-Losing Enteropathy on Inflammatory Biomarkers and Vascular Dysfunction in Fontan Circulation. 2021 , 155, 128-134	1
308	The relationship between systemic inflammation and increased left ventricular mass is partly mediated by noncalcified coronary artery disease burden in psoriasis. 2021 , 7, 100211	2
307	Interleukin-receptor antagonist and tumor necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases. 2021 , 2021,	78
306	The Utility of Circulating and Imaging Biomarkers Alone and in Combination in Heart Failure. 2021 , 17, e160721193557	0
305	Myocardial Dysfunction and Heart Failure in Rheumatoid Arthritis. 2021 ,	1
304	Management of inflammation in cardiovascular diseases. 2021 , 173, 105912	1
303	Development of an ImmunoFET for Analysis of Tumour Necrosis Factor- α in Artificial Saliva: Application for Heart Failure Monitoring. 2021 , 9, 26	13
302	Gender Dimorphism and the Use of Sex Steroid/Receptor Antagonist After Trauma. 2006 , 101-121	1
301	Neurohormonal Responses in Congestive Heart Failure: Effect of Ace Inhibitors in Randomized Controlled Clinical Trials. 1995 , 487-501	1
300	Right Heart Failure. 1994 , 258-280	1
299	Recent Insights into the Role of Tumor Necrosis Factor in the Failing Heart. 2001 , 3-12	1
298	Carnitine Deficiency: Primary and Secondary Syndromes. 1997 , 119-161	13
297	Nitric Oxide and the Heart. 1999 , 175-193	1
296	Pathophysiology and Clinical Recognition of Heart Failure. 2007 , 1379-1396	1
295	Nitric oxide in coronary artery disease: roles in atherosclerosis, myocardial reperfusion and heart failure. 1996 , 76, 33-55	38
294	Vagal Nerve Stimulation for the Treatment of Heart Failure. 2017 , 157-179	1

293	Sex differences at cellular level: "cells have a sex". 2012 , 49-65	34
292	Regulation of Cardiac Function by Nitric Oxide. 2000 , 207-234	4
291	The Role of Cytokines in the Pathogenesis of Myocarditis. 1997 , 44-56	0
290	The At Risk Patient Population. 1995 , 13-34	6
289	Immunology of Acute Renal Failure in the Critically Ill. 1995 , 346-363	1
288	Cardiac Effects of the Mediators of Sepsis. 1992 , 255-266	1
287	Utilization of propionyl-L-carnitine for the treatment of heart failure. 1995 , 323-335	2
286	Pathophysiologic alterations induced by tumor necrosis factor. 1993 , 34 Pt B, 7-25	19
285	Role of Tumor Necrosis Factor in Acute and Chronic Inflammatory Responses: Novel Therapeutic Approaches. 1994 , 97-147	2
284	Anesthesia for Cardiac Surgical Procedures. 2010 , 1889-1975	4
283	Effects and safety of Psilocybe cubensis and Panaeolus cyanescens magic mushroom extracts on endothelin-1-induced hypertrophy and cell injury in cardiomyocytes. 2020 , 10, 22314	5
282	Cytokines are not a requisite part of the pathophysiology leading to cardiac decompensation. 2000 , 223, 47-52	11
281	An overview of tumor necrosis factor alpha and the failing human heart. 1999 , 14, 206-10	68
280	Insights into the pathogenesis of chronic heart failure: immune activation and cachexia. 1999 , 14, 211-6	79
279	Human blood vessels release tumor necrosis factor-alpha from a smooth muscle cell source. 1996 , 24, 294-7	19
278	Inhibition of release of tumor necrosis factor-alpha from human vascular tissue and smooth muscle cells by glucocorticoids. 1997 , 25, 519-22	13
277	Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. 1999 , 27, 1309-18	349
276	Importance of endothelial function in chronic heart failure. 1996 , 27 Suppl 2, S9-12	27

275	Neurohormonal Activation, Oxygen Free Radicals, and Apoptosis in the Pathogenesis of Congestive Heart Failure. 1998 , 32, S22-S30	146
274	Relation between impairment in nitric oxide pathway and clinical status in patients with congestive heart failure. 1998 , 32, 562-70	26
273	Insulin resistance in chronic heart failure. 2000 , 35, S9-14	66
272	Therapeutic use of dopamine and beta-blockers modulates plasma interleukin-6 levels in patients with congestive heart failure. 2000 , 36 Suppl 2, S87-91	17
271	Effects of tumor necrosis factor-alpha on basal and stimulated endothelium-dependent vasomotion in human resistance vessel. 2000 , 36, 487-92	40
270	Altered expression of myosin heavy chain in human skeletal muscle in chronic heart failure. 1997 , 29, 860-6	72
269	Effect of enteral versus parenteral nutrition on inflammation and cardiac function in a rat model of endotoxin-induced sepsis. 2008 , 30, 280-4	9
268	The immunosuppression of macrophages underlies the cardioprotective effects of catestatin (CST).	3
267	Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure?. 1995 , 92, 1379-82	94
266	Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. 1995 , 92, 1479-86	362
265	Expression and functional significance of tumor necrosis factor receptors in human myocardium. 1995 , 92, 1487-93	240
264	Nitric oxide inhibits the positive inotropic response to beta-adrenergic stimulation in humans with left ventricular dysfunction. 1995 , 92, 2198-203	145
263	Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. 1996 , 93, 704-11	699
262	Expression of inducible nitric oxide synthase in human heart failure. 1996 , 93, 1087-94	322
261	Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. 1996 , 94, 2285-96	328
260	Predicting outcomes in severe heart failure. 1997 , 95, 2597-9	14
259	Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. 1997 , 95, 2660-7	780
258	Cytokines score a knockout. Harnessing gene targeting to gain insight into the pathogenesis of myocarditis. 1997 , 95, 551-2	1

257	Cytokines and cardiac contractile function. 1997 , 95, 778-81	147
256	Potent and long-lasting vasodilatory effects of adrenomedullin in humans. Comparisons between normal subjects and patients with chronic heart failure. 1997 , 95, 1214-21	129
255	Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. 1997 , 96, 526-34	552
254	Amiodarone inhibits production of tumor necrosis factor-alpha by human mononuclear cells: a possible mechanism for its effect in heart failure. 1997 , 96, 1386-9	63
253	Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain. 1997 , 96, 1501-6	60
252	Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. 1997 , 96, 3042-7	273
251	Tumor necrosis factor-alpha induces a biphasic effect on myocardial contractility in conscious dogs. 1996 , 78, 154-60	100
250	Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure. 1996 , 78, 58-64	186
249	Death by design. Programmed cell death in cardiovascular biology and disease. 1997 , 81, 137-44	246
248	Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. 1997 , 81, 187-95	195
247	Interleukin-1 beta inhibits phospholamban gene expression in cultured cardiomyocytes. 1997 , 81, 493-503	65
246	Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. 1997 , 81, 627-35	586
245	Congestive Heart Failure: Fifty Years of Progress. 2000 , 102,	26
244	Endothelial Nogo-B regulates sphingolipid biosynthesis to promote pathological cardiac hypertrophy during chronic pressure overload. 2016 , 1,	38
243	Tumor necrosis factor-induced reversal of adipocytic phenotype of 3T3-L1 cells is preceded by a loss of nuclear CCAAT/enhancer binding protein (C/EBP). 1992 , 89, 223-33	112
242	Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. 1993 , 92, 2303-12	532
241	Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production. 1994 , 94, 1212-7	48
240	The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beta. 1995 , 95, 677-85	199

239	Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. 1996 , 98, 2854-65	572
238	Role of nitric oxide and peroxynitrite in the cytokine-induced sustained myocardial dysfunction in dogs in vivo. 1998 , 101, 2207-14	84
237	Anorexia. 1994 , 10, 51-53	1
236	Targeted metabolomic analysis of serum phospholipid and acylcarnitine in the adult Fontan patient with a dominant left ventricle. 2020 , 11, 2040622320916031	8
235	Protective effect of heme oxygenase-1 on Wistar rats with heart failure through the inhibition of inflammation and amelioration of intestinal microcirculation. 2015 , 12, 353-65	7
234	Increased cardiomyocyte intracellular calcium during endotoxin-induced cardiac dysfunction in guinea pigs. 2000 , 47, 669-76	43
233	Comparison of Mortality Prediction Models on Long-Term Mortality in Hospitalized Patients With Acute Heart Failure - The Importance of Accounting for Nutritional Status. 2019 , 83, 614-621	4
232	Risk factor analysis of plasma cytokines in patients with coronary artery disease by a multiplexed fluorescent immunoassay. 2006 , 125, 906-13	17
231	High-sensitivity cardiac troponin-I is elevated in patients with rheumatoid arthritis, independent of cardiovascular risk factors and inflammation. 2012 , 7, e38930	16
230	Red cell distribution width and inappropriateness of left ventricular mass in patients with untreated essential hypertension. 2015 , 10, e0120300	7
229	Comparing NGS and NanoString platforms in peripheral blood mononuclear cell transcriptome profiling for advanced heart failure biomarker development. 2020 , 7, e123	5
228	Role of interleukins in heart failure with reduced ejection fraction. 2019 , 22, 287-299	15
227	Relationship between exercise intolerance and levels of neurohormonal factors and proinflammatory cytokines in patients with stable chronic heart failure. 2005 , 46, 1049-59	18
226	Impact of hydroxymethylglutaryl coenzyme A reductase inhibition on left ventricular remodeling in patients with acute anterior myocardial infarction after primary coronary angioplasty. 2005 , 46, 987-95	9
225	Role of circulatory leukocyte based indices in short-term mortality of patients with heart failure with reduced ejection fraction. 2020 , 93, 351-356	3
224	Sleep-Disordered Breathing During Congestive Heart Failure: To Intervene or Not to Intervene?. 2017 , 3, 134-139	7
223	Immunometabolic cross-talk in the inflamed heart. 2019 , 3, 240-266	10
222	The role of metabolism disorders, inflammation, myocardial injury in development chronic heart failure in metabolic syndrome patients. 2018 , 7, 5	2

221	Chronic Heart Failure in Rheumatoid Arthritis Patients (Part I): Prevalence, Etiology and Pathogenesis. 2018 , 14, 703-710	5
220	A review of levosimendan in the treatment of heart failure. 2006 , 2, 389-400	18
219	Preventive Role of Resveratrol Against Inflammatory Cytokines and Related Diseases. 2019 , 25, 1345-1371	10
218	The Role of Antithrombotic Therapy in Heart Failure. 2020 , 26, 2735-2761	0
217	The Role of TNF- α as a Proinflammatory Cytokine in Pathological Processes. 2019 , 13, 332-338	10
216	Ameliorated stress related proteins are associated with improved cardiac function by sarcoplasmic reticulum calcium ATPase gene transfer in heart failure. 2012 , 9, 269-77	2
215	Cardiac biomarkers: new tools for heart failure management. 2012 , 2, 147-64	29
214	Use of TNF Inhibitor in Particular Clinical Settings. 2009 , 16, 264	0
213	The Fontan pathway: What's down the road?. 2008 , 1, 83-92	23
212	The Relationship between Tumor Necrosis Factor Alpha and Left Ventricular Diastolic Function. 2020 , 30, 62-67	2
211	Unmet Needs in the Treatment of Rheumatoid Arthritis. 2013 , 03, 65-78	7
210	Dual effect of pre-ischemic administration of TNF-alpha on myocardial infarct size. 2013 , 03, 21-25	1
209	Clinical Implications of Tumor Necrosis Factor-Alpha, Interleukin-6 and Resistin in Coronary Artery Disease. 2014 , 04, 416-421	2
208	Sudden cardiac death in patients with rheumatoid arthritis. 2017 , 9, 562-573	16
207	Polymorphisms of tumor necrosis factor-alpha and interleukin-6 gene and C-reactive protein profiles in patients with idiopathic dilated cardiomyopathy. 2014 , 34, 407-14	9
206	Relationship between site of myocardial infarction, left ventricular function and cytokine levels in patients undergoing coronary artery surgery. 2016 , 27, 299-306	5
205	Left ventricular remodelling in chronic primary mitral regurgitation: implications for medical therapy. 2018 , 29, 51-65	12
204	Inflammation in Human Heart Failure: Major Mediators and Therapeutic Targets. 2021 , 12, 746494	8

- 203 Cerebral derailment after myocardial infarct: mechanisms and effects of the signaling from the ischemic heart to brain. **2021**, 1 0
- 202 The Role of Neurohormonal Systems, Inflammatory Mediators and Oxydative Stress in Cardiomyopathy. 0
- 201 Inflammation-Based Scores as a Common Tool for Prognostic Assessment in Heart Failure or Cancer. **2021**, 8, 725903 2
- 200 Akute kardiale Dyspnoe und Lungenödem. **2000**, 527-538
- 199 Mitral Valve repair for surgical remodeling. **2000**, 83-95 1
- 198 Neurohormones in Advanced Heart Failure. **2000**, 3-23
- 197 Pathophysiologie der chronischen Herzinsuffizienz. **2000**, 545-595
- 196 Cytokines and Heart Failure: Pathophysiological Roles and Therapeutic Implications. **2000**, 35-45
- 195 Klinik und Symptomatologie der chronischen Herzinsuffizienz. **2000**, 597-610
- 194 Effects of cytokines and nitric oxide on myocardial E-C coupling. **2000**, 141-154
- 193 Oxidative Stress and Use of Antioxidants in Patients with Congestive Heart Failure. **2000**, 211-224
- 192 Mechanisms and relevance of apoptosis. **2000**, 197-231
- 191 Definition und Epidemiologie der chronischen Herzinsuffizienz. **2000**, 539-543
- 190 The Structural Correlate of Reduced Cardiac Function in Failing Human Hearts. **2000**, 423-439 1
- 189 Cardiovascular Disease and Hypertension. **2000**, 279-316 1
- 188 Clinical Laboratory Analysis of the Genetically Manipulated Mouse. **2001**, 303-317
- 187 Literatur. **2001**, 257-287
- 186 The growth hormone axis in cachectic patients with chronic heart failure: evidence for acquired growth hormone resistance.. **2001**, 67-79

185 Immunomodulation of Cytokines in Experimental Models of Heart Failure. **2001**, 69-76

184 Interactions Between Cytokines and Neurohormonal Systems in the Failing Heart. **2001**, 49-57

183 Role of chemokines in the pathogenesis of congestive heart failure. **2003**, 351-367

182 Large Animal Model of Viral Myocarditis. **2003**, 301-324

181 Immunomodulation in Heart Failure: Experimental Models. **2003**, 203-219

180 Stress-activated signals and their role in myocardial ischemia. **2003**, 271-291

179 Flaxseed and Flaxseed Products in Kidney Disease. **2003**,

178 Dietary Prevention of CHD. **2003**,

177 Micronutrients and Cardiovascular Disease. **2003**,

176 Genetic Determinants of Susceptibility, Prognosis and Treatment in Heart Failure. **2004**, 203-222

175 Cardiac Failure. **2005**, 221-231

174 Patients with dilated cardiomyopathy possess insulin resistance independently of cardiac dysfunction or serum tumor necrosis factor-alpha. **2006**, 47, 877-87

3

173 Statins, Inflammation, and Cardiomyopathy: Old Pathways, New Targets. **2006**, 155-166

172 Hartfalen: een systemische aandoening. **2007**, 47-69

171 Cardiovascular Involvement in Acquired Immune Deficiency Syndrome. **2007**, 2371-2384

170 Heart Failure, Stress Effects. **2007**, 272-274

169 Is humoral activation in heart failure affected by a genetic predisposition?. **2007**, 49, 127-133

1

168 Receptor Signaling Pathways in Heart Failure: Transgenic Mouse Models. **2008**, 89-111

- 167 Immune System Alterations in Acute Heart Failure. **2008**, 134-147
- 166 Cytokines Are Not a Requisite Part of the Pathophysiology Leading to Cardiac Decompensation. **2000**, 223, 47-52
- 165 Heart Failure and Changes at the Periphery: Vascular, Inflammation, Neurohormonal, and Renal Systems. **2010**, 235-255
- 164 Pulmonary Edema and Acute Lung Injury. **2010**, 1283-1325 1
- 163 Myocardial Proteases and Matrix Remodeling in Acute Myocarditis and Inflammatory Cardiomyopathy. **2010**, 71-88
- 162 Left Ventricular Restoration. **2010**, 1573-1598
- 161 The role of cytokines in inflammation-induced cardiomyopathy: Pathogenesis and therapeutic implications. **2010**, 171-181
- 160 Cardiac Cachexia in Chronic Heart Failure: The Metabolic Facet of CHF. **2010**, 165-185 1
- 159 Dietary Intervention in Coronary Care Units and in Secondary Prevention. **2011**, 344-360
- 158 Alterations in the Peripheral Circulation in Heart Failure. **2011**, 279-290
- 157 1.?????????????????. **2011**, 31, 339-345 1
- 156 Omega-3 Fatty Acids and Bone Metabolism. **2011**,
- 155 Protein-losing Enteropathy after Fontan Operation: About Contribution of Inflammation. **2012**, 28, 230-232
- 154 Cytokine Profiles in Cardiac Diseases and Marrow Stromal Cells Therapy. **2013**, 421-425
- 153 Endothelial Dysfunction, Cytokines and Their Genetic Variations. **2013**, 151-170
- 152 Shock. **2014**, 159-271
- 151 The Systemic Inflammatory Response to Cardiopulmonary Bypass: Pathophysiology and Treatment. **2014**, 289-296 0
- 150 Appropriate candidates for statin use in heart failure. **2014**, 29, 730-4

149 Congestive Heart Failure. **2014**, 282-313

148 The molecular action of tumor necrosis factor- α **1991**, 245-256

147 Tumor necrosis factor and chemotherapeutic drugs targeted at DNA topoisomerase II for the treatment of genitourinary malignancies. **1992**, 59, 105-20

146 CNS and Cardiovascular Effects of TNF- α **1993**, 225-230

145 Dialysis and Hemofiltration for Congestive Heart Failure. **1994**, 568-583

144 Sepsis and Septic Shock: Update on Definitions. **1994**, 3-15

1

143 Hemodynamic Monitoring, Pharmacologic Therapy, and Arrhythmia Management in Acute Congestive Heart Failure. **1994**, 509-521

142 Nonadrenergic Hormonal Alterations in Congestive Heart Failure. **1994**, 136-144

141 The Nitric Oxide Pathway in the Control of Myocardial Function: Role of Cytokines. **1995**, 265-285

1

140 Nitric Oxide Dependent and Independent Effects of Tumor Necrosis Factor- β on Cardiomyocyte Beating Activity and Signal Transduction Pathways. **1995**, 286-309

1

139 Tumor Necrosis Factor-Alpha in Chronic Heart Failure. **1995**, 3-8

138 Cytokine Antibodies and Antagonists in the Treatment of Sepsis. **1995**, 199-224

137 Cytokines and Heart Failure: Immunomodulating Agents for the Management of Heart Failure. **1996**, 219-232

136 Impaired Cellular Signaling of the Adenylyl Cyclase and the Phosphoinositide Pathway in Septic Cardiomyopathy. **1996**, 277-310

1

135 Tumor Necrosis Factor- α and the Myocardial Stress Response. **1997**, 111-126

134 Literatur. **1997**, 139-156

133 Coronary Reperfusion and Cytokines. **1998**, 157-177

132 Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. **1998**, 32 Suppl 1, S22-30

11

- 131 The kidney in cardiac failure: today's perspective. **1998**, 983-1002
- 130 3.?????????. **1998**, 87, 69-76
- 129 Interaction of Respiratory Muscles and Circulation in Heart Failure. **1999**, 298-308
- 128 Role of Nitric Oxide in the Regulation of Cardiovascular Performance: Clinical Implications for Sepsis and Congestive Heart Failure. **1999**, 119-143
- 127 The Roles of Hypoxic Responses During the Pathogenesis of Cardiovascular Diseases. **2016**, 675-683
- 126 Cardiorenal syndrome or renocardial syndrome: A review. **2016**, 4, 14-24
- 125 Protective effects of high-intensity versus low-intensity interval training on isoproterenol-induced cardiac injury in wistar rats. **2017**, 6, 5
- 124 Molecular Changes in Heart Failure. **2017**, 1-26
- 123 Cellular Interplay and Cytokine Hierarchy Cause Pathological Cardiac Hypertrophy in RAF1-Mutant Noonan Syndrome.
- 122 Clinical Relevance in Disease States: Heart Failure and Coronary Disease. **2018**, 1-30
- 121 Stage B Heart Failure. **2018**, 456-464
- 120 Quantitative Temporal Analysis of Protein Dynamics in Maladaptive Cardiac Remodeling.
- 119 The concentration of interleukin-33 in heart failure with reduced ejection fraction. **2019**, 21, 305-313 6
- 118 Clinical Relevance in Disease States: Heart Failure and Coronary Disease. **2019**, 2491-2520
- 117 TNF-induced LDL cholesterol accumulation involves elevated LDLR cell surface levels and SR-B1 downregulation in human arterial endothelial cells.
- 116 The Correlation between Gut Microbiota and Serum Metabolomic in Elderly Patients with Chronic Heart Failure. **2021**, 2021, 5587428 2
- 115 Clinical significance of chitotriosidase in outpatients with advanced heart failure. **2021**, 69, 736-741 0
- 114 Association between platelet distribution width and prognosis in patients with heart failure. **2020**, 15, e0244608 3

- 113 Breve revisão sobre a escolha de imunobiológicos na presença de comorbidades: contraindicações relativas e absolutas. **2017**, 16-18
- 112 Correlation between Serum Markers of Adverse Left Ventricular Remodelling and Gene Expression Levels Measured in the Myocardial Tissue of Patients with Chronic Primary Mitral Regurgitation. **2020**, 2, 5
- 111 Viva voce: Adalimumab. **2020**, 6, 53
- 110 Innate Immune Signaling in Cardiac Homeostasis and Cardiac Injuries. **2020**, 183-200
- 109 Clinical Requirements for Mechanical Circulatory Support Devices. **2020**, 91-107 1
- 108 To Study the Red Cell Distribution Width in Patients of Acute Myocardial Infraction and Its Relationship with Ejection Fraction. **2020**, 7, 224-227
- 107 Heart function in juvenile idiopathic arthritis patients: A biventricular two-dimensional speckle-tracking echocardiography study. **2021**,
- 106 Use of Antioxidants in Patients with Congestive Heart Failure. **2006**, 451-476
- 105 Heart transplant candidates at high risk can be identified at the time of initial evaluation. **1996**, 9, 38-45 4
- 104 Chronische Herzinsuffizienz. **2006**, 217-335
- 103 The roles of immunity and autoimmunity in chronic heart failure. **2006**, 155-68
- 102 Biological Approach in the Treatment of Crohn's Disease. **2006**, 157-170
- 101 Molecular Mechanisms of Myocardial Remodeling. **1999**, 29-42 1
- 100 Pro-inflammatory and pro-apoptotic factors in heart failure. **2000**, 261-271
- 99 Transgenic mouse models of HIV-1/AIDS and cardiac performance. **2008**, 385-393
- 98 The Molecular Base of Exercise. **2007**, 67-76 0
- 97 Type 1 Cardio-Renal Syndrome. **2021**, 59-73
- 96 Acute heart failure. **1998**, 25, 255-9

95	Thyroid function in dogs with spontaneous and induced congestive heart failure. 1994 , 58, 157-62	9
94	Effects of carvedilol on plasma levels of pro-inflammatory cytokines in patients with ischemic and nonischemic dilated cardiomyopathy. 2007 , 34, 52-9	18
93	Heart failure in 10 years time: focus on pharmacological treatment. 2002 , 88 Suppl 2, ii40-6	2
92	Modulation of alpha smooth muscle actin and desmin expression in perisinusoidal cells of normal and diseased human livers. 1991 , 138, 1233-42	244
91	Immune modulation of cardiac cell function. 1998 , 109, 39-49; discussion 49-50	5
90	Pathogenic role of cardiac mast cell activation/degranulation, TNF-alpha, and cell death in acute drug-related fatalities. 2007 , 3, 1053-62	8
89	Mechanism of cardioprotective action of TNF-alpha in the isolated rat heart. 2002 , 7, 146-50	9
88	The G-308A polymorphism of the TNF-alpha gene does not predict changes in cardiac function in response to medical therapy for idiopathic dilated cardiomyopathy. 2008 , 19, 254-8	3
87	Salt intake is associated with inflammation in chronic heart failure. 2014 , 8, 89-93	9
86	The obesity paradox is not observed in chronic heart failure patients with metabolic syndrome. 2014 , 13, 516-25	3
85	Tumor Necrosis Factor-alpha Gene Expression in PBMCs of Iranian Azeri Turkish Patients with Premature Coronary Artery Disease (Age .50 Years). 2018 , 13, 12-16	1
84	Error Analysis of Kalman Filter Applied to Phased Array Antenna Alignment. 2021 ,	
83	Heart failure as an adverse effect of infliximab for Crohn's disease: A case report and review of the literature.. 2021 , 9, 10382-10391	1
82	Cytokine-Mediated Alterations of Human Cardiac Fibroblast's Secretome. 2021 , 22,	1
81	LncRNA TDRG1 aggravates TGF- β 1-induced fibrogenesis and inflammatory response of cardiac fibroblasts via miR-605-3p/TNFRSF21 axis. 2021 ,	1
80	Targeting Mediators of Inflammation in Heart Failure: A Short Synthesis of Experimental and Clinical Results. 2021 , 22,	2
79	Mechanisms of cardiac dysfunction in diabetic cardiomyopathy: molecular abnormalities and phenotypical variants.. 2022 , 1	4
78	Effect of malnutrition on outcomes in patients with heart failure: A large retrospective propensity score-matched cohort study.. 2022 ,	0

77	Main active components of Si-Miao-Yong-An decoction (SMYAD) attenuate autophagy and apoptosis via the PDE5A-AKT and TLR4-NOX4 pathways in isoproterenol (ISO)-induced heart failure models.. 2022 , 176, 106077	1
76	Plasma-derived extracellular vesicles from myocardial infarction patients inhibits tumor necrosis factor-alpha induced cardiac cell death.. 2021 , 70, 103323	0
75	Mineralocorticoid Receptor Antagonist Treatment of Established Pulmonary Arterial Hypertension Improves Interventricular Dependence in SU5416-Hypoxia Rat Model.. 2022 ,	0
74	Okamura Extract Suppresses Myocardial Infarction-Induced Left Ventricular Systolic Dysfunction by Inhibiting p300-HAT Activity.. 2022 , 14,	0
73	Overview of Cytokines and CoViD19. 2022 , 113-132	
72	Heart Failure in CoViD19. 2022 , 243-255	
71	Anti-inflammatory effect of cabbage (<i>Brassica oleracea</i> L var. capitata) fermented with a mixed culture of <i>Lactobacillus acidophilus</i> and <i>Lactiplantibacillus plantarum</i> . 2022 , 29, 166-174	
70	Biomarkers in Patients with Left Ventricular Assist Device: An Insight on Current Evidence.. 2022 , 12,	2
69	The association between heart rate behavior and gait performance: The moderating effect of frailty.. 2022 , 17, e0264013	0
68	Dysregulated Immunity in Pulmonary Hypertension: From Companion to Composer.. 2022 , 13, 819145	1
67	Fontan Associated Liver Disease.. 2022 ,	1
66	Pro-Inflammatory Derangement of the Immuno-Interactome in Heart Failure.. 2022 , 13, 817514	2
65	Heart Failure Severity Closely Correlates with Intestinal Dysbiosis and Subsequent Metabolomic Alterations.. 2022 , 10,	3
64	Frailty assessment using a novel approach based on combined motor and cardiac functions: a pilot study.. 2022 , 22, 199	0
63	Early Protective Role of Inflammation in Cardiac Remodeling and Heart Failure: Focus on TNF α and Resident Macrophages.. 2022 , 11,	1
62	Absolute lymphocyte count as a predictor of mortality and readmission in heart failure hospitalization.. 2022 , 39, 100981	1
61	Smoking cessation reduces systemic inflammation and circulating endothelin-1.. 2021 , 11, 24122	1
60	DIGESTIVE DISORDERS (ANNAVAHA SROTAS VYADHI) IN OLD AGE [ISSUES AND POSSIBLE SOLUTIONS. 2021 , 9, 2993-2998	

- 59 Low-Level Elevations of Procalcitonin Are Associated with Increased Mortality in Acute Heart Failure Patients, Independent of Concomitant Infection.. **2021**, 11,
- 58 Targeting the Metabolic-Inflammatory Circuit in Heart Failure With Preserved Ejection Fraction.. **2022**, 1 1
- 57 Image_1.pdf. **2018**,
- 56 Biomarkers in the clinical management of patients with atrial fibrillation and heart failure.. **2021**, 18, 908-951 2
- 55 Heart Failure Relapses in Response to Acute Stresses - Role of Immunological and Inflammatory Pathways.. **2022**, 9, 809935 0
- 54 Biological activity of Brassica oleracea var. capitata fermented with Lactobacillus plantarum. **2022**, 29, 241-253 1
- 53 Toll-Like Receptor-2 in Cardiomyocytes and Macrophages Mediates Isoproterenol-Induced Cardiac Inflammation and Remodeling.
- 52 Cardiac rehabilitation in heart failure with severely reduced ejection fraction: effects on mortality.
- 51 IL-10: A Key Molecule in the Mitigation of Heart Failure. **2022**, 257-271
- 50 Future scope and challenges for congestive heart failure: Moving towards development of pharmacotherapy. 0
- 49 Tumor Necrosis Factor-Alpha Inhibitors and Cardiovascular Risk in Rheumatoid Arthritis: A Systematic Review. **2022**,
- 48 Short-Term Prognostic Efficacy of mGPS and LCS in Patients With Acute Heart Failure. 9,
- 47 Diabetes in Elderly Cardiovascular Disease Patients: Mechanisms and Regulators. **2022**, 23, 7886
- 46 Heart Failure and Pancreas Exocrine Insufficiency: Pathophysiological Mechanisms and Clinical Point of View. **2022**, 11, 4128 0
- 45 TNF-Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis. 13, 1
- 44 Medical Treatment of Chronic Heart Failure. **2000**, 30, 88-89
- 43 Pathophysiology of Cachexia and Characteristics of Dysphagia in Chronic Diseases. **2022**, 100120
- 42 Pentraxin 3 in Circulating Microvesicles: a Potential Biomarker for Acute Heart Failure After Cardiac Surgery with Cardiopulmonary Bypass.

41	The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases. 13,	2
40	Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies.	1
39	The importance of biological sex in cardiac cachexia.	0
38	Effect of Ghrelin on the Cardiovascular System. 2022 , 11, 1190	1
37	Expression Profile of Inflammation Response Genes and Potential Regulatory Mechanisms in Dilated Cardiomyopathy. 2022 , 2022, 1-21	
36	Sex-dependent mechanisms of cell death modalities in cardiovascular disease. 2022 ,	1
35	Obesity, inflammation, and cardiovascular disorders. 2023 , 119-130	0
34	Independent Association of Thyroid Dysfunction and Inflammation Predicts Adverse Events in Patients with Heart Failure via Promoting Cell Death. 2022 , 9, 290	0
33	The role of gut dysbiosis-associated inflammation in heart failure. 2022 , 68, 1120-1124	1
32	The roles of HIF-1 β signaling in cardiovascular diseases. 2022 ,	0
31	Association of immune cell subsets with incident heart failure in two population-based cohorts.	0
30	The Gut Microbiome and Obstructive Sleep Apnea Syndrome in Children. 2022 ,	0
29	Macrophage autophagy in macrophage polarization, chronic inflammation and organ fibrosis. 13,	0
28	An in vivo assessment of inflammatory and oxidative stress responses in Echis ocellatus-venom induced cardiotoxicity. 2022 , 5-6, 100017	0
27	Systemic immune-inflammation index as a prognostic marker for advanced chronic heart failure with renal dysfunction.	0
26	Immunomodulatory Cell Therapy Using GalCer-Pulsed Dendritic Cells Ameliorates Heart Failure in a Murine Dilated Cardiomyopathy Model.	1
25	The Role of Gut Microbiota in Heart Failure: When Friends Become Enemies. 2022 , 10, 2712	0
24	The Predictive Value of Eosinophil Indices for Major Cardiovascular Events in Patients with Acute Decompensated HFrEF. 2022 , 58, 1455	1

- 23 A review of cardiac troponin I detection by surface enhanced Raman spectroscopy: Under the spotlight of point-of-care testing. 10, 0
- 22 Sarcopenia and Frailty in Heart Failure: Is There a Biomarker Signature?. 0
- 21 Physical performance and maximum tongue pressure associated with oral intake independence: a retrospective study on hospitalized patients with heart failure. **2022**, 12, 0
- 20 Recent Developments in the Evaluation and Management of Cardiorenal Syndrome: A Comprehensive Review. **2022**, 101509 1
- 19 Malnutrition Increases the Risk of Left Ventricular Remodeling. 0
- 18 Levels of TNF- α and Soluble TNF Receptors in Normal-Weight, Overweight and Obese Patients with Dilated Non-Ischemic Cardiomyopathy: Does Anti-TNF Therapy Still Have Potential to Be Used in Heart Failure Depending on BMI?. **2022**, 10, 2959 0
- 17 Revisiting skeletal myopathy and exercise training in heart failure: Emerging role of myokines. **2023**, 138, 155348 0
- 16 PCSK9: A emerging participant in heart failure. **2023**, 158, 114106 1
- 15 Isoproterenol Inhibits Bacterial Lipopolysaccharide-Stimulated Release of Tumor Necrosis Factor- α from Human Heart Tissue. **2000**, 66, 947-951 2
- 14 Malnutrition management of hospitalized patients with diabetes/hyperglycemia and heart failure. **2022**, 0
- 13 C-reactive protein and statins in heart failure with reduced and preserved ejection fraction. 9, 0
- 12 The oral microbiome in the pathophysiology of cardiovascular disease. 0
- 11 Sex and Molecular Differences in Cardiovascular Parameters at Peak Influenza Disease in Mice. 0
- 10 The impact of synbiotic on serum paraoxonase 1, (sCD163/sTWEAK) and lipid profile in patients with chronic heart failure: a randomized, triple-blind, controlled trial. 0
- 9 Single-cell transcriptome sequencing of macrophages in common cardiovascular diseases. 0
- 8 Toll-like receptor-2 in cardiomyocytes and macrophages mediates isoproterenol-induced cardiac inflammation and remodeling. **2023**, 37, 0
- 7 New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside and Back. **2023**, 11, 70 0
- 6 A Peek at LVADs Pumping to Recovery. **2022**, 16, 117954682211443 0

- 5 Association of protein intake during hospitalization with readmission in older adult patients with heart failure at risk of malnutrition. ○
- 4 Inflammation, dysregulated iron metabolism, and cardiovascular disease. 4, ○
- 3 Molecular Mechanisms and Therapeutic Implications of Endothelial Dysfunction in Patients with Heart Failure. **2023**, 24, 4321 ○
- 2 Growth differentiation factor 15 (GDF-15) in kidney diseases. **2023**, ○
- 1 Gut Failure: A Review of the Pathophysiology and Therapeutic Potentials in the Gut-Heart Axis. **2023**, 12, 2567 ○